U.S. patent application number 17/194543 was filed with the patent office on 2021-08-26 for transcription factor-based generation of pacemaker cells and methods of using same.
This patent application is currently assigned to CEDARS-SINAI MEDICAL CENTER. The applicant listed for this patent is CEDARS-SINAI MEDICAL CENTER. Invention is credited to Hee Cheol Cho, Eduardo Marban.
Application Number | 20210260158 17/194543 |
Document ID | / |
Family ID | 1000005567738 |
Filed Date | 2021-08-26 |
United States Patent
Application |
20210260158 |
Kind Code |
A1 |
Marban; Eduardo ; et
al. |
August 26, 2021 |
TRANSCRIPTION FACTOR-BASED GENERATION OF PACEMAKER CELLS AND
METHODS OF USING SAME
Abstract
Several embodiments disclosed herein relate generally to methods
and compositions for the generation of biological pacemakers. In
some embodiments, the methods comprise contacting non-pacemaker
cells with one or more transcription factors (in vivo or in vitro)
and inducing pacemaker functionality in the cells.
Inventors: |
Marban; Eduardo; (Santa
Monica, CA) ; Cho; Hee Cheol; (Los Angeles,
CA) |
|
Applicant: |
Name |
City |
State |
Country |
Type |
CEDARS-SINAI MEDICAL CENTER |
Los Angeles |
CA |
US |
|
|
Assignee: |
CEDARS-SINAI MEDICAL CENTER
Los Angeles
CA
|
Family ID: |
1000005567738 |
Appl. No.: |
17/194543 |
Filed: |
March 8, 2021 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
15678973 |
Aug 16, 2017 |
10973876 |
|
|
17194543 |
|
|
|
|
14357195 |
May 8, 2014 |
9763999 |
|
|
PCT/US2012/064204 |
Nov 8, 2012 |
|
|
|
15678973 |
|
|
|
|
61557812 |
Nov 9, 2011 |
|
|
|
Current U.S.
Class: |
1/1 |
Current CPC
Class: |
A61K 48/00 20130101;
C12N 5/0657 20130101; A61K 35/34 20130101; C12N 2506/02 20130101;
C12N 2501/60 20130101; A61K 38/1709 20130101; C12N 2799/022
20130101; C07K 14/4702 20130101 |
International
Class: |
A61K 38/17 20060101
A61K038/17; C12N 5/077 20060101 C12N005/077; C07K 14/47 20060101
C07K014/47; A61K 35/34 20060101 A61K035/34 |
Claims
1-47. (canceled)
48. A method of treating a dysfunction in cardiac electrical
activity comprising: obtaining cells capable of generating a
biological pacemaker, wherein the cells are converted from a
population of stem cells and/or progenitor cells; and administering
said converted cells to a subject suffering from a dysfunction in
cardiac electrical activity, wherein said converted cells exhibit
spontaneous, repetitive electrical activity, thereby treating said
dysfunction in cardiac electrical activity.
49. The method of claim 48, wherein the dysfunction in cardiac
electrical activity comprises a cardiac arrhythmia.
50. The method of claim 49, further comprising isolating said
converted cells prior to said administration.
51. The method according to claim 48, wherein said spontaneous,
repetitive electrical activity is within about 65% to about 100% of
the normal activity of pacemaker cells.
52. The method according to claim 48, wherein said administration
causes a change in the rhythm of the heart.
53. The method of claim 52, wherein the changed rhythm of the heart
corresponds to a new heart rate within about 25% to about 35% of a
normal heart rate.
54. The method according to claim 48, wherein said administration
is to a subject having an implanted pacemaker.
55. The method of claim 54, wherein said administration reduces the
dependence of said subject on said implanted pacemaker.
56. The method of claim 55, wherein said reduced dependence is
sufficient to allow explanting or replacement of said implanted
pacemaker.
57. The method according to claim 48, wherein said administration
is into the apex of the heart.
58. The method according to claim 48, wherein said administration
is to the right branch of the Bundle of His or the left branch of
the Bundle of His.
59. (canceled)
60. The method according to claim 48, wherein said administration
is to the Purkinje fibers.
61. The method according to claim 48, wherein said administration
is to the inter-ventricular septum.
62. The method according to claim 48, wherein said administration
is to the right ventricular free wall or the left ventricular free
wall.
63. (canceled)
64. The method according to claim 48, wherein said administration
is to the SA node.
65. The method according to claim 48, wherein said administration
is to the AV node.
66. The method according to claim 48, wherein said administration
is via the right ventricle.
67. The method according to claim 48, wherein said administration
is via the right atrium.
68. The method according to claim 48, wherein said administration
is made by accessing the heart directly.
69. The method of claim 68, wherein said accessing is facilitated
by use of one or more of a map guided catheter injection system,
fluoroscopy guidance, X-ray guidance, echocardiography guidance,
and guidance via magnetic resonance imaging.
70-76. (canceled)
77. A method of treating a cardiac arrhythmia by generating a
biological pacemaker using transcription factors, comprising:
identifying a subject suffering from cardiac arrhythmia; obtaining
a population of converted stem cells and/or progenitor cells,
wherein, prior to said conversion, said stem cells and/or
progenitor cells comprised quiescent cells that did not exhibit
spontaneous, repetitive electrical activity; wherein one or more of
Tbx18, Shox-2, Tbx3, Tbx5, functional fragments thereof, or
combinations thereof were administered to said quiescent cells to
generate converted cells that exhibit spontaneous, repetitive
electrical activity; and administering said converted cells to said
subject, wherein said administered converted cells engraft into the
cardiac tissue of said subject and continue to exhibit spontaneous,
repetitive electrical activity, thereby generating a biological
pacemaker and treating said cardiac arrhythmia.
78. The method of claim 48, wherein the cells are converted from a
population of stem cells through the use of transcription factors
into cells suitable for generation of a biological pacemaker,
comprising: obtaining a population of stem cells; culturing said
stem cells in vitro; wherein said cultured stem cells comprise
quiescent cells that do not exhibit spontaneous, repetitive
electrical activity; and delivering one or more transcription
factors to said quiescent cells to generate converted cells,
wherein the one or more transcription factors comprises Tbx18,
wherein the converted cells exhibit spontaneous, repetitive
electrical activity; thereby converting said stem cells into cells
capable of generating a biological pacemaker.
79. The method of claim 48, wherein the converted cells are capable
of generating a biological pacemaker to supplement or obviate the
need for an electrically-powered pacemaker.
80. The method of claim 48, wherein the converted cells are capable
of the generating a biological pacemaker to serve as a temporary
bridge until a replacement or alternative electronic pacemaker can
be implanted in the subject.
Description
CROSS REFERENCE TO RELATED APPLICATIONS
[0001] This application is a division of U.S. application Ser. No.
15/678,973 filed Aug. 16, 2017, which is a continuation of U.S.
application Ser. No. 14/357,195, filed May 8, 2014, now U.S. Pat.
No. 9,763,999, issued Sep. 19, 2017, which is a National Phase of
International Application No. PCT/US2012/064204, filed Nov. 8,
2012, which designated the U.S. and that International Application
was published under PCT Article 21(2) in English. This application
also includes a claim of priority under 35 U.S.C. .sctn. 119(e) to
U.S. provisional patent application No. 61/557,812, filed Nov. 9,
2011.
BACKGROUND
Field of the Invention
[0002] Several embodiments of the present application relate
generally to methods and compositions for the generation of
pacemaker cells (e.g., cardiac cells that have regular, rhythmic
electrical activity). In particular, some embodiments of the
invention relate to gene and cell therapy methods (and associated
compositions) to generate pacemaker cells using transcription
factors.
Description of the Related Art
[0003] During cardiogenesis, cardiomyocytes become specialized to
exhibit either ventricular, atrial, or pacemaker properties. The
sinoatrial node (SAN), the primary pacemaker region of the heart,
is a highly-specialized structure containing fewer than 10,000
pacemaker cells, which function to initiate contractions in the
SAN. These SAN contractions then propagate to the rest of the
excitable heart tissue and result in a heartbeat. Irregularities of
excitable cardiac tissue and/or irregularities of pacemaker cells
can lead to abnormalities in heart rhythm. Many cardiac
abnormalities typically involve irregular heartbeat, tachycardia
(where the heart rate is too high), or bradycardia (where the heart
rate is too slow). These abnormalities are collectively known as
arrhythmias.
[0004] Current therapies for cardiac arrhythmias typically rely on
drug therapy, ablation, electronic pacemaker devices or
combinations thereof. However, the usefulness of each of these
therapies has met with limited and varying success. While
antiarrhythmic drugs are widely prescribed and used, they may
result in adverse systemic side effects in certain patient
populations. Further, many drugs have a propensity to provoke new
arrhythmic events, which can lead to an increase in morbidity.
Radiofrequency ablation is used in some treatments of arrhythmias.
Ablation involves permanent removal of the tissue identified as the
source of, or critical to, the maintenance of the arrhythmias.
While this method has found some success in the treatment of
atrioventricular node reentry tachycardia, accessory pathway
tachycardia, and atrial flutter, it has found limited success in
the treatment of other arrhythmias. For instance, catheter ablation
is less successful in treating more complex cases, such as atrial
fibrillation (AF) or ventricular tachycardia (VT). Moreover,
catheter ablation is not useful in the treatment of bradycardia.
Electronic pacemaker devices can sustain heart rate, or deliver
shocks to terminate tachycardias. However, the high cost of
devices, and complications such as pulmonary collapse, hemorrhage,
bacterial infection, and lead/generator failure or other types of
malfunction represent limitations of the technology.
SUMMARY
[0005] In light of the limitations associated with traditional
therapies for dysfunctions of cardiac pacing and arrhythmias, there
is a need for alternative methods and compositions that can be used
to modulate cardiac pacing and rhythm to treat cardiac arrhythmias
(both simple and complex varieties), to treat heart failure (as in
cardiac resynchronization applications of electronic pacemakers),
and/or supplement or obviate the need for electrically-powered
pacemakers.
[0006] Currently, biological pacemakers typically elicit their
effects through the gene delivery of nucleotides that transcribe
mutant ion-channel proteins. In contrast, several embodiments of
the present invention operate through delivery to cells of
polynucleotides that encode one or more transcription factors,
which allows direct somatic-to-somatic cell reprogramming (e.g., a
non-pacemaker cell is reprogrammed to a pacemaker cell or a
malfunctioning pacemaker cell is reprogrammed to a functional
pacemaker cell). Thus, in several embodiments, pacemaker cells are
generated without the induced alteration expression of ion-channel
proteins. Additional embodiments involve the conversion of stem
cells, or in some embodiments cardiomyocytes or combinations of
stem cells and cardiomyocytes, to biological pacemaker cells in
vitro (e.g., by administration of one or more transcription factors
disclosed herein), followed by subsequent implantation of the
converted cells. Thus, delivery of the transcription factors, or
cells converted by those transcription factors, treats a variety of
cardiac rhythmic abnormalities and/or lessens or obviates the needs
for traditional therapies.
[0007] Thus, there is provided in several embodiments, methods for
generating a biological pacemaker using transcription factors in
order to modify the electrical activity of the cardiac tissue of a
subject, the method comprising identifying a subject having cardiac
tissue exhibiting abnormal electrical activity, wherein the subject
has cardiac tissue comprising quiescent cells, wherein the
quiescent cells comprise one or more of cardiomyocytes and stem
cells, wherein the quiescent cells do not exhibit spontaneous,
repetitive electrical activity; and administering one or more
transcription factors to the quiescent cells to generate treated
cells, wherein the treated cells exhibit spontaneous, repetitive
electrical activity, thereby modifying electrical activity of the
cardiac tissue the subject.
[0008] In several embodiments, the abnormal cardiac electrical
activity is due to a cardiac arrhythmia. However, other
abnormalities in cardiac electrical activity, signaling or function
can be addressed with the methods disclosed herein. For example, in
several embodiments, the subject is afflicted with a condition
selected from the group consisting of sick sinus syndrome, sinus
bradycardia, tachycardia-bradycardia syndrome, atrial fibrillation,
atrioventricular block, chronotropic incompetence, prolonged QT
syndrome, and heart failure.
[0009] In several embodiments, the administration occurs in vitro,
and the method further comprises administering the treated cells to
the subject. Advantageously, however, the methods disclosed herein
allow the administration to occur in vivo.
[0010] There are also provided methods of converting a population
of stem cells through the use of transcription factors into cells
suitable for generation of a biological pacemaker, comprising
obtaining a population of stem cells, culturing the stem cells in
vitro, wherein the cultured stem cells comprise quiescent cells
that do not exhibit spontaneous, repetitive electrical activity,
delivering one or more transcription factors to the quiescent cells
to generate converted cells, wherein the converted cells exhibit
spontaneous, repetitive electrical activity, thereby converting the
stem cells into cells capable of generating a biological
pacemaker.
[0011] There is additionally provided a method of treating a
cardiac arrhythmia using transcription factors comprising
identifying a subject suffering from cardiac arrhythmia, wherein
the subject has cardiac tissue comprising quiescent cells, wherein
the quiescent cells comprise one or more of cardiomyocytes and stem
cells, wherein the quiescent cells do not exhibit spontaneous,
repetitive electrical activity; and administering one or more of
Tbx18, Shox-2, Tbx3, Tbx5, functional fragments thereof, or
combinations thereof, to the quiescent cells to generate treated
cells, wherein the treated cells exhibit spontaneous, repetitive
electrical activity; thereby treating the cardiac arrhythmia.
[0012] There is also provided a method of treating a cardiac
arrhythmia by generating a biological pacemaker using transcription
factors, comprising identifying a subject suffering from cardiac
arrhythmia, obtaining a population of converted stem cells,
wherein, prior to the conversion, the stem cells comprised
quiescent cells that did not exhibit spontaneous, repetitive
electrical activity, wherein one or more of Tbx18, Shox-2, Tbx3,
Tbx5, functional fragments thereof, or combinations thereof were
administered to the quiescent cells to generate converted cells
that exhibit spontaneous, repetitive electrical activity; and
administering the converted cells to the subject, wherein the
administered converted cells engraft into the cardiac tissue of the
subject and continue to exhibit spontaneous, repetitive electrical
activity, thereby generating a biological pacemaker and treating
the cardiac arrhythmia.
[0013] In several embodiments, the one or more transcription
factors are regulators of embryonic sinoatrial node development
and/or promote de novo cellular differentiation into sinoatrial
nodal cells. In several embodiments, the one or more transcription
factors define the sinus venosus during development. In several
embodiments, the one or more transcription factors are negative
regulators of Nkx2.5 in the sinus venosus.
[0014] In several embodiments, the one or more transcription
factors is selected from the group consisting of Tbx18, Shox-2,
Tbx3, Tbx5, functional fragments thereof, and combinations thereof.
In several embodiments, the one or more transcription factors
comprises Tbx-18. In several embodiments, Tbx18 (or other Tbox
factors) are used to cause myocytes to generate spontaneous
electrical activity. In several embodiments, the one or more
transcription factors comprises Shox-2. In some embodiments, Shox-2
is used to convert stem cells to cells that generate spontaneous
electrical activity. However, in additional embodiments, Shox-2 may
optionally be used to convert myocytes to pacemaker cells, and/or
Tbx18 is used to convert stem cells to pacemaker cells.
[0015] In several embodiments, the administration of the
transcription factors is in vivo, and is to a site selected from
the group consisting of the apex of the heart, right branch of the
Bundle of His, the left branch of the Bundle of His, the Purkinje
fibers, the inter-ventricular septum, the right ventricular free
wall, the left ventricular free wall, the SA node, the AV node. In
several embodiments the administration site is accessed via the
right ventricle, via the right atrium, or by accessing the heart
directly. In several embodiments, direct access is achieved by a
map guided catheter injection system, by fluoroscopy guidance, by
X-ray guidance, by echocardiography guidance, by guidance via
magnetic resonance imaging, or combinations thereof. Each
particular subject may present with symptoms or other relevant
medical issues that determine an optimal rout of
administration.
[0016] In several embodiments, the administration of the
transcription factors is achieved by delivering to the target
tissue a DNA delivery system comprising a polynucleotide encoding
the one or more transcription factors. In several embodiments, the
DNA delivery system comprises a viral vector. Various viral vectors
are used, depending on the embodiment, such as, for example,
adenovirus, adeno-associated virus, lentivirus, retrovirus, HJV,
HIV, and/or HSV. In embodiments wherein more that one transcription
factor is administered, the transcription factors can optionally be
packed in different viral vectors. Alternatively, in some
embodiments, multiple transcription factors can be packaged in a
single viral vector.
[0017] In several embodiments, however, the DNA delivery system
comprises a non-viral vector. Various non-viral vectors can be
used, depending on the embodiment, such as for example, liposomal
vectors, a cationic polymers, and/or DNA binding polymers. In
several embodiments, the DNA delivery system comprises naked DNA.
In several embodiments, a patient that is immuno-suppressed or
otherwise has deficient immune function may benefit from a
non-viral delivery system.
[0018] In several embodiments, in addition to functioning like
pacemaker cells, the treated cells exhibit characteristics that are
similar to those of natural pacemaker cells. However, certain of
these characteristics need not be present in order to have the
treated cells function as pacemaker cells. In several embodiments,
the treated cells exhibit a length-to-width morphology
substantially similar to a length-to-width morphology of native SAN
cells. In several embodiments, this length-to-width ratio is at
least about 10. In several embodiments, the treated cells exhibit
an increase in spontaneous intracellular Ca.sup.++ oscillations. In
several embodiments, the spontaneous, repetitive electrical
activity increases in response to .beta.-adrenergic stimulation. In
several embodiments, the converted cells do not express atrial
natriuretic peptide (ANP) or skeletal .alpha.-actin
(.alpha.SkA).
[0019] In several embodiments, the subject has an electronic
pacemaker to modify the electrical activity of the cardiac tissue,
which in some patients may be implanted in the subject. In several
embodiments, the generation of the biological pacemaker supplements
the function of the electronic pacemaker (e.g., the workload of the
electronic pacemaker is decreased due to the generation of the
biological pacemaker). In several embodiments, the generation of
the pacemaker cells serves as a temporary bridge until a
replacement or alternative electronic pacemaker can be implanted in
a subject. In several embodiments, however, the generation of the
biological pacemaker functionally replaces the electronic
pacemaker. In several embodiments, this functional replacement
allows short-term, medium-term, long-term, or even permanent
shut-off (or explanting) of the electronic pacemaker.
[0020] In several embodiments, there is also provided a method of
generating a biological pacemaker using transcription factors to
treat a cardiac arrhythmia comprising identifying a subject
suffering from cardiac arrhythmia, wherein the subject has cardiac
tissue comprising quiescent cells, wherein the quiescent cells
comprise one or more of cardiomyocytes and stem cells, wherein the
quiescent cells do not exhibit spontaneous, repetitive electrical
activity; and administering one or more transcription factors to
the quiescent cells to generate treated cells, wherein the treated
cells exhibit spontaneous, repetitive electrical activity; thereby
treating the cardiac arrhythmia.
[0021] In several embodiments, the subject is mammalian, and in
several embodiments is a human. In several embodiments, the stem
cells that are converted into pacemaker cells are embryonic stem
cells, while in additional embodiments, they are adult stem cells,
induced stem cells, or resident stem cells.
[0022] There is also provided herein a method of treating a
dysfunction in cardiac electrical activity comprising obtaining
cells converted into pacemaker cells according to the methods
disclosed herein and administering the converted cells to a subject
suffering from a dysfunction in cardiac electrical activity,
wherein the converted cells exhibit spontaneous, repetitive
electrical activity, thereby treating the dysfunction in cardiac
electrical activity.
[0023] In several embodiments, the dysfunction in cardiac
electrical activity comprises a cardiac arrhythmia. In several
embodiments, the method further comprises isolating the converted
cells prior to the administration.
[0024] In several embodiments the spontaneous, repetitive
electrical activity is within about 65% to about 100% of the normal
activity of pacemaker cells. In several embodiments, the
administration of transcription factors causes a change in the
rhythm of the heart of the subject. In several embodiments, the
changed rhythm of the heart corresponds to a new heart rate within
about 25% to about 35% of a normal heart rate.
[0025] Additionally provided are compositions for the generation of
a biological pacemaker comprising: a DNA delivery system, the
system comprising, a viral vector encoding Tbx18, Shox-2, Tbx3,
Tbx5, functional fragments thereof, or combinations thereof, and a
eukaryotic promoter.
[0026] In several embodiments, the viral vector is an adenoviral
vector. In several embodiments, the adenoviral vector further
comprises the following operably linked components in sequence, a
first inverted terminal repeat sequence (ITR), a first lox P site,
a packaging site (W, psi), a cytomeglovirus promoter, a sequence
encoding Tbx18, Shox2, or combinations thereof, an internal
ribosome entry site (IRES), a polyadenylation signal (An), a second
lox P site, a sequence encoding the adenovirus early region 2 and
early region 4 genes; and a second inverted repeat sequence
(ITR).
[0027] Several embodiments disclosed herein relate to a population
of cells for the generation of a biological pacemaker comprising a
plurality of stem cells, wherein the stem cells have been contacted
with one or more transcription factors selected from the group
consisting of Tbx18, Shox-2, Tbx3, Tbx5, functional fragments
thereof, and combinations thereof, wherein the one or more
transcription factors induce an increase in the spontaneous,
repetitive electrical activity of the cells, wherein the increase
in the spontaneous, repetitive electrical activity of the cells is
capable of generating an ectopic contraction of the cells, and
wherein the stem cells are suitable for administration to a subject
in need of biological pacemaker function.
[0028] In several embodiments, the stem cells are selected from the
group consisting of embryonic stem cells, non-embryonic stem cells,
bone marrow-derived stem cells, adipose-derived stem cells, induced
pluripotent stem cells, and cardiac stem cells.
[0029] There is also provided for herein a use of one or more
transcription factors selected from the group consisting of Tbx18,
Shox-2, Tbx3, Tbx5, functional fragments thereof, and combinations
thereof to convert quiescent cells that do not exhibit spontaneous,
repetitive electrical activity into pacemaker cells that exhibit
spontaneous, repetitive electrical activity.
[0030] In several embodiments, there are provided methods for
generating a biological pacemaker using transcription factors
comprising identifying a subject having cardiac tissue comprising
quiescent cells that do not exhibit spontaneous, repetitive
electrical activity and administering one or more transcription
factors to the quiescent cells to generate treated cells, wherein
the treated cells exhibit spontaneous, repetitive electrical
activity, thereby treating said cardiac arrhythmia. In several
embodiments, the subject was previously suffering from cardiac
arrhythmia.
[0031] In several embodiments, there is also provided a method for
treating cardiac arrhythmia comprising identifying a subject having
cardiac tissue comprising quiescent cells, the subject suffering
from cardiac arrhythmia, wherein the quiescent cells do not exhibit
spontaneous repetitive electrical activity, and administering one
or more of Tbx18 and/or Shox2 (or fragments thereof) to the
quiescent cells to generate treated cells, wherein the treated
cells exhibit spontaneous repetitive electrical activity, thereby
treating the cardiac arrhythmia
[0032] In several embodiments, the quiescent cells comprise
cardiomyocytes. In other embodiments, the quiescent cells comprise
stem cells. In still additional embodiments, the quiescent cells
comprise malfunctioning sinoatrial node cells (e.g. sinoatrial node
cells that signal at levels that are too fast or too slow relative
to normal functioning pacemaker cells). In other embodiments, the
quiescent cells comprise other cells found in the heart and/or
other somatic cells not found in the heart.
[0033] In several embodiments, there is also provided a method of
converting a population of stem cells into cells suitable for
generation of a biological pacemaker, the method comprising
obtaining a population of stem cells, culturing the stem cells in
vitro, wherein the cultured stem cells comprise quiescent cells
that do not exhibit spontaneous repetitive electrical activity, and
administering one or more transcription factors to the quiescent
cells to generate converted cells. In several embodiments, the
converted cells exhibit spontaneous repetitive electrical activity,
and thus are capable of generating a biological pacemaker in vivo.
In several embodiments, the stem cells comprise cardiac stem cells.
In several embodiments, in vitro conversion can be performed on
cardiomyocytes, other cells found in the heart, and/or other
somatic cells not found in the heart.
[0034] In several embodiments, there are also provided methods of
treating a cardiac arrhythmia by generating a biological pacemaker
using transcription factors, the method comprising identifying a
subject suffering from cardiac arrhythmia, obtaining a population
of converted stem cells, wherein, prior to the conversion, the stem
cells comprised quiescent cells that did not exhibit spontaneous
repetitive electrical activity, wherein one or more of Tbx18 and
Shox2 (or fragments thereof) were administered to the quiescent
cells to generate converted cells, the converted cells exhibiting
spontaneous repetitive electrical activity, and administering the
converted cells to the subject, wherein the converted cells engraft
into the cardiac tissue of the subject and continue to exhibit
spontaneous repetitive electrical activity, thereby generating a
biological pacemaker and treating the cardiac arrhythmia. In
several embodiments, the converted cells are isolated, purified,
selected for, or otherwise concentrated prior to administration to
the subject. As discussed above, in several embodiments, instead
of, or in conjunction with stem cells, other quiescent cells types
are converted to pacemaker cells. In several embodiments, cells
converted in vitro to cells that exhibit spontaneous repetitive
electrical activity include cardiomyocytes.
[0035] In several embodiments, the methods provided herein utilize
mammalian stem cells to treat mammalian subjects. In several
embodiments, the subject is a human.
[0036] In several embodiments, the one or more transcription
factors are regulators of embryonic sinoatrial node development. In
several embodiments, the one or more transcription factors promote
de novo cellular differentiation into sinoatrial nodal cells. In
still additional embodiments, the one or more transcription factors
not only regulate embryonic sinoatrial node development but also
promote de novo cellular differentiation of precursor cells into
sinoatrial nodal cells. In further embodiments, the one or more
transcription factors provide a positive or negative regulatory
input on such development or differentiation pathways. In several
embodiments, the one or more transcription factors define the sinus
venosus during cardiac development. In some embodiments, the one or
more transcription factors are negative regulators of Nkx2.5 in the
sinus venosus (or other regions of the developing heart). For
example, the one or more transcription factors may negatively
regulate a pathway in which Nkx2.5 signaling is involved. Further,
the one more transcription factors may negatively regulate the
expression (either at the RNA or protein level) of Nkx2.5.
Moreover, the one or more transcription factors may indirectly
regulate Nkx2.5, or a signaling pathway related thereto (e.g., the
one or more transcription factors regulate a pathway that
thereafter negatively regulates Nkx2.5).
[0037] In several embodiments, the one or more transcription
factors is selected from the group consisting of Tbx18, Shox2,
Tbx3, Tbx5 or combinations thereof. In several embodiments,
variants of Tbx18, Shox2, Tbx3, Tbx5 are used alone or in
combination. In some embodiments, functional fragments of Tbx18,
Shox2, Tbx3, Tbx5 are used either alone or in combination. In
additional embodiments, related family members of these
transcription factors may also be used. In some embodiments, human
transcription factors are used, while in other embodiments homologs
from different species are used (either in place of or in
conjunction with the human transcription factor(s)). In further
embodiments, additional transcription factors, proteins, biologic
molecules, or pharmacological agents are administered prior to,
concurrently with, or subsequently to the one or more transcription
factors in order to enhance the effect of the one or more
transcription factors in generation of a biological pacemaker or
conversion of stem cells. In some embodiments, for example, a
traditional pharmacological agent that is used to treat cardiac
arrhythmia is administered concurrently with the one or more
transcription factors in order to provide a short-term bridge to
allow the generated biological pacemaker to take full functional
effect in a subject. In several embodiments, the one or more
transcription factors comprises Tbx18 while in some embodiments,
the one or more transcription factors comprises Shox-2. In still
additional embodiments, Tbx18 and Shox2 are both used. However, in
some embodiments, these two transcription factors are administered
at discrete time frames (that optionally overlap in some
embodiments). Additionally, Tbx18 and Shox2, are administered
separately in some embodiments (e.g., different delivery systems
are used). In several embodiments, a functional fragment of one
transcription factor is used in conjunction with one (or more) full
length transcription factors. In still additional embodiments,
combinations of functional fragments of transcription factors are
used.
[0038] In some embodiments, administration of the one or more
transcription factors comprises administration of a DNA delivery
system comprising a polynucleotide encoding the one or more
transcription factors. In several embodiments, the DNA delivery
system comprises a viral vector. A variety of different viral
vectors are used, depending on the embodiment, based on the
transcription factor(s) to be delivered, the size of the
polynucleotide(s), the route of administration, and the general
health status of the patient, among other variables. In some
embodiments, the viral vector is selected from the group consisting
of adenovirus, adeno-associated virus, lentivirus, retrovirus, HJV,
HIV, and HSV. As discussed above, more than a single transcription
factor is administered in certain embodiments. In some embodiments,
each of the transcription factors delivered is delivered in the
same type of virus. In some embodiments, however, a first
transcription factor is delivered in a first type of virus, while a
second transcription factor is delivered in a second type of virus.
In this manner, a desired expression profile of each of the
transcription factors can be generated based on the characteristics
of the virus chosen (e.g., the time from infection with the virus
to expression of the transgene carried by the virus). For example,
certain viruses provide longer-term expression of the
polynucleotides that they carry as compared to other viruses. In
still other embodiments, more than one viral vector can be used to
deliver a single transcription factor.
[0039] Alternatively, in several embodiments, the DNA delivery
system comprises a non-viral vector. Non-viral vectors, in some
embodiments, are selected from liposomal vectors, cationic
polymers, and/or DNA binding polymers. In additional embodiments
naked DNA encoding the one or more transcription factors is
delivered. In still additional embodiments wherein more than one
transcription factor is administered, a combination of viral and
non-viral delivery systems may be used.
[0040] In several embodiments, the methods disclosed herein result
in the generation of cells that exhibit spontaneous, repetitive,
electrical activity. In some embodiments that spontaneous,
repetitive, electrical activity is between about 50% to about 100%
of the normal activity of healthy pacemaker cells. In some
embodiments, a biological pacemaker can be generated even when the
generated cells exhibit spontaneous, repetitive, electrical
activity that is between about 5% to about 50% of the normal
activity of healthy pacemaker cells. Thus, the methods disclosed
herein are suitable for generating a biological pacemaker when the
generated cells exhibit spontaneous, repetitive, electrical
activity between about 5% to about 15%, about 15% to about 25%,
about 25% to about 35%, about 35% to about 45%, about 45% to about
55%, about 55% to about 65%, about 65% to about 75%, about 75% to
about 85%, about 85% to about 95%, or about 95% to about 100% of
the normal activity of healthy pacemaker cells. In several
embodiments, the generated cells exhibit spontaneous, repetitive,
electrical activity of greater than 100% of the normal activity of
healthy pacemaker cells.
[0041] In addition to changing the electrical activity of the
target cells, in several embodiments administration of one or more
transcription factors (or cells converted into biological pacemaker
cells) causes a subsequent change in the rhythm of the heart. In
several embodiments, the resultant heart rhythm is within about 5%
to about 15%, about 15% to about 25%, about 25% to about 35%, about
35% to about 45%, about 45% to about 55%, about 55% to about 65%,
about 65% to about 75%, about 75% to about 85%, about 85% to about
95%, or about 95% to about 100% of normal heart rhythm (taking into
account the age and health history of a particular patient). In
several embodiments, increases in heart rhythm of greater than 100%
are achieved.
[0042] In several embodiments, the administration of one or more
transcription factors (or cells converted into biological pacemaker
cells) is to a subject having an implanted electronic pacemaker. In
some embodiments, the generation of a biological pacemaker due to
set administration reduces the dependence of the subject on the
implanted electronic pacemaker. In some embodiments, generation of
the biological pacemaker is for the purpose of providing a bridge
therapy during which time all or a portion of the electronic
pacemaker can be replaced (e.g., if a portion of the electronic
pacemaker has become infected). In still additional embodiments,
the generation of a biological pacemaker obviates the need for an
implanted electronic pacemaker, and as such, the implanted
electronic pacemaker can be permanently removed from the subject.
In further embodiments, an electronic pacemaker may be implanted in
conjunction with administration of one or more transcription
factors (or converted biological pacemaker cells) such that
reliance on the electronic pacemaker is reduced.
[0043] Multiple routes of administration may optionally be used,
depending on the embodiment. Various factors determine what target
site will be used including, but not limited to, where healthy
tissue is available to generate a biological pacemaker, if the
methods disclosed herein are to be used to re-functionalize a
malfunctioning pacemaker cell, if one or more transcription factors
are to be administered or if converted cells are to be
administered. In some embodiments, administration is into the apex
of the heart. In some embodiments, administration is to the
inter-ventricular septum. In some embodiments, administration is to
the right ventricular free wall. In some embodiments,
administration is to the left ventricular free wall. In some
embodiments, administration is via the right ventricle. In some
embodiments, administration is via the right atrium. In several
such embodiments, a right-sided approach advantageously reduces the
risk of embolism and/or stroke. In some embodiments, administration
is made via more than one of the above routes, either concurrently
or at different times.
[0044] As discussed above, in some embodiments, the methods
disclosed herein are used to restore (either partially or fully)
the function of an existing pacemaker cell, or a cell within the
cardiac conduction system. In some embodiments, administration is
to the right or left branch of the Bundle of His. In some
embodiments, administration is to the Purkinje fibers. In still
additional embodiments, administration is to the SA node and/or to
the AV node.
[0045] In certain embodiments wherein converted cells are
delivered, intravenous administration is used. In some embodiments,
intra-coronary administration is used.
[0046] Depending on the circumstance, in some embodiments
administration (of one or more transcription factors or of
converted biological pacemaker cells) is made by accessing the
heart directly (e.g., injection during removal of an electronic
pacemaker). In some embodiments, a catheter is used for
administration. In some embodiments, the catheter comprises a map
guided catheter injection system. In some embodiments, fluoroscopy
guidance is used to guide a catheter (or other administration
system) to the target tissue within the heart. In some embodiments,
x-ray guidance is used. Echocardiography guidance is used in
additional embodiments as well as magnetic resonance imaging, in
certain embodiments. In some embodiments, more than one of the
above modes of guidance vehicles are used concurrently or at
different times during administration.
[0047] In addition to the methods disclosed above, there is also
provided herein a composition for the generation of a biological
pacemaker comprising a DNA delivery system, the system comprising a
viral vector encoding Tbx18, Shox2, or combinations thereof, and a
eukaryotic promoter. In one embodiment, the viral vector is an
adenoviral vector however, as discussed above a variety of
different viral vectors may also be used, depending on the
embodiment. In several embodiments, the adenoviral vector further
comprises the following operably linked components in sequence: a
first inverted terminal repeat sequence (ITR), a first lox P site,
a packaging site (V, psi), a cytomeglovirus promoter, a sequence
encoding Tbx18, Shox2, or combinations thereof, an internal
ribosome entry site (IRES), a polyadenylation signal (An), a second
lox P site, a sequence encoding the adenovirus early region 2 and
early region 4 genes, and a second inverted repeat sequence
(ITR).
[0048] In several embodiments, the dose of a viral construct to be
administered is based on plaque-forming units, which is a
well-established unit of measurement in the viral arts. In some
embodiments, a dose of between about 1.times.10.sup.8 and
1.times.10.sup.10 pfu (in volumes ranging from 50 to 200
microliters) are used. With respect to delivery of cells converted
to be biological pacemaker cells, doses of cells range between
1.times.10.sup.5 and 1.times.10.sup.8 cells. Higher or lower doses
may be used, depending (among other factors) on the severity of
cardiac arrhythmia in the subject, the presence or absence of an
electronic pacemaker, and/or the size of the heart of the
subject.
[0049] Also provided for herein is a population of cells for the
generation of a biological pacemaker comprising a plurality of stem
cells, wherein the stem cells have been contacted with one or more
transcription factors selected from the group consisting of Tbx18,
Shox2, and combinations thereof, wherein the one or more
transcription factors induce an increase in the spontaneous,
repetitive electrical activity of the cells, wherein the increase
in the spontaneous, repetitive electrical activity of the cells
generates spontaneous, repetitive ectopic contractions, and wherein
the stem cells are suitable for administration to a subject in need
of biological pacemaker function.
[0050] In several embodiments, the stem cells are selected from the
group consisting of embryonic stem cells, non-embryonic stem cells,
bone marrow-derived stem cells, adipose-derived stem cells, induced
pluripotent stem cells, and cardiac stem cells. In one embodiment,
the population of cells comprises harvested adult cardiac stem
cells that have been converted to cells with the biological
pacemaker phenotype.
[0051] Also provided for herein is the use of one or more
transcription factors selected from the group consisting of Tbx18
and Shox2 to convert quiescent cells that do not exhibit
spontaneous, repetitive electrical activity into pacemaker cells
that exhibit spontaneous, repetitive electrical activity.
BRIEF DESCRIPTION OF THE DRAWINGS
[0052] FIGS. 1A-1B depict the immunohistochemistry of neonatal
(FIG. 1A) and adult (FIG. 1B) rat heart SAN cells. The SAN is
demarcated by HCN4 co-staining and separated from the surrounding
atria. Scale bar: 50 .mu.m.
[0053] FIGS. 2A-2I depict the effects of Tbx18 transduction into
neonatal rat ventricular myocytes (NRVM). FIG. 2A depicts a
significant increase in the number of spontaneously beating NRVM
cultures. Each "n" represents one well of a 24-well plate.
[0054] FIG. 2B shows representative action potential (AP) traces
from GFP- (2B left) and Tbx18-NRVMs (2B right). FIG. 2C depicts the
maximum diastolic potential (left), index of automaticity (center),
and the total cell number (right) of spontaneously-oscillating
Ca.sup.++ transients are summarized. FIG. 2D depicts representative
I.sub.K1 raw traces on the left and the summarized I.sub.K1
densities at -140 mV are on the right. FIG. 2E depicts HCN4
immunostaining (HCN4-white, nuclei-blue) in GFP- (left) or
Tbx18-NRVMs (middle). Summary data are shown on the right. FIG. 2F
(left) depicts that Tbx18 transduction leads to a 3.8-fold increase
in the number of NVRMs expressing HCN4 while 2F (right) depicts a
1.4-fold increase in HCN4 protein levels in Tbx18-NVRMs. FIG. 2G
depicts that Tbx18-transduced cells exhibited f at a density
(-5.2.+-.1.3 pA/pF at -140 mV, n=3) consistent with that reported
in rabbit SAN cells. FIG. 2H and FIG. 2I depict the changes of
relative mRNA levels of selected genes comparing Tbx18-NRVMs
normalized to GFP-NRVMs (left) and SAN normalized to LV (right).
SAN and Tbx18-NRVMs demonstrate similar pattern of normalized
transcript levels.
[0055] FIGS. 3A-3J depict the effects of Tbx18 expression on
various aspects of cardiac calcium signaling in NRVMs. FIG. 3A
depicts line-scan confocal imaging of Tbx18-NRVMs resolved
localized Ca.sup.2+ release events (LCRs) preceding each whole-cell
Ca.sup.2+ transient (n=8 out of 10 cells), recapitulating the LCRs
observed in native SAN pacemakers.
[0056] FIG. 3B depicts LCRs in control cells. Occasional
randomly-distributed sparks were observed. FIG. 3C depicts that
LCRs had an average period of 72.+-.1% of that of the cycle length.
FIG. 3D depicts spatially averaged dF/F.sub.0 plots of changes in
Ca.sup.2+ concentration which depict a 2.3 fold increase in the
caffeine (20 mM) induced Ca.sup.2+ transients in the Tbx18-NRVMs
compared to the controls. FIG. 3E depicts the spontaneous Ca.sup.2+
transients were suppressed by 47.+-.6% on superfusion with the RyR
blocker, ryanodine (10 .mu.M) in Tbx18-NRVMs in comparison to only
12.+-.2% suppression in controls. FIG. 3F depicts Western blot
experiments demonstrated a decrease in the total PLB levels and an
increase in phosphorylated PLB (sel6) akin to the adult rat SAN.
FIG. 3G indicates that no changes in the protein levels of SERCA2A,
NCXI and RyR were observed in the Tbx18-NRVMs in comparison to the
controls. The relative p-PLB (Ser16) level was 65-fold higher in
Tbx18-NRVMs in comparison to GFP-NRVMs (FIG. 3F, left panel),
mimicking the augmentation of pPLN found in the SAN compared to
that in the ventricular myocardium (FIG. 3F, right panel).
Differences in the protein levels of SERCA2a, NCXl and ryanodine
receptor (RyR) were not detectable between Thx18- and GFP-NRVMs
(FIG. 3G), consistent with findings in the rabbit SAN versus left
ventricle. FIG. 3H depicts data related to the intracellular cAMP
levels in GFP-NVRMs (open bars) and Tbx18-NVRMs (hatched bars).
Intracellular cAMP levels were significantly higher in Tbx18-NRVMs
compared to GFP-NRVMs, which mimics the increase known to exist
between the rabbit SAN compared to ventricular myocardium. FIG. 3I
depicts data related to Ca.sup.2+ transients in GFP- or Tbx18
NVRMs. Application of the PKA inhibitor (PKI, 15 .mu.M) led to
cessation of spontaneous whole-cell Ca.sup.2+ transients in
Tbx-NRVMs, but had no effect on GFP-NRVMs. FIG. 3J indicates LCRs
from Tbx18-NRVMs are longer and wider than spontaneous Ca.sup.2+
release events from GFP-NRVMs, measured as full width at
half-maximal duration (FWHD, left panel) and full duration at
half-maximal width (FDHW, left panel) and. Amplitudes of the
Ca.sup.2+ signals (measured in arbitrary units of F/F.sub.0, right
panel) are similar between the two groups.
[0057] FIGS. 4A-4C depict data related to the expression of various
cardiac proteins, function and channel expression after Tbx-18
transduction. FIG. 4A depicts neonatal rat SANs, demarcated by HCN4
expression (top middle), that exhibit weaker and unstructured
sarcomeric .alpha.-actinin (.alpha.-SA) expression (top panel).
Bottom left: Zoom-in image of the boxed area in top left. FIG. 4B
indicates a 28% reduction in cell area and a 33% reduction (left
and right, respectively) in Tbx18-NRVMs membrane capacitance
compared to control. FIG. 4C: tri-methylation level on H3K27 (left)
indicates that Tbx18 increased the inactivity of Cx43, Kir2.1, and
.alpha.-SA promoters while relieving its repressive epigenetic
pressure on HCN4 promoter normalized to control. H3K4me3 levels
(right) indicate that ratio of active HCN4 promoter regions
increased upon Tbx18 expression while the transcriptionally active
promoter regions of Cx43, Kir2.1, and .alpha.-SA have decreased
upon Tbx18 expression.
[0058] FIGS. 5A-5H depict investigations of genes and cell markers
characteristic of the fetal heart. The data supports Tbx18-induced
specific re-engineering rather than dedifferentiation to an
embryonic/fetal state. FIG. 5A and FIG. 5B depict the expression of
atrial natriuretic peptide (ANP) in NRVMs induced by 24-hour
stimulation with endothelin-I (100 nM). ANP expression was
suppressed by Tbx18 expression (FIG. 5B, bottom panel) while GFP
had no effect (FIG. 5A, bottom panel). FIG. 5C depicts the
expression of skeletal .alpha.-actin (.alpha.SkA) in Tbx18-NRVMs.
FIG. 5D depicts expression of phosphohistone 3 (H3P, a
mitotically-active cell marker) and incorporation of EdU (an analog
of BrdU, a marker for mitosis and nascent DNA synthesis) in GFP-
and Tbx18-NRVMs (n=3). Immunohistochemical data are shown in the
top panels and summary data in the corresponding lower panels.
Expression and incorporation of these markers in Tbx18- and
GFP-NRVMs is comparable, supporting the conclusion that the
Tbx18-NRVMs did not dedifferentiate to an embryonic/fetal state.
FIG. 5E and FIG. 5G indicate the existence of only minor global
differences between Tbx18- and GFP-NRVMs in a comparison of
expression of 84 genes related to chromatin remodeling. FIG. 5F and
FIG. 5H show a similar comparison between iPS cells and their
parental fibroblasts.
[0059] FIGS. 6A-6B depict data related to ventricular ectopic
beats. FIG. 6A indicates that the focal expression of Tbx18 in the
apex of guinea pig hearts in vivo created ectopic ventricular beats
(right panel) as compared to GFP (left panel). FIG. 6B indicates
that the rate of ectopic ventricular beats in Tbx18-injected
animals at day 3-5 after gene delivery is significantly higher than
the control.
[0060] FIGS. 7A-7D indicate that the focal expression of Tbx18
(FIG. 7A) in the apex of guinea pig hearts in in vivo created
ectopic ventricular beats (as compared to GFP controls (FIG. 7B)).
These data are also represented in EKG traces from TBX18 animals
(FIG. 7C) and GFP controls (FIG. 7D).
[0061] FIG. 8 depicts a Tbx18-injected adult guinea pig heart where
a single myocyte is isolated five days after injection. The induced
SAN pacemaker cells are created by Tbx18 somatic reprogramming
(lower right panel).
[0062] FIGS. 9A-9G depict various characteristics of
Tbx18-transduced ventricular myocytes and GFP-ventricular myocytes
(VM). FIG. 9A depicts a Tbx18-transduced induced SAN (iSAN) cell
(GFP-positive cell, top photographs) versus a native cell (bottom).
FIG. 9B depicts SAN myocytes compared to Tbx18-VMs and GFP-VMs. The
upper panels are bright field images, while the lower fields are
fluorescent images. Immunostaining against .alpha.-SA revealed
disorganized myofibrillar structure in Tbx18-VMs similar to that of
native SAN myocytes. FIG. 9C depicts representative bight field
images of freshly-isolated, living SAN myocytes, Tbx18-VMs
(reported by GFP expression), and GFP-VMs (top panels) and
immunostained, fixed myocytes (lower panels). FIG. 9D depicts an
analysis of myocyte length-to-width ratio and whole-cell
capacitance as measures of cell shape and size from
freshly-isolated, living myocytes. Tbx18-VMs are smaller in size
and spindle-shaped compared to GFP-VMs (n=53 for Tbx18-VMs and 80
for GFB-VMs and non-transduced VMs, p<0.01), but are similar to
native SAN myocytes (n=24). FIG. 9E depicts spontaneous action
potentials recorded from freshly-isolated single Tbx18-VMs (n=5,
middle panels) using a perforated-patch current-clamp technique.
These data indicate that Tbx18 display robust and rhythmic APs with
prominent diastolic depolarization, similar to the native SAN
myocytes (left panels). The same recordings are expanded in the
lower panels to show prominent diastolic depolarization in
Tbx18-VMs and native SAN myocytes. The right panels depicts GFP-VMs
displaying a stable resting membrane potential and firing a single
action potential only upon electrical stimulation. FIG. 9F
indicates the action potential parameters of Tbx18-VMs (n=5) were
closer to native SAN myocytes (n=6) than to GFP-VMs (n=6). FIG. 9G
depicts length-to-width ratio of Tbx18-VMs at 1 week, 3 weeks, and
6 weeks, compared to native SAN myocytes, GFP-VMs at 1 week, and a
no-virus control.
[0063] FIGS. 10A-10D depict data related to sternness of Tbx-18
transduced cells. FIG. 10A and FIG. 10B depict scatter plots for
Tbx18-NVRMs vs. GFP-NVRMs and iPS vs. parental fibroblasts (Fibs),
respectively. The scatter plot depicts no discernible changes to
transcripts levels related to sternness in Tbx18-NRVMs compared to
control. FIG. 10C and FIG. 10D depict RT-PCR array of 84 gene
transcripts related to related to the identification, growth and
differentiation of stem cells.
[0064] FIG. 11A depicts a schematic of the cells derived from the
growth of embryoid bodies (EB). FIG. 11B depicts a schematic for
embryoid body (EB) EB growth. On day 3 the hanging EBs were
cultivated in suspension. On day 6 the EBs were plated in tissue
culture plates.
[0065] FIGS. 12A-12B depict endogenous expression of Tbx18 (FIG.
12A) and Tbx3 (FIG. 12B) relative to control murine embryonic stem
cells (mESCs) during the growth of EBs.
[0066] FIG. 13A depicts a treatment schedule of cells with Shox2.
Treatment with vectors carrying the Shox2 gene occur at day three
(in this general scheme), then twice at day 6. FIG. 13B depicts
endogenous Shox2 mRNA expression at differing time points after
transduction.
[0067] FIG. 14A depicts the percentage of beating EBs that were
transduced with Shox2 relative to a control that was treated only
with GFP. FIG. 14B depicts the number of beating foci per beating
EB.
[0068] FIG. 15A depicts the increase in HCN4 mRNA expression for
cells treated with Shox2 expression factors relative to cells
treated with GFP. FIG. 15B shows the Western Blot analysis for the
corresponding time points in FIG. 15A.
[0069] FIG. 16A-16B depict the HCN4 co-expression with troponin I
in Shox2 transduced mESCs-derived cardiomyocytes (FIG. 16B) as
compared to GFP controls (FIG. 16A).
[0070] FIG. 17A-17B depict the NCX1 mRNA (FIG. 17A) and protein
levels (FIG. 17B) in Shox2 transduced cells versus a GFP control at
day 6+7 (post transduction).
[0071] FIG. 18A-18B depict the NCX1 mRNA (FIG. 18A) and protein
levels (FIG. 18B) in Shox2 transduced cells versus a GFP control at
day 6+14 (post transduction).
[0072] FIG. 19A-19B depict the Cx45 mRNA (FIG. 19A) and protein
levels (FIG. 19B) in Shox2 transduced cells versus a GFP control at
day 6+14 (post transduction).
[0073] FIG. 20A-20B depict the Cx43 mRNA (FIG. 20A) and protein
levels (FIG. 20B) in Shox2 transduced cells versus a GFP control at
day 6+14 (post transduction).
[0074] FIG. 21A depicts the Cx43 mRNA fold change in Shox2
transduced cells versus a GFP control. FIG. 21B depicts the Cx45
mRNA fold change in Shox2 transduced cells versus a GFP
control.
[0075] FIG. 22 depicts HCN4 and Cx45 expression in Shox2 transduced
mESCs-derived cardiomyocytes.
[0076] FIG. 23A shows that endogenous mouse Shox2 mRNA is
upregulated in respect to transduction of ESC-derived
cardiomyocytes with exogenous Shox2. FIG. 23B shows endogenous
human Shox2 mRNA is upregulated in respect to transduction of
ESC-derived cardiomyocytes with exogenous Shox2.
[0077] FIG. 24A shows Tbx18 mRNA levels relative to
hydroxymethylbilane synthase (HMBS). FIG. 24B shows Tbx3 mRNA
levels relative to HMBS.
[0078] FIGS. 25A-25G indicate de novo automaticity in response to
autonomic regulation. FIG. 25A depicts the layout of the 6-well
multi-electrode array (MEA, left panel) and a representative image
of NRVMs cultured as a monolayer on such a well. FIG. 25B depicts
the average firing rates recorded from the MEAs demonstrating a
significantly faster baseline chronotropy in Tbx18-NRVMs compared
to that in control. Firing rates of Tbx18-NRVMs increased
significantly upon .beta.-adrenergic stimulation by changing the
basal media with one containing 1 .mu.M isoproterenol (ISO).
Subsequent cholinergic challenge with 1 .mu.M acetylcholine (ACh)
significantly slowed the firing rates of Tbx18-NRVMs. In contrast,
the chronotropy of GFP-NRVMs responded little to the autonomic
inputs. FIG. 25C depicts representative raw traces from an
electrode of a 6-well MEA plated with Tbx18-NRVMs.
[0079] FIG. 25D depicts immunostaining on Tbx18-NRVMs (GFP.sup.+
cells), demonstrating robust expression of .beta.-adrenergic
receptors and M2 muscarinic receptors. FIG. 25E and FIG. 25G depict
electrocardiographic recordings of an intact perfused heart
injected with Tbx18 at the apex, in vivo. As discussed below, other
sites of administration are used, depending on the embodiment.
Seven days post-injection, the heart was harvested, perfused, and
cryoablated at the AV junctional region. The polarity and
morphology of the ectopic beats (FIG. 25E, left panel) is identical
to those of electrode-paced beats at the site of transgene
injection (FIG. 25E, right panel). In contrast, most control hearts
(7/10) showed a narrow-QRS junctional escape rhythm (FIG. 25F, left
panel), which were opposite in polarity and morphology to those of
electrode-paced beats at the apex (FIG. 25F, right panel). FIG. 25G
indicates the chronotropic response of Tbx18-injected hearts to
autonomic inputs, assessed by changing the perfusate (normal
Tyrode's solution) to one containing 1 .mu.M isoproterenol for
0-adrenergic stimulation followed by one containing 1 .mu.M
acetylcholine for cholinergic suppression.
[0080] FIGS. 26A-26C depict results of single-cell, quantitative
RT-PCR of long-term Tbx18-VMs. The data indicates persistent
automaticity even after Tbx18 expression had waned. FIG. 26A
depicts Tbx18-transduced ventricular myocytes assayed three days
after in vivo gene transfer to validate the sensitivity of
single-cell transcript detection by RT-qPCR. The data indicates
Tbx18 transcript levels could be reliably detected over a wide
range from very low (2.6% of GAPDH, cell 1) to very high (168% of
GAPDH, cell 8). FIG. 26B depicts RT-qPCR results of VMs freshly
isolated from the guinea pigs 6-8 weeks after the initial in vivo
gene transfer, indicating that the transcript levels of Tbx18 in
spontaneously-beating cells were either small (cells 1 and 2) or
negligible (cells 3 and 4). A Tbx18-Vm with a strong GFP signal
(cell 5) exhibited a larger relative amount of Tbx18. FIG. 26C
depicts a negative control (VMs expressing GFP alone were assayed
for Tbx18).
[0081] FIG. 27A and FIG. 27B depict histological sections from a
Tbx18-injected guinea pig heart, indicating strong and focal Tbx18
transduction in the injection region.
[0082] FIG. 28A and FIG. 28B depict the placement of leads for ex
vivo intact whole-heart ECG recordings. The heart was
retrograde-perfused via aorta at 60 mmHg with oxygenated Tyrode's
solution at 36.degree. C. The perfused heart was placed in a
sylgard-coated plate filled with warm Tyrode's solution. ECG leads
were stationed at appropriate sites to record leads I and II.
[0083] FIGS. 29A-29C depict electrocardiograms of Tbx18-injected
hearts three to four weeks after gene transfer. FIG. 29A indicates
an ectopic idioventricular rhythm at 165.+-.14 bpm (n=3/3). FIG.
29B depicts electrocardiograms consistent with biological pacing
from the Tbx18 injection site. FIG. 29C indicates the hearts
responded to autonomic regulation in a manner similar to the
short-term, Tbx18-injected hearts (FIG. 25G).
[0084] FIG. 30A and FIG. 30B depict results of real-time PCR to
examine Tbx18 mRNA levels in individual myocytes. Standard curves
for each of the 3 primer sets were constructed with serial
dilutions of input DNA templates and validated comparable
amplification efficiencies (curve slopes: -3.32 to -3.64). Relative
mRNA levels of human Tbx18, guinea pig GAPDH, and guinea pig TnnT2
were obtained by extrapolation of Ct values with the slopes of the
standard curve for each primer sets. Tbx18 mRNA amount in each cell
was then normalized to GAPDH or TnnT2 level.
DETAILED DESCRIPTION
Background
Abnormalities of Excitable Tissue
[0085] Cardiac arrhythmias belong to a heterogeneous group of
conditions in which there is abnormal electrical activity in the
heart. As the result of an arrhythmia, heart rate may be too fast,
too slow and/or may be regular or irregular. Normal electrical
activity in the heart results from an electrical impulse that
originates from the right atrium of the heart, in particular the
sinus node (also referred to as the sino-atrial node, the SA node
and/or SAN). This impulse induces contraction of both atria. The
impulse then passes through the atrioventricular (or AV) node and
through both ventricles via the Bundle of His and the Purkinje
fibers. The result is a synchronized contraction of the heart
muscle, and thus, blood flow. Normal adult heart rates range from
60 to 80 beats per minute, while the resting heart rate in children
is typically much faster.
[0086] Bradycardias (HR of <60 bpm) have multiple possible
etiologies, namely slowed signals from the sinus node (sinus
bradycardia), pauses in the normal activity of the sinus node
(sinus arrest), or blockages of the electrical impulse from the
atria to the ventricles (AV block). Tachycardias (resting HR of
>100 bpm) may cause mere palpitations (a subject becomes
abnormally aware their heart beat) and may simply be the result of
sympathetic nervous system stimulation of the sinus node (known as
sinus tachycardia), for example during exercise or physical stress.
Tachycardia that is not sinus tachycardia may result from abnormal
impulses in addition to the normal cardiac cycle. Abnormal impulses
can begin by one of three mechanisms: automaticity, reentry or
triggered activity.
[0087] Certain cardiac tissues are capable of initiating an
electrical impulse on their own, which is known as automaticity.
Normally, such automatic cells are located in the conduction system
of the heart (the SA node, AV node, Bundle of His and Purkinje
fibers). The sinoatrial node is a single specialized location in
the atrium which has a higher automaticity (a faster pacemaker)
than the rest of the heart, and therefore is usually responsible
for setting the heart rate, and initiating each heartbeat.
[0088] Re-entry arrhythmias occur when an electrical impulse
recurrently circulates through a small region of the heart, rather
than propagating from the atria to the ventricles. If conduction is
abnormally slow in some areas of the heart, for example due to
damaged or diseased cardiac tissue, impulse propagation times will
vary, and certain impulses may potentially be treated as an
entirely new impulse. Such disjointed impulse propagation can
produce sustained abnormal circuit rhythms, which are responsible
for atrial flutter, most paroxysmal supraventricular tachycardia,
and dangerous ventricular tachycardia.
[0089] When an entire chamber of the heart has multiple reentry
circuits, the chamber is considered to be in fibrillation, and
quivers due to the chaotic electrical stimulation, rather than
smoothly contracting and delivering blood. The lack of smooth and
sustained blood and chaotic contraction can result in cardiogenic
shock, cessation of effective blood circulation, and sudden cardiac
death. Fibrillation can affect the atrium (atrial fibrillation) or
the ventricle (ventricular fibrillation); ventricular fibrillation
is imminently life-threatening.
Conventional Treatments for Abnormalities of Excitable Tissue
[0090] Traditional arrhythmia treatments include pharmacological
therapy, electronic pacemakers, implantable
cardioverter-defibrillators (ICDs), ablation, and combinations
thereof. While these traditional treatments have been used in the
past to treat various types of cardiac arrhythmias, these
approaches have several shortcomings. Implanted pacemakers and ICDs
may cause complications from device implantation, malfunction or
hardware infection. Pharmacological therapies may not be tolerated
well in some patients, and have the capacity to induce additional
arrhythmias during treatment. Thus, there is a need for
alternatives or supplements to pharmacological therapies and
implantable devices to modulate cardiac contractility and/or
conductance.
[0091] There exist various approaches to generation of biological
pacemakers that are distinct from those disclosed herein, in that
several such methods employ delivery of ion channels, or subunits
of ion channels to cardiac cells. In particular, dominant negative
ion channels (or subunits thereof) have been investigated.
Generally, as a result of expression of a dominant negative ion
channel in cardiac cells, the ionic current across the cell
membrane is altered, thereby resulting in pacemaker-like firing in
these cells. Such methods generally rely on the delivery of genes
that effectively manipulate the function of the treated cells by
altering the ability of the cell with respect to conduction of
certain ions. In other words, such approaches typically take the
existing cell, and augment or alter its existing structures (e.g.,
ion channels) to change its function.
[0092] In contrast, several embodiments of the invention result in
quiescent cells that are reprogrammed to become biological
pacemaker cells. Several embodiments of the invention are
particularly advantageous because the reprogramming of quiescent
cells converts cells to their natural state, rather than treating
cells with genetic sequences that did not exist naturally in the
cell make-up. For example, several embodiments are advantageous
because the reprogramming of the quiescent cells with transcription
factors (e.g., not with ion channels) reduces the risk of induced
abnormalities in the reprogrammed cell. In some embodiments, the
transcription factors are less bulky (e.g., smaller genetic
sequences can be used) which reduces logistical complications and
opens up additional delivery options. Some embodiments of the
invention are particularly beneficial because, by converting a cell
to a natural (or native) pacemaker state, that cell will have a
higher likelihood of success in generating and maintaining an
appropriate pacemaker rhythm with reduced possibilities of side
effects that may occur with other approaches (e.g., induction of
arrhythmias due to the treatment itself). Further, several
embodiments of the invention are beneficial in that they reduce the
need for "fine-tuning" of the desired effect (e.g., requiring
increased dose or number of treatments to achieve a particular
result) as the conversion of the cells to a natural pacemaker-state
enables the cells to operate at naturally defined, and therefore
balanced, frequencies. As a result, several embodiments of the
methods require fewer administrations (or doses) of the
compositions in order to achieve conversion of a sufficient number
of cells to generate a new pacemaker in the heart. Thus, in several
embodiments, the methods disclosed herein may be less invasive to a
patient, requiring fewer administration procedures, thereby
presenting fewer risks to the patient and lowering morbidity due to
the therapy itself.
[0093] Moreover, several embodiments of the methods disclosed
herein are advantageous in that they do not rely on modification
(by "non-native" sequences) of existing complex functional units of
cardiac cells (e.g., the ion channels), rather, the conversion of
the cells to a pacemaker state results in the generation of a
complete complement of functional endogenous pacemaker channels.
The reduced requirement for modification of existing channels
reduces the likelihood that adverse results occur (e.g.,
mis-formation of channels or formation of channels that produce a
greater or lesser impact on function than anticipated).
[0094] Additionally, several embodiments advantageously reduce the
risk of unwanted side effects due to unbalanced electrical activity
in the cells, as the cells converted to pacemakers by the methods
herein have a complete and functionally balanced complement of
ionic currents (and hence electrical activity), rather than cells
having had a single current that was been exogenously
manipulated.
[0095] As disclosed herein, the delivery of transcription factors
involved in the early natural development of pacemaker cells (whose
expression is reduced after development is complete) can
unexpectedly reprogram non-pacemaker cells into pacemaker cells.
These approaches are unexpected because the general view of cardiac
cells is that they are terminally differentiated (e.g., once a
contractile cell, always a contractile cell). However, several
embodiments of the present methods allow the reprogramming of these
cells, without direct exogenous alteration of their ion channels.
Thus, rather than manipulating the functional units (ion channels)
of the non-pacemaker cells, several embodiments of the methods
disclosed herein change the functional fate and functional identity
of the cells into pacemaker cells. As such, several embodiments of
the methods and compositions disclosed herein result in the
generation of a reprogrammed biological pacemaker, which lessens or
obviates the need for such traditional pharmacological therapies,
ablation, or artificial pacemakers.
Transcription Factors to Generate Biological Pacemakers
[0096] The use of transcription factor based biological pacemakers
reduces and/or obviates the need for traditional arrhythmia
therapies. In several embodiments, generation of a biological
pacemaker is used to supplement traditional therapies for
bradycardias or other arrhythmias. In several embodiments,
generation of a biological pacemaker reduces dependence (e.g.,
patients are weaned from) on traditional therapies. In several
embodiments, cardiac arrhythmias are treated by generating a
biological pacemaker that drives the heart at a normal or
substantially normal rhythm that was not possible when a subject
was untreated or when treated with a non-biological therapy (e.g.,
pharmaceutical or electronic pacemaker therapy). In several
embodiments, generation of a biological pacemaker is used as a
bridge therapy (e.g., for patients with cardiac damage sufficient
to necessitate a transplant).
[0097] In several embodiments, the generation of a biological
pacemaker comprises inducing the conversion of quiescent cardiac
cells into pacemaker cells by transfer of transcription factors to
cells (transfer can occur, for example, through the use of gene
delivery techniques used to deliver polynucleotides that encode one
or more of the transcription factors disclosed herein). As used
herein the term "quiescent cardiac cells" shall be given its
ordinary meaning and shall also refer to cardiac cells that exhibit
no, little, or an inappropriate firing rate and/or cardiac cells
are not spontaneously active. It shall be appreciated that
identification of quiescent cardiac cells depends, in some
embodiments, on the cell type being targeted. For example,
ventricular and/or atrial myocardium normally responds to
electrical signals generated by pacemaker cells, and thus typically
has lower spontaneous firing rates as compared to normal pacemaker
cells. Thus, if targeting the ventricular and/or atrial myocardium
quiescent cells having little firing rate comprise, in some
embodiments, cells having less than about 20%, less than about 15%,
or less than about 10% of the spontaneous firing as compared to
normal pacemaker cells. Alternatively, certain embodiments
disclosed herein target a malfunctioning region (or regions) of the
conduction system of the heart. For example, in several embodiments
a malfunctioning region of the sinoatrial node is target, in for
example, sick sinus syndrome. In additional embodiments, the
atrioventricular (AV) node is targeted, for example, in patients
having AV block. In still additional embodiments, the secondary
conduction pathways of the heart (e.g., the His-Purkinje system
and/or Bundle of His) are targeted. In such tissues that normally
exhibit spontaneous repetitive electrical activity, quiescent cells
are those that fire at a reduced rate compared to a normal cell in
that region of the heart, with said reduced rate being insufficient
to maintain an appropriate cardiac firing rate and/or cardiac
output. Thus, quiescent cells, in some embodiments, are recognized
as those cells which, if responsible for driving the electrical
activity of the heart, would do so at a level of electrical firing
that is insufficient to maintain appropriate blood flow throughout
the cardiovascular system (e.g., those cells firing at a
hemodynamically non-sustainable rate).
[0098] In several embodiments, the generation of a biological
pacemaker results from delivery of transcription factors to cardiac
tissue in vivo, resulting in the conversion of quiescent
cardiomyocytes, endogenous cardiac stem cells, or combinations
thereof, to pacemaker cells. In several embodiments, the generation
of a biological pacemaker is performed by delivery of transcription
factors in vitro resulting in the conversion of cultured somatic
cells, cardiomyocytes, stem cells (including embryonic, induced
pluripotent, pluripotent, multipotent, unipotent and/or adult stem
cells), or combinations thereof to pacemaker cells. In several
embodiments, these generated pacemaker cells can subsequently be
implanted in vivo to treat abnormalities of cardiac rhythm.
[0099] In several embodiments, the conversion of somatic cells,
cardiomyocytes, and/or stem cells to pacemaker cells is achieved
using transcription factors that are regulators of embryonic
sinoatrial node (SAN) development. Potential transcription factors
that are regulators of embryonic SAN development include, but are
not limited to: Tbx18, Shox2, Tbx3, and/or Tbx5. Tbx18 is a
transcription factor that is required for embryonic development of
the SAN head area, but, as discussed in more detail below,
typically becomes undetectable by birth and remains undetectable in
adulthood (FIG. 1). Shox2 is a negative regulator of Nkx2.5 in the
sinus venosus. This protein is critical for tissue differentiation.
Further, Shox2-deficient mouse and zebrafish embryos display
bradycardia. Tbx3 is a potent regulator of SAN specialization, with
developmental errors resulting from either deficiency or ectopic
expression. Tbx5, which shows an inverse correlation between its
dosage and abnormal cardiac morphogenesis in Holt-Oram syndrome, is
a positive regulator of Shox2 and Tbx3.
[0100] As described above, several embodiments of biological
pacemaker generation are based on in vivo therapy. In several
embodiments Shox2, Tbx18, or combinations thereof are delivered in
vivo to induce ectopic pacemaker activity in non-pacemaker somatic
cells, cardiomyocytes, endogenous stem cells, or combinations of
the three. In several embodiments other combinations of SAN
regulating transcription factors (or transcription factors that are
related to cardiac development, but not specifically SAN
regulation) can be used with or without Shox2 and Tbx18, or Shox2
and Tbx18 individually to convert cells in vivo to pacemaker cells.
Those other transcription factors include, but are not limited to
Tbx3 and Tbx5. Sequences for Tbx3, Tbx5, Tbx18, Shox2, and variants
thereof are shown in Appendix A, B, C, and D, respectively.
[0101] In several embodiments, Tbx18, Shox2, or a combination of
Tbx-18 and Shox2 are delivered to cardiomyocytes or stem cells in
vitro, which, as discussed below, yields cultured pacemaker cells.
These cells can subsequently be administered to patients as a cell
therapy for biological pacemaker generations. In several
embodiments, administration comprises direct administration of the
cells to the heart of a subject (e.g., injection). Other
administration routes disclosed herein are used. For example, in
some embodiments, catheter-based administration is employed. In
additional embodiments, the generated pacemaker cells are
incorporated into a matrix, graft, or other biomaterial that aids
in cell retention at a target site within the heart. Cells used for
in vitro generation of biological pacemakers, are, in some
embodiments, harvested from healthy tissue of the patient that they
are to be transplanted into (e.g., autologous transplant of induced
pacemaker cells). Then these cells can be converted to pacemaker
cells by transcription factors in vitro and can be reinserted into
the same patient for the treatment of arrhythmias. In other
embodiments, allogeneic transplant of induced pacemaker cells is
performed (e.g., cells are harvested from a first subject, cultured
in vitro, contacted with one or more of the transcription factors
disclosed herein, and then transplanted to a second subject). In
several embodiments other SAN regulating transcription factors or
combinations of such transcription factors are used (e.g.,
transcription factors in addition to or in place of Tbx18, Shox2,
and/or Tbx-18+Shox2) to convert cells in vitro to pacemaker cells.
Those other transcription factors include, but are not limited to
Tbx3 and Tbx5.
[0102] Patients having abnormalities of excitable tissue that may
be treated with the methods disclosed herein include mammals and in
particular humans. Patients include those suffering from or
diagnosed with one or more of the cardiac conditions disclosed
herein or other conditions known in the art to affect cardiac
activity, conductivity, rhythm, and the like.
Gene Delivery Vectors
[0103] Reprogramming cardiomyocytes is accomplished, in several
embodiments disclosed herein by using gene delivery as a means of
delivering exogenous genetic material to somatic cells,
cardiomyocytes, stem cells, or combinations thereof. In several
embodiments, polynucleotides are administered in a nucleic acid
delivery system. In several embodiments, a nucleic acid delivery
system comprises a non-viral vector linked to the polynucleotide.
Examples of such non-viral vectors include the polynucleotide alone
(e.g., naked DNA) or the polynucleotide in combination with a
suitable protein, polysaccharide or lipid formulation.
[0104] In several embodiments, the nucleic acid delivery systems
comprise one or more viral vectors, including but not limited to
adenovirus, adenovirus-associated virus (AAV), helper-dependent
adenovirus, lentivirus, retrovirus, or hemaglutinating virus of
Japan-liposome (HVJ) complex. Various serotypes of adenovirus
and/or AAV are also used in several embodiments. In several
embodiments the viral vector comprises a eukaryotic promoter. In
several embodiments cytomegalovirus (CMV) promoters are used. Other
promoters, including tissue-specific promoters are well-established
in the art and may be used in certain embodiments. Additional
vectors include retroviral vectors such as moloney murine leukemia
viruses and HIV-based viruses. In one embodiment, an HIV-based
viral vector comprises at least two vectors wherein the gag and pol
genes are from an HIV genome and the env gene is from another
virus. DNA viral vectors are used in some embodiments, which
include, but are not limited to pox vectors such as orthopox or
avipox vectors, herpes virus vectors such as a herpes simplex I
virus (HSV) vector.
[0105] In several embodiments, polynucleotides (e.g. those encoding
one or more transcription factors) are administered in vivo and/or
in vitro to convert cells (stem, cardiomyocytes, and/or other
somatic cells) into pacemaker cells. In some embodiments,
polynucleotides that encode a functional fragment of the
transcription factor are delivered in addition to, or in place, of
the entire transcription factor. As used herein, the terms
"fragment", "functional fragment" or similar terms shall be given
their ordinary meaning and shall refer to a portion of an amino
acid sequence (or polynucleotide encoding that sequence) that has
at least about 70%, preferably at least about 80%, more preferably
at least about 90%, 95%, 96%, 97%, 98% or 99% of the function of
the corresponding full-length amino acid sequence (or
polynucleotide encoding that sequence). Methods of detecting and
quantifying functionality of such fragments are established in the
art.
Delivery Methods
[0106] In several embodiments, administration of the compositions
(being transcription factors or cells) disclosed herein to modulate
cardiac electrical activity is via direct cardiac injection (e.g.,
during electronic pacemaker implantation or explantation). In some
embodiments, systemic injection is used. Intracoronary injection is
used in some embodiments. In still additional embodiments,
catheter-directed administration is used. In some embodiments, a
map-guided catheter system (e.g., NOGA.RTM.) is used, in order to
focally administer the compositions. Other mapping or guidance
techniques are used in some embodiments. For example, in several
embodiments fluoroscopy-based guidance is used. Electroanatomical
guidance is also used in some embodiments. Mapping of specific
structures (including but not limited to the His Bundle, the right
or left portions of the bundle, the Purkinje fibers, etc) by
intracardiac electrograms are also used in some embodiments.
Moreover, X-rays or magnetic catheters are also used in some
embodiments to guide delivery of a catheter, needle, or other
delivery device(s) to a desired target location.
[0107] In several embodiments, a focal delivery approach
advantageously reduces the time to generation of an active
biological pacemaker. In some embodiments, the tissue-specific (or
cell type-specific) delivery of several of the constructs disclosed
herein is advantageous in that the construct is particularly suited
for facilitating the generation of a biological pacemaker based on
the expression profile of endogenous tissues. In some such
embodiments, combinations of transcription factors are delivered to
the same target site, while in other embodiments, individual
constructs are delivered to distinct target sites, with the overall
effect resulting in biological pacemaker generation.
[0108] In several embodiments, transduction is achieved by focal
injection into the apex of the heart. In several embodiments,
transduction is achieved by focal injection to the left ventricular
apex. In several embodiments, a right-sided (e.g., right side of
the heart, either atrium or ventricle) approach is used, in order
to reduce the risk of stroke or other embolism. However, in several
embodiments, left-sided approaches are used. In several
embodiments, an injection catheter is introduced via the right
atrium (rather than the right ventricle), in order to access the
Bundle of His or AV node from above. In several embodiments,
trans-septal catheter methods are used to introduce an injection
catheter into the left atrium or left ventricle without the need
for arterial access, thereby reducing stroke risk. In still
additional embodiments, the introduction of an injection catheter
is by way of the cardiac veins via the sinus of Valsalva for
injection of a biologic as disclosed herein into various targets of
the ventricles. Such an approach is similar to that used for the
placement of pacer leads in cardiac resynchronization therapy.
[0109] Thus, in several embodiments, the compositions as disclosed
herein can be used to deliver one or more transcription factors (or
cells that have been previously contacted with the transcription
factors) to either the right atrium, right ventricle, SA node, AV
node, bundle of his, and/or left and right bundle branches.
Moreover, through cannulation of the coronary sinus and its venous
branches delivery to multiple left ventricular sites is achieved in
several embodiments. Advantageously, in those patients with
unfavorable coronary venous anatomy, access to the left side is
achieved, in several embodiments, from the right side through a
trans-septal puncture which allows direct access to left sided
structures without the need of arterial access.
[0110] Supplemental methods are used in several embodiments and
include administration of compounds to increase the microvascular
permeability of the cardiac tissue. Suitable vascular permeability
agents (administered prior to, during, or after administration of a
gene transfer vector) include a solution having less than about 500
micromolar calcium: substance P, histamine, acetylcholine, an
adenosine nucleotide, arachidonic acid, bradykinin, endothelin,
endotoxin, interleukin-2, nitroglycerin, nitric oxide,
nitroprusside, a leukotriene, an oxygen radical, phospholipase,
platelet activating factor, protamine, serotonin, tumor necrosis
factor, vascular endothelial growth factor, a venom, a vasoactive
amine, or a nitric oxide synthase inhibitor, serotonin, vascular
endothelial growth factor (VEGF), or a functional VEGF
fragment.
Biological Pacemaker Effect on Tissues
[0111] In several embodiments, administration of transcription
factors (or cells contacted with those transcription factors in
vitro) disclosed herein induces or otherwise causes the spontaneous
repetitive electrical signals to be generated in cells that
previously responded to such signals, but did not generate them.
For example, for treated myocardial cells that exhibited little
(e.g., an index of automaticity between about 40% to about 30%,
about 30% to about 20%, about 20% to about 10%, or about 10% to
about 0%, or overlapping ranges thereof) or no firing rate, exhibit
an increased frequency of firing rate or electrical signal output
post-administration (e.g., an index of automaticity of between
about 5% to about 15%, about 15% to about 25%, about 25% to about
35%, about 35% to about 45%, about 45% to about 55%, about 55% to
about 65%, about 65% to about 75%, about 75% to about 85%, about
85% to about 95%, about 95% to about 100%, or more) as compared to
the cells pre-administration.
[0112] The resultant changes in cardiac contraction and/or an
electrical property of converted pacemaker cells, by the methods
disclosed herein, modulate cardiac rhythm in several embodiments.
In several embodiments, the methods and compositions disclosed
herein achieve a heart rate within about 25%, within about 20%,
within about 15%, within about 10%, within about 5%, within about
2%, or within about 1% of a clinically desired heart rate. In
several embodiments, the methods and compositions disclosed herein
are used to treat subjects suffering from or susceptible to a
disease or disorder such as a cardiac-related syncope (e.g.,
Stokes-Adam syncope), an abnormality of sinus node function such as
persistent sinus bradycardia, sino-atrial (S-A) block manifested as
S-A Wenckebach, complete S-A block or sinus arrest, and high-grade
atrioventricular block; or bradycardia-tachycardia syndrome or
other bradycardia related condition. In several embodiments,
modulation is used to increase or slow down the function of an
implanted pacemaker (e.g., to achieve a desired heart rate that the
implanted pacemaker fails to provide on its own).
Changes to the Cells as a Result of Administration of Transcription
Factors
[0113] In several embodiments, the administration of Tbx18, Shox2,
or a combination thereof produces several physiological changes to
the contacted cells in addition to or separate from the generation
of spontaneous repetitive electrical signals discussed above. In
some embodiments, these physiological changes even if first seen in
vitro, are also detectable in vivo, where they may serve as
supplemental markers of the efficacy of biological pacemaker
generation (e.g., they are recognized as characteristics or
hallmarks of pacemaker cells). In some embodiments, the
administration of one or more transcription factors results in an
increased percentage of spontaneously beating monolayer cultures
compared to control. In several embodiments, the presence, or
amount, of spontaneous beating is use to screen cultures for
functionality prior to transplant or to evaluate other combinations
of transcription factors for their utility in generating pacemaker
cells in vitro. In some embodiments, the administration of one or
more transcription factors results in spontaneous intracellular
Ca.sup.2+ oscillations of myocardial cells are administered. In
some embodiments, the administration of one or more transcription
factors results in a gradual phase-4 depolarization. In some
embodiments, the delivery of one or more transcription factors
disclosed herein increases or decreases the expression of HCN4 in
cells. Because calcium flux is a primary component of cardiac
electrical signaling and HCN4 expression is important in pacemaker
cell function, changes in these endpoints correspond, in some
embodiments, to more SAN-like behavior in induced biological
pacemaker cells. In some embodiments, the administration of one or
more transcription factors results in modulation of
sub-sarcolemmal, spontaneous localized Ca.sup.2+ release events. In
some embodiments, the administration of one or more transcription
factors results in modulation of intracellular cAMP levels. Thus,
as a result of administration of one or more of the above types of
transcription factors, cardiac electrical activity can be modulated
and abnormalities in excitable cardiac tissue can be treated.
[0114] In several embodiments, the administration of Tbx18, Shox2,
or a combination thereof will result in cells new phenotypes of the
contacted cells in addition to or separate from the generation of
spontaneous repetitive electrical signals. In some embodiments, the
administration of one or more transcription factors results in
disorganized and markedly lower sarcomeric .alpha.-actin expression
in transduced cells, which is indicative of pacemaker cells. In
some embodiments, the administration of one or more transcription
factors results in a change in cell size. In some embodiments, the
administration of one or more transcription factors results in
changes to the chromatin state. In some embodiments, the
administration of one or more transcription factors results in
chromatin modification and will cause lower or higher expression
and or activity of one or more of the following genes: Cx43,
Kir2.1, Actc2, and HCN4. These phenotypic changes, mirror those of
natural SAN cells and as a result of the administration of one or
more of these transcription factors, can be used, in several
embodiments, as an additional means to evaluate the generation of
biological pacemaker cells.
[0115] In several embodiments, the administration of the one or
more transcription factors to the heart will result in frequent
ectopic ventricular beats that originate from the site of gene
injection resulting in targeted generation of pacemaker activity.
In some embodiments, the administration of one or more
transcription factors results in gene-related epigenetic changes in
cells and de novo pacemaker activity. This pacemaker activity, in
some embodiments, is a result of somatic reprogramming, and not due
to dedifferentiation to a progenitor state. Somatic to somatic
transdifferentiation will lower the threat of neoplasia from
transduced cells (e.g., teratoma formation is reduced). In other
embodiments, however, the administration of one or more
transcription factors may result in dedifferentiation to a
progenitor state. In certain such embodiments, differentiation into
pacemaker cells is induced using one or more of the transcription
factors disclosed herein. Using such methods, biological pacemaker
cells can safely and effectively be made from a wide variety of
cells.
EXAMPLES
[0116] Examples provided below are intended to be non-limiting
embodiments of the invention.
Methods:
Heterologous Transduction of NRVMs
[0117] The human Tbx18 gene with a C-terminal myc/FLAG tag was
excised from pCMV6-Tbx18 (Origene, Rockville, Md.) by digestion
with FseI and SalI. The Tbx18 gene was then sub cloned into a NotI-
and XhoI digested lentiviral expression vector with the desired
reporter gene, pLVX-IRES-ZsGreen1 (Clontech, Mountain View,
Calif.), thus generating the pLV-Tbx18-IRES-ZsGreen1 (.about.10.1
kb) vector. ZsGreen1 was used as the reporter protein for
Tbx18-transduced cardiomyocytes, due to its similar spectral
characteristics as the commonly used GFP. Thus, throughout the
disclosure, the terms ZsGreen1 and GFP are used interchangeably.
The recombinant target gene was then introduced to an adenovirus
vector backbone by Gateway recombination cloning using
Gateway-adapted vectors (Invitrogen, Carlsbad, Calif.). An LR
recombination reaction was performed between the entry clone and
the destination vector, pAd/CMV/V5-DEST (.about.36.7 kb), to
generate the desired adenoviral expression construct,
pAd-CMV-TBX18-IRES-GFP (.about.39.8 kb). Positive constructs were
verified to have the correct target gene by DNA sequencing
(Laragen, Los Angeles, Calif.).
Electrophysiology
[0118] Whole-cell electrophysiology recordings were performed as
described below. Experiments were carried out using standard
microelectrode whole-cell patch-clamp techniques with an Axopatch
200B amplifier (Axon instruments) with a sampling rate of 20 kHz
and low-pass Bessel-filtered at 5 kHz. All experiments were
performed at a room temperature. Cells were washed with a normal
Tyrode's solution containing (mmol/L): NaCl 138, KCl 5,
CaCl.sub.2), 2, glucose 10, MgCl.sub.2 0.5, and HEPES 10; pH 7.4.
The micropipette electrode solution was composed of (mmol/L):
K-glutamate 130, KCl 9, NaCl 8, MgCl.sub.2 0.5, HEPES 10, EGTA 2,
and Mg-ATP 5; pH 7.2. Microelectrodes had tip resistances of 2 to 4
M.OMEGA. when filled with the internal recording solution.
Voltage-clamp experiments were performed with an inter-episode
interval of 2.5 seconds. Action potentials were either initiated by
short depolarizing current pulses (2 to 3 ms, 500 to 800 pA) on
GFP-NRVMs or recorded with I=0 mode on Tbx18-NRVMs. Data were
corrected for the measured liquid junction potential (-mV). A xenon
arc lamp was used to view GFP fluorescence at 488/530 nm
(excitation/emission).
Adenovirus Construction and Purification
[0119] The expression constructs as discussed above were digested
with PacI to expose inverted terminal repeats before transfecting
into 293A cells to produce adenoviral stocks for use in subsequent
expression of the transgene. Adenoviruses were plaque-purified,
amplified, and affinity-column purified using Adenopure kit
(Puresyn, Inc), and stored at -80.degree. C.
Myocyte Isolation and Transduction
[0120] NRVMs were isolated from 1-2 day old rat pups and cultured
as a monolayer using established culture methods. Only the lower
one third of the heart (from the apex to the midline) was excised
in order to minimize contaminating atrioventricular nodal cells. In
some embodiments, other portions of the heart are used, including
the lower third, the middle third, and combinations of these
portions, or whole hearts (or portions thereof) where endogenous
pacemaker cells are selectively removed. In some embodiments,
biopsies (e.g., guided biopsies) are used to obtain non-pacemaker
tissue). A monolayer of NRVMs was transduced with either
Ad-Tbx18-IRES-GFP or Ad-GFP (control vector; moi=1-10) one day
after cell isolation, and cultured for 2-5 days. Tbx20, known to be
critical for cardiac chamber differentiation, was employed in order
to control for non-specific, embryonic transcription factor-related
effects.
Isolation of SA Myocytes
[0121] SA nodal myocytes were isolated from adult Sprague-Dawley
rats. Animals were anesthetized with isoflurane. Hearts were
quickly removed, the atria separated from the ventricles, and the
sinoatrial node region dissected in Tyrode solution, which
consisted of (in mM) 140 NaCl, 5.4 KCl, 1.2 KH.sub.2PO.sub.4, 5
HEPES, 5.55 glucose, 1 MgCl.sub.2, 1.8 CaCl.sub.2); pH adjusted to
7.4 with NaOH. The rat sinoatrial node region was defined by the
borders of the crista terminalis, the interatrial septum, and the
superior and inferior vena cavae.
Embryonic Stem Cell Transduction
[0122] Mouse embryonic stem cells were transfected with an
adenoviral vector expressing Shox2 or a control gene. Established
embryoid body methods were used for differentiation. Pooled data
are n.gtoreq.3 with p<0.05 for all reported differences.
Intracellular Calcium Recordings and Analyses
[0123] For measurements of intracellular Ca.sup.2+ oscillations,
2.times.10.sup.6 NRVMs were plated in 35-mm glass bottom dishes
(MatTek Cultureware) or 22 mm fibronectin-coated glass coverslips,
transduced, and analyzed 4 days post-transduction. Cells were
loaded with Rhod2-AM (2 .mu.mol/L) (Molecular Probes) for 18
minutes, then washed once and subsequently placed in normal
Tyrode's solution with 2 mmol/L calcium. Calcium transients were
recorded at 37.degree. C. from AdTbx18IS-IRES-GFP and Ad-GFP
transduced NRVMs. Images were acquired on an inverted confocal
laser-scanning microscope (Perkin Elmer/Nikon) or Leica SP5
confocal microscope. Offline analysis was performed using Ultraview
(Perkin Elmer) and ImageJ. Whole-cell Ca.sup.2+ transients were
obtained from confocal line scan images through single NRVMs by
averaging the signal of an individual cell. Ca.sup.2+ transients
are presented as background-subtracted, normalized fluorescence
(F/F.sub.0). For 2-D confocal Ca.sup.2+ imaging calcium transients
were obtained by averaging the signal through the entire cell.
Immunostaining
[0124] Frozen sections of neonatal rat sinoatrial node and NRVMs 4
days post adenoviral transduction were fixed with 4%
paraformaldehyde and permeabilized with 0.1% Triton-X 100 and then
incubated with the appropriate primary antibody: sarcomeric
.alpha.-actinin (Sigma-Aldrich; A5044; 1:800), ANP (AbCam;
ab-14348; 1:1000), HCN4 (Abcam; ab85023; 1:500) and Alexa
Fluor-conjugated secondary antibodies (Invitrogen).
Immunoblotting
[0125] Western blots were performed using specific antibodies
against to Cx43 (Sigma-Aldrich, C6219; 1:1000), PLN (Alomone;
A010-14: 1:5000), p-PLB (Alomone; A010-12: 1:5000) HCN4 (AbCam;
ab85023; 1:500) Briefly, Ad-Tbx18, Ad-GFP transduced NRVMs, rat SAN
and Left ventricle were homogenized in RIP A buffer containing a
protease inhibitor cocktail (Sigma). Protein content was quantified
by BCA assay and cell lysates (15 .mu.g per lane) were run on a 12%
SDS-PAGE gel and transferred onto a PVDF membrane. Then the
transferred membrane was incubated with a primary antibody
overnight at 4.degree. C., followed by 1-hour incubation with a
peroxidase-conjugated secondary antibody. Immunoreactivity was
detected by chemiluminescence (ECL Western Blotting Analysis
System, Amersham). Equal protein loading of the gels was assessed
by re-probing the membrane with monoclonal anti-GAPDH antibody
(Abeam; ab9482; 1:10000) or anti-.beta.-actin (Sigma-Aldrich;
A3848: 1:25000).
In Vivo Gene Transfer
[0126] Adenoviruses were injected into the left ventricular apex of
guinea pigs. Adult female guinea pigs (weight, 250 to 300 g;
Charles River) were anesthetized with 4% isoflurane, intubated, and
placed on a ventilator with a vaporizer supplying 1.5% to 2%
isoflurane. After lateral thoracotomy, a 30-gauge needle was
inserted at the free wall apex of the left ventricle. 100 .mu.l of
adenovirus containing 1.times.10.sup.9 plaque-forming units of
Ad-Tbx18-IRES-GFP or Ad-GFP (control group) was injected into the
left ventricle apex. As discussed above, other delivery routes are
used in some embodiments.
In Vivo and Ex Vivo Electrocardiographs (ECGs)
[0127] Methacholine (0.1-0.5 mg per kg of body weight in saline,
Sigma-Aldrich, St. Louis, Mo.) was delivered via the jugular vein
in order to slow the animals' sinus rhythm prior to ECG recordings
under general anesthesia (2% isoflurane, 98% 02). ECGs were
recorded using a 2-lead digital ECG system at 2 kHz (Lead I and
Lead 3, BIOPAC Systems, Goleta, Calif.) and Lead 2 was offline
calculated by Einthoven's triangle using Acqknowlege 3.7.3 software
(BIOPAC Systems, Goleta, Calif.). In all animals, methacholine was
administered until complete heart block was achieved. Heart block
was accompanied by a reduction of the animals' sinus rhythm to
<100 bpm. In most of the Tbx18-injected guinea pigs, ectopic
ventricular rhythms were manifested well before the sinus rhythm
reached 100 bpm (FIG. 3D, right panel). In contrast, control
animals exhibited no evidence of such ectopic ventricular beats
even when the sinus rhythm was brought to <100 bpm (FIG. 3D,
left panel). FIG. 3D highlights the lack of any ectopic ventricular
rhythm in the control animals even at a very slow escape rate
compared to Tbx18-injected animals.
[0128] For ex vivo, intact whole-heart ECG recordings, the heart
was retrograde-perfused via the aorta at 60 mmHg with oxygenated
Tyrode's solution at 36.degree. C. The perfused heart was placed in
a sylgard-coated plate filled with warm Tyrode's solution. ECG
leads were stationed at appropriate sites to record leads I and II
(FIG. 28). After a 20-minute equilibration period, the region of
the atrioventricular node was ablated with a cryogun (Brymill
Cryogenic Systems, Ellington, Conn.) filled with liquid N.sub.2.
Electrode-pacing was performed at the site of transgene injection
(anterior, left ventricular apex) at 200-ms intervals with a
platinum electrode connected to an isolated pulse stimulator (Model
2100, A-M Systems, Carlsborg, Wash.).
RT-PCR for Gene Arrays
[0129] Rat sinoatrial node, left ventricle and Tbx18- and
GFP-transduced NRVMs (4 days post transduction) were collected and
mRNA was extracted (Qiagen mRNA Isolation Kit). The mRNA samples
were converted to first strand cDNA, using the RT2 First Strand Kit
(SA Biosciences). Then, the cDNA template was mixed with the RT2
qPCR Master Mix and the mixture was aliquoted into each well of the
same plate containing pre-dispensed gene specific primer sets. PCR
was performed on a 7900HT Fast Real-Time PCR System (Applied
Biosystems/Life Technologies Corporation, Carlsbad, Calif.) and the
relative expression of the genes was calculated.
cAMP Assay
[0130] The Cyclic AMP Elisa Assay Kit (catalog #STA-501; Cell
Biolabs, INC) was used to determine cAMP levels in NRVMs transduced
with Ad-Tbx18 or Ad-GFP. Briefly, 50 .mu.l Tbx18- and GFP-NRVM cell
lysates were added to the Goat Anti-Rabbit Antibody Coated Plate 96
well plate. 25 .mu.l of diluted Peroxidase cAMP Tracer Conjugate
was added to each tested well. Then, 50 .mu.l of diluted Rabbit
Anti-cAMP Polyclonal Antibody was added to each tested well and the
plate was incubated at room temperature for 30 minutes with
shaking. After washing 100 .mu.l of Chemiluminescent Reagent was
added to each well. After incubation at room temperature for 5
minutes on an orbital shaker, the plate was read for luminescence
of each microwell on a plate luminometer. Measurement of light
emission (RLU) allowed calculating the amount of cAMP in samples
which were then normalized to .beta.-actin for comparison of the
samples.
Solutions
[0131] Tyrode solution containing (mm): NaCl 140, KCl 5.4,
CaCl.sub.2) 1.5, MgCl.sub.2 1.5, glucose 10 and Hepes 5; pH
adjusted to 7.38 with NaOH. Ryanodine and Protein kinase I (PKI)
were purchased from Tocris biosciences and caffeine was purchased
from Sigma. Rhod-2/AM and was purchased from Invitrogen.
Chromatin Immunoprecipitation
[0132] NRVMs transduced with either Tbx18 or GFP were fixed two- to
four-days after viral vector transduction with 10% formaldehyde for
8 min at room temperature. Cells were sheared using a sonicator
with ten pulses of 20 seconds each, with a 30-second rest on ice
between each pulse. Chromatin immunoprecipitation was performed
using ChIP-IT.RTM. Express Chromatin Immunoprecipitation kit
(Active Motif, Carlsbad, Calif.) following the manufacturer's
protocol. Primary antibodies for the H3K4me3 and H3K27me3 were
purchased from Active Motif.
qPCR after Chromatin Immunoprecipitation
[0133] Gene specific (Cx43, Kir2.1, .alpha.-SA, HCN4) primers,
already validated for qPCR in rat, were purchased from SA
Biosciences. For each gene, three sets of primers were employed
corresponding to -2 kb (upstream), -lkb, and +lkb (downstream) of
the transcription start site. The .DELTA.Ct values from the three
tiles were averaged from each experiment for data analyses.
Single-Cell Quantitative Real-Time PCR
[0134] Single myocytes were collected in PBS with a wide-opening
patch pipette, placed on dry ice and then stored at -80.degree. C.
Tbx18 mRNA levels in individual myocytes were examined by
quantitative real-time PCR with an Ambion.RTM. Single
Cell-to-CT.TM. Kit (Life Technologies) according to manufacturer's
instructions. Briefly, single cells were treated with cell lysis
solution and DNase I for 5 minutes at room temperature. Reverse
transcription was performed at 25.degree. C. for 10 minutes, at
42.degree. C. for 60 minutes and at 85.degree. C. for 5 minutes
after addition of SupersScript RT and VILO RT mix. Preamplification
was performed with 14 cycles of 95.degree. C. for 15 seconds and
60.degree. C. for 4 minutes with addition of PreAmp mix and
0.2.times. TaqMan Gene Expression Assays, containing primers for
human Tbx18 (assay ID: Hs01385457_ml), guinea pig GAPDH (assay ID:
Cp03755742_g1), and guinea pig TnnT2 (assay ID: Cp04182357_g1). The
custom primers were synthesized by Applied Biosystems (Carlsbad,
Calif.). Preamplification products (1:20 dilution) were used for
real-time PCR with TaqMan Gene Expression Assays using an Applied
Biosystems 7900HT Fast Real-Time PCR System. Standard curves for
each of the 3 primer sets were constructed with serial dilutions of
input DNA templates (FIG. 30) and validated comparable
amplification efficiencies (curve slopes: -3.32 to -3.64). Relative
mRNA levels of Tbx18, GAPDH, and TnnT2 were obtained by
extrapolation of Ct values with the slopes of the standard curve
for each primer sets. Tbx18 mRNA expression in each cell was then
normalized to GAPDH or TnnT2 level.
Statistical Analyses
[0135] Data were analyzed for mean, standard deviation and standard
error of the mean (SEM). The quantitative figures in this work
represent the mean.+-.SEM. Data sets were statistically evaluated
using an unpaired t test. p<0.05 was considered significant
unless indicated otherwise.
Example 1--Pacemaker Cells Created by Gene Delivery to NVRMs
[0136] As discussed above, present therapies for cardiac
arrhythmias caused by abnormalities of excitable tissue rely
primarily on pharmacotherapy, radiofrequency ablation, implantable
devices, and other such related approaches. These methods, while
useful for the treatment of some forms of arrhythmias, have
limitations (as discussed above). Biological pacemakers offer
advantages over the use of traditional pacemakers and can be used
instead of, or in conjugation with traditional pacemakers. The
present study evaluated the use of transcription factor inducing
agents for the generation of biological pacemakers.
[0137] To demonstrate that transduction of transcription factors to
cardiac cells produces biological pacemakers, singular,
heterologous transduction of selected transcription factors in
bicistronic adenoviral vectors was performed in freshly-isolated
NRVMs. As an initial screen, the number of spontaneously-beating
cultures 36-48 hrs post-transduction was analyzed.
Tbx18-transfected NRVMs (Tbx18-NRVMs) exhibited an increased
percentage of spontaneously-beating monolayer cultures compared to
control and other transcription factors screened (minimum of five
different cell isolations per group, FIG. 2A). Beyond two days of
culture, multiple, spontaneously-beating foci were observed in
individual Tbx-NRVM monolayers, as expected from the downregulation
of Cx43 (but not Cx45 or Cx40) by Tbx. Accordingly, Tbx was
selected as a candidate for converting ventricular cardiomyocytes
to pacemaker cells. Thus, in several embodiments, Tbx18 is used to
create a biological pacemaker. However, in several embodiments,
other transcription factors are used, including one or more of
those screened in the current experiment. In several embodiments,
combinations of two or more transcription factors will be used. In
several embodiments, Shox2 will be used in conjugation with Tbx18
to achieve these results. In several embodiments, one or more of
the following transcription factors will be selected for use:
Tbx18, Shox 2, Tbx3, and Tbx5.
[0138] Although NRVMs exhibit spontaneous, syncytial contractions
when cultured as monolayers, such a phenomenon is driven by a
relatively small number of autonomously-beating cells. FIG. 2B
shows representative action potential (AP) traces. When sparsely
plated at a density of .about.4 NRVMs/mm.sup.2 such that a given
cell is unlikely to make physical contact with neighboring cells, a
majority of the control (GFP) ventricular myocytes were quiescent
(7 of 9), firing single action potentials only upon stimulation
(FIG. 2B, left). Tbx18 expression transformed the electrical
phenotype to that of SAN cells; most Tbx18-NRVMs (7 of 9) beat
autonomously and spontaneously (FIG. 2B, right). It will be
appreciated that, in several embodiments, Shox2 could be used
instead of or in conjunction with Tbx18. In several embodiments,
one or more of the following transcription factors will be selected
for use: Tbx18, Shox2, Tbx3, and Tbx5. The Tbx18-NRVMs exhibited
spontaneous APs with prominent gradual phase-4 depolarization.
Gradual phase-4 depolarization underlies automaticity in SAN
pacemaker cells, and is prominent in Tbx-NRVMs (FIG. 2B). This
increase in autonomous beats and gradual depolarization indicates
that these cells are functioning in a manner consistent with
natural sinoatrial node cells, which suggests that Tbx18 (alone or
in combination with other transcription factors) is generating
pacemaker cells. In some embodiments, similar functions are
detected in stem cells, and which therefore indicates that the
cells are useful in the generation of biological pacemakers and in
the treatment of arrhythmias.
[0139] The maximum diastolic potential (MDP) of -47.+-.10 mV (n=6)
in Tbx18-NRVMs was depolarized relative to the resting membrane
potential (RMP) of -73.+-.6 mV in GFP-NRVMs (n=5, FIG. 2C, left).
This suggests that Tbx-18 transduced cells will fire more
frequently than the control cells, much like pacemaker cells are
expected to. GFP- and Tbx18-groups are indicated by white and
cross-hatched bars, respectively, throughout the data presented. As
used herein, the term "index of automaticity" shall be given its
ordinary meaning and shall also be defined as the percentage of
autonomously-beating cells multiplied by the frequency of action
potential (AP) oscillations in those cells, was much larger in
Tbx-NRVMs (70.+-.16% bpm) compared to control (13.+-.4% bpm, FIG.
2C, middle). As shown in FIG. 2C middle, automaticity increased
relative to the GFP control by around 60%. In some embodiments, the
increase in index of automaticity will be 5% to about 15%, about
15% to about 25%, about 25% to about 35%, about 35% to about 45%,
about 45% to about 55%, about 55% to about 65%, about 65% to about
75%, about 75% to about 85%, about 85% to about 95%, about 95% to
about 100%, and overlapping ranges thereof, relative to the
automaticity of normal pacemaker cells. The number of cells having
spontaneous Ca.sup.2+ oscillations also increased relative to the
controls (FIG. 2C, right). The number of Tbx18-NRVMs exhibiting
spontaneous intracellular Ca.sup.2+ oscillations was about 6-fold
higher relative to control (FIG. 2C, right). Because Ca.sup.2+ is
necessary for the generation of an action potential in pacemaker
cells, these data also demonstrate that transduction of cells with
Tbx18 (alone or in combination with other transcription factors)
can be successfully used in the generation of pacemaker cells.
[0140] The change in diastolic potential, automaticity, and
Ca.sup.2+ oscillation was complemented by a 78% reduction in
I.sub.K1 density in Tbx18-NRVMs (FIG. 2D). Left: representative
I.sub.K1 raw traces elicited by a ramp protocol from -140 to -20
mV. The summarized I.sub.K1 densities at -140 mV are shown in 2D
right. In several embodiments the reduction in I.sub.K1 density
will be between about 5% to about 15%, about 15% to about 25%,
about 25% to about 35%, about 35% to about 45%, about 45% to about
55%, about 55% to about 65%, about 65% to about 75%, about 75% to
about 85%, about 85% to about 95%, about 95% to about 100%, and
overlapping ranges thereof. The reduction in I.sub.K1 density also
indicates that the transduced cells will fire with higher frequency
relative to untreated cells (e.g., non-pacemaker cells). This
increase in firing indicates that these transduced cells are
functioning as pacemaker cells. Thus, the methods used to generate
these cells, or methods used to generate pacemaker cells from stem
cells, can be used in the treatment of cardiac arrhythmias, or
other maladies that are associated with a disrupted cardiac cell
firing rate.
[0141] HCN4 is the molecular correlate of the
hyperpolarization-activated current, If, which contributes to
pacemaker activity in the SAN. Tbx18 transduction led to a 3.8-fold
increase in the number of cells expressing HCN4 (FIG. 2E). HCN4
immunostaining image (HCN4-white, nuclei-blue) of GFP- or
Tbx18-NRVMs are shown in left and middle, respectively. Scale bar:
200 .mu.m. Right panel: summary of the percent HCN4-positive cells
per GFP- or Tbx18-transduced cells. Tbx18 expression also led to a
1.4-fold increase in HCN4 protein level (FIG. 2F) in Tbx18-NRVMs.
Such cells also exhibited If (FIG. 2G) at a density (-5.2.+-.1.3
pA/pF at -140 mV, n=3) consistent with that reported in rabbit SAN
cells. Western blot indicates higher HCN4 protein level in
Tbx18-NRVMs relative to control (left) comparable to the level HCN4
observed in adult rat SAN (right). Ca.sup.2+ cycling events
complement and couple with sarcolemmal ionic currents to generate
automaticity. Comparison of transcript levels for selected
components of the voltage- and calcium-dependent mechanisms
revealed differences in Tbx18- vs. GFP-NRVMs which closely
recapitulate those between native SAN and ventricular myocardium,
used here as positive controls (FIG. 2H). Changes of relative mRNA
levels of selected genes comparing Tbx18-NRVMs normalized to
GFP-NRVMs (left) and SAN normalized to LV (right). SAN and
Tbx18-NRVMs demonstrate similar pattern of normalized transcript
levels. Thus, in several embodiments, Tbx18 also elicits gene and
protein expression changes that are associated with biological
pacemaker formation.
[0142] FIG. 2B shows Tbx18 cells were more likely to fire and fire
in a manner (with slow depolarization) like that of native SAN
cells. FIG. 2C shows that Tbx18 cells have a lower diastolic
potential (middle) resulting in a higher index of automaticity
(middle) and more spontaneous whole-cell oscillations of Ca.sup.2+
(left). FIG. 2D shows that the current density of the Tbx18 cells
have less repolarization time, and thus a higher chance of firing.
Together these data indicated that, in some embodiments, Tbx18
changes the electrical properties of cells and make them SAN-like.
Each of these results indicates a higher likelihood that these
cells will fire automatically when implanted into or generated in
the living heart. Thus, in several embodiments, these induced
pacemaker cells are able to beat and can modulate heart rhythm to
treat cardiac arrhythmias, or other maladies associated with
abnormal cardiac rhythm.
[0143] While membrane-delimited electrophysiological pathways
contribute to pacemaking, SAN cells are triggered to fire
rhythmically by finely-orchestrated, distinctive intracellular
Ca.sup.2+ cycling events. Sub-sarcolemmal, spontaneous localized
Ca.sup.2+ release events (LCRs) are a hallmark of automaticity in
sinoatrial node cells. During late diastole, LCRs activate
Na+-Ca.sup.2+ exchanger currents (INCX), which then contribute to
the exponential phase of phase-4 depolarization. LCR measurements
were performed on Tbx18-NRVMs to characterize their Ca.sup.2+
cycling profiles.
[0144] During late diastole, LCRs activate Na+-Ca.sup.2+ exchanger
currents (INCX), which then contribute to the exponential phase of
phase-4 depolarization. Line-scan confocal imaging of Tbx18-NRVMs
resolved LCRs preceding each whole-cell Ca.sup.2+ transient (FIG.
3A, n=8 out of 10 cells), recapitulating the LCRs observed native
SAN pacemakers. Representative confocal line-scan images of changes
in [Ca.sup.2+].sub.i in Rhod2/AM loaded Tbx18-NRVMs (FIG. 3A) and
GFP-NRVMs (FIG. 3B) 4 days post transduction depict LCRs preceding
the whole cell Ca.sup.2+ transient only in the Tbx18-NRVMs whereas
occasional Ca.sup.2+ sparks could be detected in the GFP-NRVMs. The
LCR period is defined as the period between the start of the
Ca.sup.2+ transient to the beginning of the subsequent LCR. Cycle
length is defined as the period between the start of the whole cell
Ca.sup.2+ transient to the start of the subsequent Ca.sup.2+
transient. LCRs depicted periodicity with an average period of
72.+-.1% of that of the cycle length (FIG. 3C). Thus, Tbx18 alone
or with other transcription factors, functionally converts
cardiomyocytes into cells having pacemaker-like Ca.sup.2+
activities.
[0145] The LCRs in Tbx18-NRVMs occurred at an average period of
343.+-.8 ms, which was 72.+-.1% of the whole-cell Ca.sup.2+
transient cycle length (474.+-.7 ms, FIG. 3D). In some embodiments
the LCR will occur between about 5% to about 15%, about 15% to
about 25%, about 25% to about 35%, about 35% to about 45%, about
45% to about 55%, about 55% to about 65%, about 65% to about 75%,
about 75% to about 85%, about 85% to about 95%, about 95% to about
100%, and overlapping ranges thereof, of the whole-cell Ca.sup.2+
transient cycle length. Spatially averaged F/F0 plots of changes in
[Ca.sup.2+].sub.i depicted a 2.3 fold increase in the caffeine (20
mM) induced Ca.sup.2+ transients in the Tbx-NRVMs compared to the
controls. In contrast, LCRs were not detected in control cells
(n.about.12 out of 12 cells, FIG. 3D), although occasional
randomly-distributed sparks were observed (e.g., FIG. 3B). Larger
Ca.sup.2+ stores in the sarcoplasmic reticulum (SR) would be likely
to promote automaticity. The amplitude of caffeine-induced
Ca.sup.2+ transients was 2.3-fold larger in Tbx18-NRVMs compared to
control (FIG. 3D).
[0146] Western blot experiments demonstrated a decrease in the
total PLB levels and an increase in phosphorylated PLN (se16) akin
to the adult rat SAN (FIG. 3F). No changes in the protein levels of
SERCA2A, NCXI and RyR were observed in the Tbx18-NRVMs in
comparison to the controls (FIG. 3G). The Ca.sup.2+ release channel
blocker, ryanodine (10 .mu.M), suppressed the rate of spontaneous
Ca.sup.2+ transients by 47.+-.6% in Tbx-NRVMs but only by 12.+-.2%
in control (FIG. 3E). These results indicate that transduction with
Tbx18 (alone or in combination with other transcription factors)
can be used, in several embodiments, to generate biological
pacemakers, or in some embodiments, used to generate cells which
can later be implanted to function as biopacemakers.
[0147] Phospholamban (PLN), in its unphosphorylated state, inhibits
sarcoplasmic reticulum Ca.sup.2+-ATPase 2a (SERCA2a), thereby
suppressing the reuptake of Ca.sup.2+ by internal stores. Such
inhibition is relieved upon phosphorylation of the protein (P-PLB).
The relative p-PLN (Ser16) level was 65-fold higher in Tbx-NRVMs in
comparison to GFP-NRVMs (FIG. 3F, left panel), mimicking the
augmentation of p PLN found in the SAN compared to that in the
ventricular myocardium (FIG. 3F, right panel). Meanwhile,
differences in the protein levels of SERCA2a, NCX1 and ryanodine
receptor (RyR) were not detectable between Tbx- and GFP-NRVMs (FIG.
3G), consistent with findings in the rabbit sinoatrial node versus
left ventricle. Intracellular cAMP levels were 1.7 fold higher in
Tbx18-NRVMs compared to GFP-NRVMs (FIG. 3H), reproducing the higher
[cAMP].sub.i observed in the rabbit SAN compared to ventricular
myocardium as known in the art. Application of a PKA inhibitor
(PKI, 15 .mu.M) led to cessation of spontaneous whole-cell
Ca.sup.2+ transients in Tbx-NRVMs, but had no effect on GFP-NRVMs
(FIG. 3I). Thus, Tbx18 expression in NRVMs produced changes in key
Ca.sup.2+ cycling components which recapitulate key features of
sinoatrial node pacemaker cells, thereby allowing, in several
embodiments, transduction of cells with Tbx18 (alone or in
combination with other transcription factors, depending on the
embodiment) to be used in therapeutic methods for treating cardiac
arrhythmias.
Phenotypic Changes to the Reprogrammed Cell
[0148] In addition to the electrophysiological changes, cellular
reprogramming replicates key features of cell structure in
pacemaker tissue. Native sinoatrial node pacemaker cells are
distinctive in their morphology: they are smaller and exhibit
less-organized myofibrils than working cardiomyocytes. To test
whether Tbx18-NRVMs had phenotypic changes, the morphology of the
cells was investigated.
[0149] Sections of neonatal rat heart demonstrate that cardiac
sarcomeric .alpha.-actinin (.alpha.-SA) expression is markedly
lower and disorganized in the sinoatrial node compared to the
adjacent right atrium (RA, FIG. 4A, top left and bottom left).
Tbx18-NRVMs resembled native sinoatrial node cells in their
morphology, with myofibrillar disorganization and weak expression
of .alpha.-SA (FIG. 4A, bottom right). Neonatal rat sinoatrial
node, demarcated by HCN4 expression (top middle), exhibits weaker
and unstructured sarcomeric .alpha.-actinin (.alpha.-SA) expression
(top panel). Bottom left: Zoom-in image of the boxed area in top
left. The pattern is faithfully recapitulated in Tbx18-NRVMs
compared to GFP-NRVMs (bottom right and middle, respectively).
Scale bar: 30 .mu.m. The data are corroborated by the observed
downregulation of .alpha.-SA transcript levels in Tbx18-NRVMs (FIG.
2H). Cell size, measured by two complementary methods, is 28-33%
smaller in Tbx18-NRVMs than in control NRVMs (FIG. 4B),
recapitulating the smaller size of SAN cells relative to working
cardiomyocytes. Thus, Tbx18-NRVMs underwent both structural
(morphology) as well as functional (electrophysiology)
reprogramming.
[0150] Whether the shifts to sinoatrial node-like phenotype are
associated with a sinoatrial node-like chromatin state in
Tbx18-NRVMs was then investigated. Trimethylation of lysine 27 in
histone 3 (H3K27me3) is a heterochromatin mark which promotes the
recruitment of Polycomb group proteins for gene silencing.
Conversely, trimethylation of lysine 4 (H3K4me3) marks genes
transcriptionally active. Histone modification profiles in the
promoter regions of four genes, Cx43, Kir2.1, Actc2, and HCN4, were
then investigated. Tbx18 is a transcription factor that is required
for embryonic development of the sinoatrial node head area. Shox2
is a negative regulator of Nkx2.5 in the sinus venosus (as
discussed above). Tbx3 is a potent regulator of sinoatrial node
specialization, with developmental errors resulting from either
deficiency or ectopic expression. Tbx5 is a positive regulator of
Shox2 and Tbx3. These genes exhibit relevant molecular and
functional changes in Tbx18-NRVMs. Tri-methylation level on H3K27
indicates that Tbx18 increased inactivity of Cx43, Kir2.1, and
.alpha.-SA promoters while relieving its repressive epigenetic
pressure on HCN4 promoter normalized to control. These results were
measured by chromatin immunoprecipitation followed by qPCR.
Meanwhile, H3K4me3 (FIG. 4C right) levels indicate that ratio of
active HCN4 promoter regions increased upon Tbx18 expression while
the transcriptionally active promoter regions of Cx43, Kir2.1, and
.alpha.-SA have decreased upon Tbx18 expression. Cx43, Kir2.1, and
Actc2 became epigenetically inactive (higher H3K27me3 and lower
H3K4me3) in Tbx18-NRVMs compared to control (FIG. 4C). As a result,
these data suggest that Tbx18 expression would reduce one or more
of Cx43, Kir2.1, and .alpha.-SA expression while HCN4 would be
upregulated. As HCN4 is involved in repetitive signals, these data
are consistent with biological pacemaker formation. Moreover, the
chromatin histone modifications are consistent with durable
epigenetic reprogramming rather than transient functional
re-engineering.
[0151] In FIG. 5, the expression of atrial natriuretic peptide
(ANP) in NRVMs was induced by 24-hour stimulation with endothelin-1
(100 nM), a vasoconstrictor. However, induced ANP expression was
suppressed by Tbx18 expression (5B, bottom panel) while GFP had no
effect (5A, bottom panel). Scale bar: 20 .mu.m. Each of these
phenotypic changes show that Tbx18-transduced cells appear to be
more sinoatrial node-like than cardiomyocytes that are untreated.
This reflects a reprogramming of the cell that is structural as
well as physiological, thus generating a biological pacemaker cell
that is similar to sinoatrial node cells.
[0152] In several embodiments, at least one of Cx43, Kir2.1, and
Actc2 may become epigenetically inactive in iSAN cells as compared
to the quiescent cells. In several embodiments, expression of
sarcomeric .alpha.-actinin in iSAN cells may be weak as compared to
the quiescent cells. Furthermore, in several embodiments, the iSAN
cells may exhibit myofibrillar disorganization. Only one of such
changes may occur, or combinations thereof may occur, depending on
the embodiment; however, each of the above are consistent with a
shift of a cell towards a sinoatrial node-like phenotype. Moreover,
in several embodiments pacemaker cells are generated without the
induced alteration expression of ion-channel proteins, the genetic
introduction of which may be contrary to the data above (e.g., the
reduction in Kir2.1 that contributes, at least in part, to iSAN
formation, would potentially be offset by genetic introduction of
Kir2.1 channels).
Example 2: In Vivo Application of Transcription Factor Induced
Biological Pacemakers
[0153] The prior example established the ability of Tbx18 to induce
changes in gene/protein expression and function in vitro. Thus, the
possibility of reprogramming adult ventricular myocytes into
pacemaker cells in vivo was also investigated. An adenoviral vector
encoding Tbx18 was directly and focally injected into the apex of
guinea pig hearts. In some embodiments, the injection will be to
other areas of the heart and sometimes in several areas at once. It
shall be appreciated that the guinea pig is an accepted model for
use in cardiovascular studies, and data can be readily extrapolated
to other mammals, including the human. In some embodiments, the
administration of the Tbx18 adenoviral vector will be performed on
various mammalian hearts, including that of the human heart.
[0154] Two to four days after injection into the guinea pig hearts,
the hearts were checked for pacemaker-like signals originating from
the site of injection. Upon slowing of the sinus rhythm, none of
the seven control (GFP-injected) animals exhibited wide-complex
escape rhythms, which would indicate pacemaker function (FIG. 6A
left). Under the same conditions, 5 of 7 Tbx18-injected animals
demonstrated frequent ectopic ventricular beats (wider QRS
complexes with negative polarity in Lead II, FIG. 7A) at a rate of
40.+-.21 bpm (FIG. 6B). The rate of ectopic ventricular beats in
Tbx18-injected animals at day 3-5 after gene delivery is
significantly higher than the control (FIG. 6B). In some
embodiments, the rate of beating of the pacemaker cells will be
between about 5% to about 15%, about 15% to about 25%, about 25% to
about 35%, about 35% to about 45%, about 45% to about 55%, about
55% to about 65%, about 65% to about 75%, about 75% to about 85%,
about 85% to about 95%, about 95% to about 100%, and overlapping
ranges thereof, of the normal beating rate of healthy pacemaker
cells. This beating will correspond to a new heart rate of the
mammal, including the human, of about 5% to about 15%, about 15% to
about 25%, about 25% to about 35%, about 35% to about 45%, about
45% to about 55%, about 55% to about 65%, about 65% to about 75%,
about 75% to about 85%, about 85% to about 95%, about 95% to about
100%, or overlapping ranges thereof, of the normal heart.
Electrocardiographic vector analysis revealed that ectopic beats
originated at the site of gene injection (apex) and propagated
towards the base (FIG. 6A, right). In contrast, the rare escape
beats seen in controls did not originate from the site of
injection: they were narrow and propagated toward the apex from the
atrioventricular junction (FIG. 6A, left). Thus, in vivo
transduction of the ventricles with Tbx18 induced ectopic pacemaker
activity, which indicates that Tbx18 can be used in treat
abnormalities of excitable tissue. In several embodiments, Shox2
could be used instead of or in addition to Tbx18. In several
embodiments, one or more of the following transcription factors
will be selected for use: Tbx18, Shox2, Tbx3, and Tbx5. It will
also be appreciated that, in several embodiments, stem cells,
progenitor cells, somatic cells, and/or cardiomyocytes could be
transfected with genes for the above transcription factors. Then
these cells, after verifying generation of pacemaker activity, can
be implanted in vivo to treat abnormalities of excitable
tissues.
Morphological Changes
[0155] The fidelity of reprogramming was tested by expressing Tbx18
in adult guinea pig ventricles and comparing the properties of
Tbx18-transduced ventricular myocytes (Tbx18-VMs) with those of
GFP-transduced ventricular myocytes (as controls; control-VMs) and
native SAN cells. Adenoviruses co-expressing Tbx18 and GFP, or GFP
alone, were directly injected in the apex of the guinea pig heart
(4.times.10.sup.7 cfu/heart). Five days after injection, the heart
was harvested and cardiomyocytes were isolated from the site of
gene injection.
[0156] Native sinoatrial node cells are smaller and leaner than
nontransduced ventricular myocytes: length-to-width (LtW) ratios
equal 14.7.+-.1.5 (n=24) and 7.6.+-.0.7 (n=9, p<0.05),
respectively. Freshly-isolated control-ventricular myocytes
maintained their native shape (with LtW=7.4.+-.0.9, n=4); in
contrast, Tbx18-ventricular myocytes were leaner (LtW=16.0.+-.1.0,
n=12, p<0.05) than control-ventricular myocytes and were often
spindle-shaped, reproducing the morphological hallmark of SAN
cells. Control-ventricular myocytes had stable resting potentials
at -76 mV, with action potentials elicited only upon electrical
stimulation. In contrast, Tbx18-VMs demonstrated diastolic
depolarization (maximal diastolic potential=-59 mV) and fired
spontaneous action potentials at 26 bpm. Thus the Tbx18 transduced
cells function more like pacemaker cells. Whole-cell capacitance, a
measure of cell size, was smaller in Tbx18-ventricular myocytes vs.
control-ventricular myocytes (40.8.+-.3.6 vs. 119.+-.16 pF,
respectively). The electrophysiological and morphological features
of Tbx18-VMs generally resembled those of native SAN cells (FIGS. 8
and 9). These data show that somatic gene transfer of Tbx18 in the
ventricle in vivo yielded induced SAN (iSAN) cells which faithfully
recapitulate the key phenotypic properties of genuine SAN cells.
The in situ reprogramming was effective and rapid in speed (as
little as five days), offering a novel approach to creating a
biological pacemaker as an alternative to electronic devices. The
data indicates that in several embodiments the iSAN cells will have
a length-to-width ratio greater than the nontransduced ventricular
myocytes. In several embodiments, this LtW ratio will be greater
than about 2, about 4, about 6, about 8, or about 10. In several
other embodiments, this LtW ratio will be about equal to 15. In
still additional embodiments, the ratio will range from about 10 to
about 12, about 12 to about 14, about 14 to about 16, about 16 to
about 20, or greater. In several embodiments, other phenotypic
characteristics of the iSAN cells resemble that of native pacemaker
cells (e.g., more closely than nontransduced ventricular
cells).
Example 3: Testing for Somatic to Somatic Transformation Instead of
Dedifferentiation
[0157] Tbx18 is a marker of multipotent progenitors in cardiac
development, and has been associated with neoplasia. Pluripotent
stem cells (embryonic or induced) are known to differentiate
spontaneously into pacemaker cells. Thus, to reduce concern with
neoplasia. testing was performed to ensure that Tbx18 transduction
did not produce pacemaker cells via a pluripotent/neoplastic state,
which could occur by accelerating the dedifferentiation known to
occur in cultured cardiomyocytes. However, the data presented
herein indicate that the SAN-like morphology of Tbx18-VMs is not
indicative of nonspecific regression. For example,
dedifferentiating adult VMs lose the longitudinal, `bricklike`
shape and become rather circular, similar to their neonatal
counterparts, but do not become thinner. Further indicating that
Tbx18 induces specific re-engineering rather than reversion to a
fetal state are the following. First, dedifferentiation is
accompanied by re-expression of genes characteristic of the fetal
heart, including atrial natriuretic peptide (ANP) and skeletal
.alpha.-actin (.alpha.SkA). Neither ANP nor .alpha.SkA was
re-expressed in Tbx18-NRVMs (iSAN cells); in fact, ANP expression
was strongly suppressed (FIGS. 5C and 5A, B, respectively). Second,
dedifferentiation would bring the transduced myocytes closer to a
progenitor state, and expression of early ventricular transcription
factors such as Nkx2-5 would be enhanced. Instead, Tbx18 lowered
the transcript level of Nkx2-5 (FIG. 2I), consistent with
conversion to mature pacemaker cells but not reversion to a fetal
state. Third, if the de novo automaticity of Tbx18-NRVMs were a
consequence of dedifferentiation to an embryonic/fetal state, the
proliferative index of those cells would be expected to increase.
This is because the embryonic ventricle grows by hyperplasia, an
ability which plummets after birth. On the contrary, phosphohistone
3 (H3P, a mitotically-active cell marker) expression and EdU (an
analog of BrdU, a marker for mitosis and nascent DNA synthesis)
incorporation were comparable in Tbx18- and GFP-NRVMs (n=3, FIG.
5D). Finally, reversion to an embryonic state would be expected to
require extensive epigenetic changes. Investigation of 84 genes
related to chromatin remodeling identified only minor global
differences between Tbx18-NRVMs and GFP-NRVMs (FIG. 5E-H).
Furthermore, the investigation expression of 84 genes related to
stemness verified that Tbx18-NRVMs remained differentiated with no
discernible increase in stemness factors 2-4 days post-transduction
(FIG. 10A). These findings contrasted sharply with the increased
stemness and decreased differentiation seen in induced pluripotent
stem cells relative to their parental dermal fibroblasts (FIG.
10B). In light of the specific gene-related epigenetic changes
(FIG. 4C), it was concluded that the de novo pacemaker activity in
Tbx18-NRVMs arises from straightforward somatic reprogramming
without dedifferentiation to a progenitor state. Fold changes in
specific genes are represented as bar graphs for Tbx18 (relative to
GFP) and iPSCs (relative to parental fibroblasts) in FIG. 10C and
FIG. 10D, respectively. It will be appreciated that, in several
embodiments, Shox2 could be used instead of or in conjugation with
Tbx18. In several embodiments, one or more of the following
transcription factors will be selected for use to achieve
transdifferentiation: Tbx18, Shox2, Tbx3, and Tbx5.
[0158] From these data it shall be appreciated that, in several
embodiments, the quiescent cells will transdifferentiate to iSAN
cells without first dedifferentiating to an embryonic/fetal state.
Thus, in several embodiments the iSAN cells may exhibit similar
morphology to that of native SAN cells consistent with conversion
from quiescent cells to iSAN cells without dedifferentiation.
Likewise, in several embodiments, expression of ANP and .alpha.SkA
will be suppressed in the iSAN cells. Additionally, in several
embodiments, iSAN cells may exhibit transcript levels of Nkx2.5
similar to that of mature native pacemaker cells. In several
embodiments the iSAN cells will remain differentiated without any
discernible increase in sternness factors. In several embodiments
this transdifferentiation may occur in vitro, while in other
embodiments this transdifferentiation may occur in vivo. In several
embodiments, the quiescent cells will be mammalian, including
several embodiments in which the quiescent cell is human.
Example 4: Differentiation of Embryonic Stem Cells Using Shox2 to a
Pacemaker Phenotype
[0159] Embryonic stem cells can spontaneously differentiate into
heterogeneous aggregates of cardiomyocytes with atrial,
ventricular, and pacemaker properties. Experiments were thus
performed to test whether Embryonic stem cells could be biased from
random cardiogenesis toward a dominant pacemaker phenotype. Shox2
is an embryonic transcription factor essential for the patterning
of pacemaker cells in the sinoatrial node. Using Shox2
overexpression, the developmental program for the embryonic stem
cells was tilted and dominated toward pacemaker myocytes. It will
be appreciated that, in several embodiments, Tbx18 could be used
instead of or in conjugation with Shox2. In several embodiments,
one or more of the following transcription factors could be
selected for use: Tbx18, Shox2, Tbx3, and Tbx5.
Results:
[0160] Mouse embryonic stem cells were cultured on a MEFs feeder
layer. Embryoid body formation was cultivated using established
hanging drop culture methods. On day 3, cultivation of embryoid
bodies was performed. On day 6, plating of embryoid bodies on
tissue culture plates was performed (FIG. 11).
[0161] Endogenous levels of transcription factor RNA were measured
at several time points. As shown in FIG. 12, endogenous levels of
Tbx18 RNA increased sharply upon formation of embryoid bodies and
leveled after plating of the embryoid bodies. Endogenous Tbx3 RNA
however, decreased relative to mouse embryonic stem cells. FIG. 13
shows the administration of Shox2 expression vectors. As shown by
the graph in 13B, the level of mRNA relative to control mouse
embryonic stem cells increased after the third administration of
Shox2-vector to levels higher than for control mouse embryonic stem
cells.
[0162] Transient overexpression of Shox2 in embryonic stem cells
increased the quantity of spontaneously-beating embryoid bodies by
8-fold (80.+-.27%) compared to control (9.+-.6%)(FIG. 14A). Within
each beating embryoid body, twice as many beating foci (2.1.+-.0.8
per embryoid body) were found in Shox2-embryoid bodies compared to
control (1.0.+-.0.6 per embryoid bodies) (FIG. 14B). Na+/Ca.sup.2+
exchanger (NCX1) and HCN4 are important for pacemaker
electrophysiology. As shown in FIG. 15, HCN4 protein level was
up-regulated at all differentiation stages, with heightened cell
surface expression in Shox2-embryoid bodies. Confocal imaging in
FIG. 16, also shows an increase in HCN4 expression relative to GFP
control cells. NCXl protein level increased >6-fold in
Shox2-embryoid bodies compared to control at the early and late
stages of differentiation (FIG. 17). This level began to decrease
and by day 14 after the last administration of Shox2 gene, the NCX1
was 1.4 fold higher than the control. Action potentials are mainly
propagated by connexin (Cx) 45 but not Cx43 in the sinoatrial node,
which is mirrored in the atrial/ventricular myocardium,
Shox2-overexpression led to an increase in the transcript
(.about.1.5-fold) and protein (.about.3-fold) levels of Cx45. In
contrast, Cx43 transcript and protein levels were reduced in
Shox2-embryoid bodies by 33.+-.5% and 30.+-.10%, respectively,
compared to control (FIG. 20). This decrease in Cx43 transcript
remained below the control for the 14 day time period of the
experiment (FIG. 21A). In contrast, Cx45 remained increased
relative to the control until day 14, with a decline at day 7 after
the administration of the Shox2 vector (FIG. 21B). The increased
level of HCN4 expression and Cx45 is also apparent from confocal
imaging of cells that were transduced (FIG. 22). The Shox2
expression after transfection also remained at elevated levels
relative to control HMBS and GFP transfected cells (FIG. 23). The
hShox2 mRNA decreased after transduction of the Shox2 gene
eventually falling below the level of control cells. Tbx18 and Tbx3
mRNA levels relative to HMBS are shown in FIG. 24. These data
suggest that exogenous Shox2 induced an increase in endogenous
Shox2 that resulted expression changes in a variety of genes that
suggest pacemaker generation. For example, HCN4 is known to be
important for pacemaker function and its upregulation the
transduced cells indicates that these cells i) are taking on
characteristics of pacemakers due to Shox2 and/or, ii) may be
useful themselves as biological pacemaker cells (e.g., transplanted
cells). Further the upregulation of Cx45, which is primarily
responsible for the propagation of action potentials, indicates
that these Shox2-transduced stem cells were biased in their
differentiation toward a pacemaker lineage. As such, these data
indicate that Shox2 (alone, as tested here, or in combination with
other transcription factors, e.g., Tbx18) are useful in the in vivo
and/or in vitro generation of biological pacemaker cells.
[0163] Shox2 overexpression singularly biased embryonic stem cell
differentiation toward more pacemaker cells, increased expression
of NCX1, HCN4, Cx45, and down-regulated Cx43. All of these features
are hallmarks of SA nodal cell biology. In several embodiments, one
or more of the following transcription factors will be selected for
use in differentiating embryonic stem cells: Tbx18, Shox 2, Tbx3,
and Tbx5. Further, it will be appreciated that the use of
multipotent and/or other pluripotent stem cells will also afford
hallmarks of sinatrial nodal cell biology and/or pacemaker function
when contact with one or more of the transcription factors
disclosed herein. The data provide a novel and efficient platform
to develop biological pacemakers from pluripotent cells.
Example 5: De Novo Automaticity Responds to Autonomic Regulation In
Vitro and in the Intact Perfused Heart
[0164] SAN pacemaker cells respond to autonomic inputs with altered
firing rates. To assess adrenergic and muscarinic responses in iSAN
cells, Tbx18- and GFP-NRVMs were plated on multi-electrode arrays
(MEAs) to record extracellular field potentials from
spontaneously-beating cells (FIG. 25A). Beta-adrenergic stimulation
(with 1 .mu.M isoproterenol) increased the firing rates of
Tbx18-NRVMs from 101.+-.30 bpm to 183.+-.44 bpm (n=12, p<0.05).
Subsequent exposure to a cholinergic agonist, acetylcholine (1
.mu.M), suppressed the rate to 69.+-.33 bpm (n=12, p<0.05, FIG.
25B, C). In contrast, GFP-NRVMs exhibited a very slow spontaneous
beating rate which changed little with either isoproterenol or
acetylcholine (FIG. 25B, C). Immunostaining confirmed prominent
expression of 0-adrenergic receptors and muscarinic receptor type 2
in Tbx18-NRVMs (FIG. 25D). Thus, Tbx18-NRVMs respond appropriately
to adrenergic and muscarinic stimuli.
[0165] A disease model of atrioventricular (AV) block, which is a
common indication for the placement of an electronic pacemaker, was
created to investigate autonomic regulation of induced biological
pacemakers in the intact heart. Electrocardiographic recordings of
the beating hearts, perfused ex vivo (FIG. 28), revealed ectopic
ventricular beats in 8 of 8 Tbx18-injected hearts, at a rate of
154.+-.6 bpm. The polarity and morphology of the ectopic beats was
identical to that of electrode-paced beats at the location of
transgene injection (FIG. 25E), linking the origin of the ectopic
beats to the site of Tbx18 transduction. Conversely, most control
hearts showed a narrow-QRS junctional escape rhythm at an average
rate of 120.+-.7 bpm (n=7/10), which originated on the opposite end
of the ventricle (FIG. 25F). Tbx18-injected hearts responded well
to autonomic regulation; .beta.-adrenergic stimulation followed by
cholinergic suppression increased and then decreased the heart rate
to 235.+-.19 and then to 150.+-.23 bpm, respectively (n=7, FIG.
25G). Collectively, the data demonstrate that Tbx18-NRVM cells
respond to autonomic regulation in vitro and in the intact heart
with proper chronotropy.
[0166] It shall be appreciated that, in several embodiments, Shox2
could be used instead of or in conjugation with Tbx18. In several
embodiments, one or more of the following transcription factors
could be selected for use: Tbx18, Shox2, Tbx3, and Tbx5. In several
embodiments, the iSAN cells may generate ectopic ventricular beats.
In several embodiments the Tbx18-NRVM cells (iSAN cells) may
respond to autonomic regulation to alter the pacing ectopic beats
in a way substantially similar to natural SAN cells. Thus, in
several embodiments, iSAN cells will respond to autonomic
regulation such as .beta.-adrenergic stimulation and cholinergic
suppression in vivo. In several other embodiments, iSAN cells
converted from quiescent cells in vitro may be capable of
responding to autonomic regulation. In several embodiments, the
iSAN cells may generate ectopic beats at a rhythm controlled by
autonomic regulation. It shall be appreciated that in several
embodiments in which iSAN cells respond to autonomic regulation,
the iSAN cells can function to treat a cardiac arrhythmia in a
patient suffering from said arrhythmia. In several embodiments,
iSAN cells responding to autonomic regulation can replace or
supplement electronic pacemaker devices in a patient.
Example 6: The Induced Pacemaker Phenotype is not Dependent Upon
Continued Expression of Tbx18 Transcript
[0167] Reprogrammed cells remain altered without sustained
transcription factor expression. In order to investigate the
persistence of the SAN phenotype, Tbx18-VMs were isolated 6-8 weeks
after the initial in vivo gene transfer, and the transcript levels
of Tbx18 were quantified by single-cell, quantitative RT-PCR. Tbx18
transcripts exhibited a wide dynamic detection range in Tbx18-VMs
isolated just 3 days after in vivo gene transfer (FIG. 26A, bottom
panel). To examine the durability of conversion to SAN-like
pacemaker cells, 5 spontaneously-beating ventricular myocytes
(114.+-.10 bpm, identified by live-cell video recording or
whole-cell patch-clamp) isolated 6-8 weeks after in vivo gene
transfer were examined. PCR primer sets were designed to detect
Tbx18, cardiac troponin T (TnT2, to verify cardiomyocyte identity)
and GAPDH. The levels of Tbx18 transcript in 4 of the 5
spontaneously-beating myocytes were negligible (FIG. 26B, cell 1,
2, 3 and 4, bottom panel), close to the negative control level
(FIG. 26C) in ventricular myocytes expressing GFP alone. Taking the
cell length-to-width (L-to-W) ratio as the criteria, the percentage
of SAN-like Tbx18-VMs (iSAN cells) up to six weeks after initial
gene transfer was examined. A significant proportion of iSAN cells
persists, although the percentage tends to decline over time (FIG.
9C). In several embodiments therefore, the persistent positive
effects due to administration of iSAN cells (e.g., to treat cardiac
arrhythmia) persists for an extended period of time after
administration. For example, in several embodiments, the effects
last from about 2 to about 4 weeks, about 3 to about 5 weeks, about
4 to about 6 weeks, about 5 to about 7 weeks, about 6 to about 8
weeks, post-administration, and overlapping ranges thereof. In
several embodiments, longer periods of persistence are realized,
depending on the embodiment.
[0168] The persistence of the induced pacemaker phenotype beyond
the first few days of transduction was examined using the perfused
intact heart AV block model. Three to four weeks after gene
transfer, Tbx18-injected hearts demonstrated ectopic
idioventricular rhythm at 165.+-.14 bpm (n=3/3, FIG. 29A), with
electrocardiograms consistent with biological pacing from the Tbx18
injection site (FIG. 29B). Furthermore, these hearts responded to
autonomic regulation (FIG. 29C) in a manner similar to the
short-term, Tbx18-injected hearts (FIG. 25G). Taken together, the
data indicate that SAN-like cells maintain pacemaker function even
after exogenous Tbx18 expression has waned, indicative of genuine
reprogramming.
[0169] From this data it shall be appreciated that in several
embodiments the iSAN cells will not continue to express Tbx18 after
conversion from quiescent cells to pacemaker-like cells. Thus, in
several embodiments, it shall be appreciated that a single
administration of Tbx18 to the quiescent cells may be sufficient to
convert the quiescent cells to iSAN cells and for the iSAN cells to
maintain their pacemaker function for a period of at least 6-8
weeks in vivo even if Tbx18 expression wanes in the iSAN cells. In
some embodiments, this period during which the converted iSAN cells
maintain pacemaker function could be a period of less than 6 weeks.
In some embodiments, this period could be a period of more than 8
weeks. In some embodiments, more than one administration of Tbx18
transcript may be administered to the quiescent cells. Furthermore,
it shall be appreciated that, in several embodiments, Shox2 could
be used instead of or in conjugation with Tbx18. In several
embodiments, one or more of the following transcription factors
could be selected for use: Tbx18, Shox2, Tbx3, and Tbx5 and/or
functional fragments or combinations thereof. In some embodiments,
the administration of the transcription factor or transcription
factors could occur in vitro. It shall be appreciated that in
several embodiments the ability of the iSAN cell to generate an
ectopic rhythm after expression of Tbx18 in the iSAN cell has waned
indicates that the iSAN cell may be suitable to replace or
supplement an electronic pacemaker in a subject with a cardiac
arrhythmia or act to treat said cardiac arrhythmia in said
subject.
[0170] Although the embodiments of the inventions have been
disclosed in the context of a certain preferred embodiments and
examples, it will be understood by those skilled in the art that
the present inventions extend beyond the specifically disclosed
embodiments to other alternative embodiments and/or uses of the
inventions and obvious modifications and equivalents thereof. In
addition, while a number of variations of the inventions have been
shown and described in detail, other modifications, which are
within the scope of the inventions, will be readily apparent to
those of skill in the art based upon this disclosure. It is also
contemplated that various combinations or subcombinations of the
specific features and aspects of the embodiments may be made and
still fall within one or more of the inventions. Further, the
disclosure herein of any particular feature, aspect, method,
property, characteristic, quality, attribute, element, or the like
in connection with an embodiment can be used in all other
embodiments set forth herein. Accordingly, it should be understood
that various features and aspects of the disclosed embodiments can
be combined with or substituted for one another in order to form
varying modes of the disclosed inventions. For all of the
embodiments described herein the steps of the methods need not be
performed sequentially. Thus, it is intended that the scope of the
inventions herein disclosed should not be limited by the particular
disclosed embodiments described above.
TABLE-US-00001 Homo sapiens T-box 3 (TBX3), transcript variant 1,
mRNA Accession Number-NM_005996.3 SEQ ID No. 1
GAATTCTAGAGGCGGCGGAGGGTGGCGAGGAGCTCTC
GCTTTCTCTCGCTCCCTCCCTCTCCGACTCCGTCTCT
CTCTCTCTCTCTCTCTCTCCCCTCCCTCTCTTTCCCT
CTGTTCCATTTTTTCCCCCTCTAAATCCTCCCTGCCC
TGCGCGCCTGGACACAGATTTAGGAAGCGAATTCGCT
CACGTTTTAGGACAAGGAAGAGAGAGAGGCACGGGAG
AAGAGCCCAGCAAGATTTGGATTGAAACCGAGACACC
CTCCGGAGGCTCGGAGCAGAGGAAGGAGGAGGAGGGC
GGCGAACGGAAGCCAGTTTGCAATTCAAGTTTTGATA
GCGCTGGTAGAAGGGGGTTTAAATCAGATTTTTTTTT
TTTTAAAGGAGAGAGACTTTTTCCGCTCTCTCGCTCC
CTGTTAAAGCCGGGTCTAGCACAGCTGCAGACGCCAC
CAGCGAGAAAGAGGGAGAGGAAGACAGATAGGGGGCG
GGGGAAGAAGAAAAAGAAAGGTAAAAAGTCTTCTAGG
AGAACCTTTCACATTTGCAACAAAAGACCTAGGGGCT
GGAGAGAGATTCCTGGGACGCAGGGCTGGAGTGTCTA
TTTCGAGCTCAGCGGCAGGGCTCGGGCGCGAGTCGAG
ACCCTGCTCGCTCCTCTCGCTTCTGAAACCGACGTTC
AGGAGCGGCTTTTTAAAAACGCAAGGCACAAGGACGG
TCACCCGCGCGACTATGTTTGCTGATTTTTCGCCTTG
CCCTCTTTAAAAGCGGCCTCCCATTCTCCAAAAGACA
CTTCCCCTCCTCCCTTTGAAGTGCATTAGTTGTGATT
TCTGCCTCCTTTTCTTTTTTCTTTCTTTTTTGTTTTG
CTTTTTCCCCCCTTTTGAATTATGTGCTGCTGTTAAA
CAACAACAAAAAAACAACAAAACACAGCAGCTGCGGA
CTTGTCCCCGGCTGGAGCCCAGCGCCCCGCCTGGAGT
GGATGAGCCTCTCCATGAGAGATCCGGTCATTCCTGG
GACAAGCATGGCCTACCATCCGTTCCTACCTCACCGG
GCGCCGGACTTCGCCATGAGCGCGGTGCTGGGTCACC
AGCCGCCGTTCTTCCCCGCGCTGACGCTGCCTCCCAA
CGGCGCGGCGGCGCTCTCGCTGCCGGGCGCCCTGGCC
AAGCCGATCATGGATCAATTGGTGGGGGCGGCCGAGA
CCGGCATCCCGTTCTCCTCCCTGGGGCCCCAGGCGCA
TCTGAGGCCTTTGAAGACCATGGAGCCCGAAGAAGAG
GTGGAGGACGACCCCAAGGTGCACCTGGAGGCTAAAG
AACTTTGGGATCAGTTTCACAAGCGGGGCACCGAGAT
GGTCATTACCAAGTCGGGAAGGCGAATGTTTCCTCCA
TTTAAAGTGAGATGTTCTGGGCTGGATAAAAAAGCCA
AATACATTTTATTGATGGACATTATAGCTGCTGATGA
CTGTCGTTATAAATTTCACAATTCTCGGTGGATGGTG
GCTGGTAAGGCCGACCCCGAAATGCCAAAGAGGATGT
ACATTCACCCGGACAGCCCCGCTACTGGGGAACAGTG
GATGTCCAAAGTCGTCACTTTCCACAAACTGAAACTC
ACCAACAACATTTCAGACAAACATGGATTTACTATAT
TGAACTCCATGCACAAATACCAGCCCCGGTTCCACAT
TGTAAGAGCCAATGACATCTTGAAACTCCCTTATAGT
ACATTTCGGACATACTTGTTCCCCGAAACTGAATTCA
TCGCTGTGACTGCATACCAGAATGATAAGATAACCCA
GTTAAAAATAGACAACAACCCTTTTGCAAAAGGTTTC
CGGGACACTGGAAATGGCCGAAGAGAAAAAAGAAAAC
AGCTCACCCTGCAGTCCATGAGGGTGTTTGATGAAAG
ACACAAAAAGGAGAATGGGACCTCTGATGAGTCCTCC
AGTGAACAAGCAGCTTTCAACTGCTTCGCCCAGGCTT
CTTCTCCAGCCGCCTCCACTGTAGGGACATCGAACCT
CAAAGATTTATGTCCCAGCGAGGGTGAGAGCGACGCC
GAGGCCGAGAGCAAAGAGGAGCATGGCCCCGAGGCCT
GCGACGCGGCCAAGATCTCCACCACCACGTCGGAGGA
GCCCTGCCGTGACAAGGGCAGCCCCGCGGTCAAGGCT
CACCTTTTCGCTGCTGAGCGGCCCCGGGACAGCGGGC
GGCTGGACAAAGCGTCGCCCGACTCACGCCATAGCCC
CGCCACCATCTCGTCCAGCACTCGCGGCCTGGGCGCG
GAGGAGCGCAGGAGCCCGGTTCGCGAGGGCACAGCGC
CGGCCAAGGTGGAAGAGGCGCGCGCGCTCCCGGGCAA
GGAGGCCTTCGCGCCGCTCACGGTGCAGACGGACGCG
GCCGCCGCGCACCTGGCCCAGGGCCCCCTGCCTGGCC
TCGGCTTCGCCCCGGGCCTGGCGGGCCAACAGTTCTT
CAACGGGCACCCGCTCTTCCTGCACCCCAGCCAGTTT
GCCATGGGGGGCGCCTTCTCCAGCATGGCGGCCGCTG
GCATGGGTCCCCTCCTGGCCACGGTTTCTGGGGCCTC
CACCGGTGTCTCGGGCCTGGATTCCACGGCCATGGCC
TCTGCCGCTGCGGCGCAGGGACTGTCCGGGGCGTCCG
CGGCCACCCTGCCCTTCCACCTCCAGCAGCACGTCCT
GGCCTCTCAGGGCCTGGCCATGTCCCCTTTCGGAAGC
CTGTTCCCTTACCCCTACACGTACATGGCCGCAGCGG
CGGCCGCCTCCTCTGCGGCAGCCTCCAGCTCGGTGCA
CCGCCACCCCTTCCTCAATCTGAACACCATGCGCCCG
CGGCTGCGCTACAGCCCCTACTCCATCCCGGTGCCGG
TCCCGGACGGCAGCAGTCTGCTCACCACCGCCCTGCC
CTCCATGGCGGCGGCCGCGGGGCCCCTGGACGGCAAA
GTCGCCGCCCTGGCCGCCAGCCCGGCCTCGGTGGCAG
TGGACTCGGGCTCTGAACTCAACAGCCGCTCCTCCAC
GCTCTCCTCCAGCTCCATGTCCTTGTCGCCCAAACTC
TGCGCGGAGAAAGAGGCGGCCACCAGCGAACTGCAGA
GCATCCAGCGGTTGGTTAGCGGCTTGGAAGCCAAGCC
GGACAGGTCCCGCAGCGCGTCCCCGTAGACCCGTCCC
AGACACGTCTTTTCATTCCAGTCCAGTTCAGGCTGCC
GTGCACTTTGTCGGATATAAAATAAACCACGGGCCCG
CCATGGCGTTAGCCCTTCCTTTTGCAGTTGCGTCTGG
GAAGGGGCCCCGGACTCCCTCGAGAGAATGTGCTAGA
GACAGCCCCTGTCTTCTTGGCGTGGTTTATATGTCCG
GGATCTGGATCAGATTCTGGGGGCTCAGAAACGTCGG
TTGCATTGAGCTACTGGGGGTAGGAGTTCCAACATTT
ATGTCCAGAGCAACTTCCAGCAAGGCTGGTCTGGGTC
TCTGCCCACCAGGCGGGGAGGTGTTCAAAGACATCTC
CCTCAGTGCGGATTTATATATATATTTTTCCTTCACT
GTGTCAAGTGGAAACAAAAACAAAATCTTTCAAAAAA
AAAATCGGGACAAGTGAACACATTAACATGATTCTGT
TTGTGCAGATTAAAAACTTTATAGGGACTTGCATTAT
CGGTTCTCAATAAATTACTGAGCAGCTTTGTTTGGGG
AGGGAAGTCCCTACCATCCTTGTTTAGTCTATATTAA
GAAAATCTGTGTCTTTTTAATATTCTTGTGATGTTTT
CAGAGCCGCTGTAGGTCTCTTCTTGCATGTCCACAGT
AATGTATTTGTGGTTTTTATTTTGAACGCTTGCTTTT
AGAGAGAAAACAATATAGCCCCCTACCCTTTTCCCAA
TCCTTTGCCCTCAAATCAGTGACCCAAGGGAGGGGGG
GATTTAAAGGGAAGGAGTGGGCAAAACACATAAAATG
AATTTATTATATCTAAGCTCTGTAGCAGGATTCATGT
CGTTCTTTGACAGTTCTTTCTCTTTCCTGTATATGCA
ATAACAAGGTTTTAAAAAAATAATAAAGAAGTGAGAC
TATTAGACAAAGTATTTATGTAATTATTTGATAACTC
TTGTAAATAGGTGGAATATGAATGCTTGGAAAATTAA
ACTTTAATTTATTGACATTGTACATAGCTCTGTGTAA
ATAGAATTGCAACTGTCAGGTTTTGTGTTCTTGTTTT
CCTTTAGTTGGGTTTATTTCCAGGTCACAGAATTGCT
GTTAACACTAGAAAACACACTTCCTGCACCAACACCA
ATACCCTTTCAAAAGAGTTGTCTGCAACATTTTTGTT
TTCTTTTTTAATGTCCAAAAGTGGGGGAAAGTGCTAT
TTCCTATTTTCACCAAAATTGGGGAAGGAGTGCCACT
TTCCAGCTCCACTTCAAATTCCTTAAAATATAACTGA
GATTGCTGTGGGGAGGGAGGAGGGCAGAGGCTGCGGT
TTGACTTTTTAATTTTTCTTTTGTTATTTGTATTTGC
TAGTCTCTGATTTCCTCAAAACGAAGTGGAATTTACT
ACTGTTGTCAGTATCGGTGTTTTGAATTGGTGCCTGC
CTATAGAGATATATTCACAGTTCAAAAGTCAGGTGCT
GAGAGATGGTTTAAAGACAAATTCATGAAGGTATATT
TTGTGTTATAGTTGTTGATGAGTTCTTTGGTTTTCTG
TATTTTTCCCCCTCTCTTTAAAACATCACTGAAATTT
CAATAAATTTTTATTGAAATGTCTAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAA Homo
sapiens T-box 3 (TBX3), transcript variant 2, mRNA Accession
Number-NM_016569.3| SEQ ID No. 2
GAATTCTAGAGGCGGCGGAGGGTGGCGAGGAGCTCTC
GCTTTCTCTCGCTCCCTCCCTCTCCGACTCCGTCTCT
CTCTCTCTCTCTCTCTCTCCCCTCCCTCTCTTTCCCT
CTGTTCCATTTTTTCCCCCTCTAAATCCTCCCTGCCC
TGCGCGCCTGGACACAGATTTAGGAAGCGAATTCGCT
CACGTTTTAGGACAAGGAAGAGAGAGAGGCACGGGAG
AAGAGCCCAGCAAGATTTGGATTGAAACCGAGACACC
CTCCGGAGGCTCGGAGCAGAGGAAGGAGGAGGAGGGC
GGCGAACGGAAGCCAGTTTGCAATTCAAGTTTTGATA
GCGCTGGTAGAAGGGGGTTTAAATCAGATTTTTTTTT
TTTTAAAGGAGAGAGACTTTTTCCGCTCTCTCGCTCC
CTGTTAAAGCCGGGTCTAGCACAGCTGCAGACGCCAC
CAGCGAGAAAGAGGGAGAGGAAGACAGATAGGGGGCG
GGGGAAGAAGAAAAAGAAAGGTAAAAAGTCTTCTAGG
AGAACCTTTCACATTTGCAACAAAAGACCTAGGGGCT
GGAGAGAGATTCCTGGGACGCAGGGCTGGAGTGTCTA
TTTCGAGCTCAGCGGCAGGGCTCGGGCGCGAGTCGAG
ACCCTGCTCGCTCCTCTCGCTTCTGAAACCGACGTTC
AGGAGCGGCTTTTTAAAAACGCAAGGCACAAGGACGG
TCACCCGCGCGACTATGTTTGCTGATTTTTCGCCTTG
CCCTCTTTAAAAGCGGCCTCCCATTCTCCAAAAGACA
CTTCCCCTCCTCCCTTTGAAGTGCATTAGTTGTGATT
TCTGCCTCCTTTTCTTTTTTCTTTCTTTTTTGTTTTG
CTTTTTCCCCCCTTTTGAATTATGTGCTGCTGTTAAA
CAACAACAAAAAAACAACAAAACACAGCAGCTGCGGA
CTTGTCCCCGGCTGGAGCCCAGCGCCCCGCCTGGAGT
GGATGAGCCTCTCCATGAGAGATCCGGTCATTCCTGG
GACAAGCATGGCCTACCATCCGTTCCTACCTCACCGG
GCGCCGGACTTCGCCATGAGCGCGGTGCTGGGTCACC
AGCCGCCGTTCTTCCCCGCGCTGACGCTGCCTCCCAA
CGGCGCGGCGGCGCTCTCGCTGCCGGGCGCCCTGGCC
AAGCCGATCATGGATCAATTGGTGGGGGCGGCCGAGA
CCGGCATCCCGTTCTCCTCCCTGGGGCCCCAGGCGCA
TCTGAGGCCTTTGAAGACCATGGAGCCCGAAGAAGAG
GTGGAGGACGACCCCAAGGTGCACCTGGAGGCTAAAG
AACTTTGGGATCAGTTTCACAAGCGGGGCACCGAGAT
GGTCATTACCAAGTCGGGAAGGCGAATGTTTCCTCCA
TTTAAAGTGAGATGTTCTGGGCTGGATAAAAAAGCCA
AATACATTTTATTGATGGACATTATAGCTGCTGATGA
CTGTCGTTATAAATTTCACAATTCTCGGTGGATGGTG
GCTGGTAAGGCCGACCCCGAAATGCCAAAGAGGATGT
ACATTCACCCGGACAGCCCCGCTACTGGGGAACAGTG
GATGTCCAAAGTCGTCACTTTCCACAAACTGAAACTC
ACCAACAACATTTCAGACAAACATGGATTTACTTTGG
CCTTCCCAAGTGATCACGCTACGTGGCAGGGGAATTA
TAGTTTTGGTACTCAGACTATATTGAACTCCATGCAC
AAATACCAGCCCCGGTTCCACATTGTAAGAGCCAATG
ACATCTTGAAACTCCCTTATAGTACATTTCGGACATA
CTTGTTCCCCGAAACTGAATTCATCGCTGTGACTGCA
TACCAGAATGATAAGATAACCCAGTTAAAAATAGACA
ACAACCCTTTTGCAAAAGGTTTCCGGGACACTGGAAA
TGGCCGAAGAGAAAAAAGAAAACAGCTCACCCTGCAG
TCCATGAGGGTGTTTGATGAAAGACACAAAAAGGAGA
ATGGGACCTCTGATGAGTCCTCCAGTGAACAAGCAGC
TTTCAACTGCTTCGCCCAGGCTTCTTCTCCAGCCGCC
TCCACTGTAGGGACATCGAACCTCAAAGATTTATGTC
CCAGCGAGGGTGAGAGCGACGCCGAGGCCGAGAGCAA
AGAGGAGCATGGCCCCGAGGCCTGCGACGCGGCCAAG
ATCTCCACCACCACGTCGGAGGAGCCCTGCCGTGACA
AGGGCAGCCCCGCGGTCAAGGCTCACCTTTTCGCTGC
TGAGCGGCCCCGGGACAGCGGGCGGCTGGACAAAGCG
TCGCCCGACTCACGCCATAGCCCCGCCACCATCTCGT
CCAGCACTCGCGGCCTGGGCGCGGAGGAGCGCAGGAG
CCCGGTTCGCGAGGGCACAGCGCCGGCCAAGGTGGAA
GAGGCGCGCGCGCTCCCGGGCAAGGAGGCCTTCGCGC
CGCTCACGGTGCAGACGGACGCGGCCGCCGCGCACCT
GGCCCAGGGCCCCCTGCCTGGCCTCGGCTTCGCCCCG
GGCCTGGCGGGCCAACAGTTCTTCAACGGGCACCCGC
TCTTCCTGCACCCCAGCCAGTTTGCCATGGGGGGCGC
CTTCTCCAGCATGGCGGCCGCTGGCATGGGTCCCCTC
CTGGCCACGGTTTCTGGGGCCTCCACCGGTGTCTCGG
GCCTGGATTCCACGGCCATGGCCTCTGCCGCTGCGGC
GCAGGGACTGTCCGGGGCGTCCGCGGCCACCCTGCCC
TTCCACCTCCAGCAGCACGTCCTGGCCTCTCAGGGCC
TGGCCATGTCCCCTTTCGGAAGCCTGTTCCCTTACCC
CTACACGTACATGGCCGCAGCGGCGGCCGCCTCCTCT
GCGGCAGCCTCCAGCTCGGTGCACCGCCACCCCTTCC
TCAATCTGAACACCATGCGCCCGCGGCTGCGCTACAG
CCCCTACTCCATCCCGGTGCCGGTCCCGGACGGCAGC
AGTCTGCTCACCACCGCCCTGCCCTCCATGGCGGCGG
CCGCGGGGCCCCTGGACGGCAAAGTCGCCGCCCTGGC
CGCCAGCCCGGCCTCGGTGGCAGTGGACTCGGGCTCT
GAACTCAACAGCCGCTCCTCCACGCTCTCCTCCAGCT
CCATGTCCTTGTCGCCCAAACTCTGCGCGGAGAAAGA
GGCGGCCACCAGCGAACTGCAGAGCATCCAGCGGTTG
GTTAGCGGCTTGGAAGCCAAGCCGGACAGGTCCCGCA
GCGCGTCCCCGTAGACCCGTCCCAGACACGTCTTTTC
ATTCCAGTCCAGTTCAGGCTGCCGTGCACTTTGTCGG
ATATAAAATAAACCACGGGCCCGCCATGGCGTTAGCC
CTTCCTTTTGCAGTTGCGTCTGGGAAGGGGCCCCGGA
CTCCCTCGAGAGAATGTGCTAGAGACAGCCCCTGTCT
TCTTGGCGTGGTTTATATGTCCGGGATCTGGATCAGA
TTCTGGGGGCTCAGAAACGTCGGTTGCATTGAGCTAC
TGGGGGTAGGAGTTCCAACATTTATGTCCAGAGCAAC
TTCCAGCAAGGCTGGTCTGGGTCTCTGCCCACCAGGC
GGGGAGGTGTTCAAAGACATCTCCCTCAGTGCGGATT
TATATATATATTTTTCCTTCACTGTGTCAAGTGGAAA
CAAAAACAAAATCTTTCAAAAAAAAAATCGGGACAAG
TGAACACATTAACATGATTCTGTTTGTGCAGATTAAA
AACTTTATAGGGACTTGCATTATCGGTTCTCAATAAA
TTACTGAGCAGCTTTGTTTGGGGAGGGAAGTCCCTAC
CATCCTTGTTTAGTCTATATTAAGAAAATCTGTGTCT
TTTTAATATTCTTGTGATGTTTTCAGAGCCGCTGTAG
GTCTCTTCTTGCATGTCCACAGTAATGTATTTGTGGT
TTTTATTTTGAACGCTTGCTTTTAGAGAGAAAACAAT
ATAGCCCCCTACCCTTTTCCCAATCCTTTGCCCTCAA
ATCAGTGACCCAAGGGAGGGGGGGATTTAAAGGGAAG
GAGTGGGCAAAACACATAAAATGAATTTATTATATCT
AAGCTCTGTAGCAGGATTCATGTCGTTCTTTGACAGT
TCTTTCTCTTTCCTGTATATGCAATAACAAGGTTTTA
AAAAAATAATAAAGAAGTGAGACTATTAGACAAAGTA
TTTATGTAATTATTTGATAACTCTTGTAAATAGGTGG
AATATGAATGCTTGGAAAATTAAACTTTAATTTATTG
ACATTGTACATAGCTCTGTGTAAATAGAATTGCAACT
GTCAGGTTTTGTGTTCTTGTTTTCCTTTAGTTGGGTT
TATTTCCAGGTCACAGAATTGCTGTTAACACTAGAAA
ACACACTTCCTGCACCAACACCAATACCCTTTCAAAA
GAGTTGTCTGCAACATTTTTGTTTTCTTTTTTAATGT
CCAAAAGTGGGGGAAAGTGCTATTTCCTATTTTCACC
AAAATTGGGGAAGGAGTGCCACTTTCCAGCTCCACTT
CAAATTCCTTAAAATATAACTGAGATTGCTGTGGGGA
GGGAGGAGGGCAGAGGCTGCGGTTTGACTTTTTAATT
TTTCTTTTGTTATTTGTATTTGCTAGTCTCTGATTTC
CTCAAAACGAAGTGGAATTTACTACTGTTGTCAGTAT
CGGTGTTTTGAATTGGTGCCTGCCTATAGAGATATAT
TCACAGTTCAAAAGTCAGGTGCTGAGAGATGGTTTAA
AGACAAATTCATGAAGGTATATTTTGTGTTATAGTTG
TTGATGAGTTCTTTGGTTTTCTGTATTTTTCCCCCTC
TCTTTAAACATCACTGAAATTTCAATAAATTTTTATT
GAAATGTCTAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAA Homo sapiens T-box 5
(TBX5), transcript variant 1, mRNA Accession Number-NM_000192.3 SEQ
ID No. 3 CATGCCTTATGCAAGAGACCTCAGTCCCCCGGAACAA
CTCGATTTCCTTCCAATAGAGGTCTGAGGTGGACTCC
CACCTCCCTTCGTGAAGAGTTCCCTCCTCTCCCCCT
TCCTAAGAAAGTCGATCTTGGCTCTATTTGTGTCTT
ATGTTCATCACCCTCATTCCTCCGGAGAAAGCCGGG
TTGGTTTATGTCTTTATTTATTCCCGGGGCCAAGAC
GTCCGGAACCTGTGGCTGCGCAGACCCGGCACTGAT
AGGCGAAGACGGAGAGAAATTTACCTCCCGCCGCTG
CCCCCCAGCCAAACGTGACAGCGCGCGGGCCGGTTG
CGTGACTCGTGACGTCTCCAAGTCCTATAGGTGCAG
CGGCTGGTGAGATAGTCGCTATCGCCTGGTTGCCTC
TTTATTTTACTGGGGTATGCCTGGTAATAAACAGTA
ATATTTAATTTGTCGGAGACCACAAACCAACCTTGA
GCTGGGAGGTACGTGCTCTTCTTGACAGACGTTGGA
AGAAGACCTGGCCTAAAGAGGTCTCTTTTGGTGGTC
CTTTTCAAAGTCTTCACCTGAGCCCTGCTCTCCAGC
GAGGCGCACTCCTGGCTTTTGCGCTCCAAAGAAGAG
GTGGGATAGTTGGAGAGCAGAACCTTGCGCGGGCAC
AGGGCCCTGGGCGCACCATGGCCGACGCAGACGAGG
GCTTTGGCCTGGCGCACACGCCTCTGGAGCCTGACG
CAAAAGACCTGCCCTGCGATTCGAAACCCGAGAGCG
CGCTCGGGGCCCCCAGCAAGTCCCCGTCGTCCCCGC
AGGCCGCCTTCACCCAGCAGGGCATGGAGGGAATCA
AAGTGTTTCTCCATGAAAGAGAACTGTGGCTAAAAT
TCCACGAAGTGGGCACGGAAATGATCATAACCAAGG
CTGGAAGGCGGATGTTTCCCAGTTACAAAGTGAAGG
TGACGGGCCTTAATCCCAAAACGAAGTACATTCTTC
TCATGGACATTGTACCTGCCGACGATCACAGATACA
AATTCGCAGATAATAAATGGTCTGTGACGGGCAAAG
CTGAGCCCGCCATGCCTGGCCGCCTGTACGTGCACC
CAGACTCCCCCGCCACCGGGGCGCATTGGATGAGGC
AGCTCGTCTCCTTCCAGAAACTCAAGCTCACCAACA
ACCACCTGGACCCATTTGGGCATATTATTCTAAATT
CCATGCACAAATACCAGCCTAGATTACACATCGTGA
AAGCGGATGAAAATAATGGATTTGGCTCAAAAAATA
CAGCGTTCTGCACTCACGTCTTTCCTGAGACTGCGT
TTATAGCAGTGACTTCCTACCAGAACCACAAGATCA
CGCAATTAAAGATTGAGAATAATCCCTTTGCCAAAG
GATTTCGGGGCAGTGATGACATGGAGCTGCACAGAA
TGTCAAGAATGCAAAGTAAAGAATATCCCGTGGTCC
CCAGGAGCACCGTGAGGCAAAAAGTGGCCTCCAACC
ACAGTCCTTTCAGCAGCGAGTCTCGAGCTCTCTCCA
CCTCATCCAATTTGGGGTCCCAATACCAGTGTGAGA
ATGGTGTTTCCGGCCCCTCCCAGGACCTCCTGCCTC
CACCCAACCCATACCCACTGCCCCAGGAGCATAGCC
AAATTTACCATTGTACCAAGAGGAAAGAGGAAGAAT
GTTCCACCACAGACCATCCCTATAAGAAGCCCTACA
TGGAGACATCACCCAGTGAAGAAGATTCCTTCTACC
GCTCTAGCTATCCACAGCAGCAGGGCCTGGGTGCCT
CCTACAGGACAGAGTCGGCACAGCGGCAAGCTTGCA
TGTATGCCAGCTCTGCGCCCCCCAGCGAGCCTGTGC
CCAGCCTAGAGGACATCAGCTGCAACACGTGGCCAA
GCATGCCTTCCTACAGCAGCTGCACCGTCACCACCG
TGCAGCCCATGGACAGGCTACCCTACCAGCACTTCT
CCGCTCACTTCACCTCGGGGCCCCTGGTCCCTCGGC
TGGCTGGCATGGCCAACCATGGCTCCCCACAGCTGG
GAGAGGGAATGTTCCAGCACCAGACCTCCGTGGCCC
ACCAGCCTGTGGTCAGGCAGTGTGGGCCTCAGACTG
GCCTGCAGTCCCCTGGCACCCTTCAGCCCCCTGAGT
TCCTCTACTCTCATGGCGTGCCAAGGACTCTATCCC
CTCATCAGTACCACTCTGTGCACGGAGTTGGCATGG
TGCCAGAGTGGAGCGACAATAGCTAAAGTGAGGCCT
GCTTCACAACAGACATTTCCTAGAGAAAGAGAGAGA
GAGAGGAGAAAGAGAGAGAAGGAGAGAGACAGTAGC
CAAGAGAACCCCACGGACAAGATTTTTCATTTCACC
CAATGTTCACATCTGCACTCAAGGTCGCTGGATGCT
GATCTAATCAGTAGCTTGAAACCACAATTTTAAAAA
TGTGACTTTCTTGTTTTGTCTCAAAACTTAAAAAAA
CAAACACAAAAAGATGAGTCCCACCCCCCACTACCA
CCACACCCATCAACCAGCCACATTCACGCTACTCCC
CAGATCTCTTCCCCCATTCCTTCTTTTGGGCTCTAG
AAAGTCTTGCCTCATTGAGTGTTTTTCCCTAGTGCG
TAGTTGGAGTCTGTCCCTGTCTTGGTGTTAATGTTG
ACATTGTTATATAATAAATGATAATATATTTTTTTC
TTTCAATTTTCTTAATGGGACCCAGTCCCTTATTTG
GGGGGAGGTCTGAGGCAAGTATATTTCAAAATATGT
ACTTGCGGGATTCCCTTCAAGTAAACCATCCCTGAA
ACCTAAATTCACGTTTCCCCTTGACTAAGAAAAGCA
CCTACCTCTGCCATGTGATGTTTCTGAAAAGCCTCT
GTATGTCCCCATTTGCTTTGGTTTTGTCCTGCCTTC
TCCAATATCACGTGCTCAGTTTTGCCTCTACTTACC
CATGGAGTCAGGATAACACTGACGCTCCCTGGCATC
CTATCTTATTCAGCCCTACCATCTTGCCAGCTCTGT
CTTTCCAGCTGTCTGTCGCTAAAACGTGGCCTATAG
CTTCCCTTCCGGAAAGCTTGCTTTGAAAAACTTAAA
AAGCCCCCGTTTACATGTAGGCAGGACTGTGATAAC
AGTGCAAGCTCTGTGTTGACAAGAGTTGTGGACAAA
AAGCCAAAATAAATATTCTTCCTGATTAAAAAAATT
TTTTTTGAAAAAAACAAGGCCAGCCCCAACCTTCCA
AACCTCCATCACCAACAACCCAAACTGGATGTCAAG
CAAAATGCACAATTCCTACAGAAGAGGCAAGACACA
GTCACCAATGATATCTCGCCAAAGAAACCACGCCCA
CACCAATGCCAACACAAAACTGTGTTTACTGAAAGC
CGAAAACAGTATTAAAAAAAGTGTGTAAGTAAAGTG
TTATGGTAGGGTTCTTCAGATGTAATATTTTACTGG
TACTATTTATTTATAAATAGGAATTCTAATTAAGTA
ATAACATGAAATGAAACCCAGCATAGGAGCTGGCCA
AGAGCTTTTAATTTTATTGATACTCAAAACCAAGTT
TGTGTTTTTTTGTTTTTTTTTGTTTTTTTCCTCTTT
CGAATGTGCTTTGCTTTTTTTGATTAAAAAGAATTT
TTTTTTTCCTTTTTTATAAACAGACCCTAATAAAGA
GAACAGGGTAAGATGTGAGGCTGAGTGTGTTTAAGT
ACGTGAGAGAGTGTGAGTGTGTTTGTAAGTGAGTGT
CCCTATGCGATTATGTCTCTTTACGTTGCTAAGGGG
GGAGGGTGAGGATTAAGTACTCGTGCCTTATATTTG
TGTGCCAATTAATGCCTAATAAATACCATGTGCTTA
AACAAGTAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA Homo sapiens T-box 5 (TBX5),
transcript variant 2, mRNA
Accession Number-NM_080718.1 SEQ ID NO. 4
ATGGCCGACGCAGACGAGGGCTTTGGCCTGGCGCACAC
GCCTCTGGAGCCTGACGCAAAAGACCTGCCCTGCGATT
CGAAACCCGAGAGCGCGCTCGGGGCCCCCAGCAAGTCC
CCGTCGTCCCCGCAGGCCGCCTTCACCCAGCAGGGCAT
GGAGGGAATCAAAGTGTTTCTCCATGAAAGAGAACTGT
GGCTAAAATTCCACGAAGTGGGCACGGAAATGATCATA
ACCAAGGCTGGAAGGCGGATGTTTCCCAGTTACAAAGT
GAAGGTGACGGGCCTTAATCCCAAAACGAAGTACATTC
TTCTCATGGACATTGTACCTGCCGACGATCACAGATAC
AAATTCGCAGATAATAAATGGTCTGTGACGGGCAAAGC
TGAGCCCGCCATGCCTGGCCGCCTGTACGTGCACCCAG
ACTCCCCCGCCACCGGGGCGCATTGGATGAGGCAGCTC
GTCTCCTTCCAGAAACTCAAGCTCACCAACAACCACCT
GGACCCATTTGGGCATATTATTCTAAATTCCATGCACA
AATACCAGCCTAGATTACACATCGTGAAAGCGGATGAA
AATAATGGATTTGGCTCAAAAAATACAGCGTTCTGCAC
TCACGTCTTTCCTGAGACTGCGTTTATAGCAGTGACTT
CCTACCAGAACCACAAGATCACGCAATTAAAGATTGAG
AATAATCCCTTTGCCAAAGGATTTCGGGGCAGTGATGA
CATGGAGCTGCACAGAATGTCAAGAATGCAAAGTAAAG
AATATCCCGTGGTCCCCAGGAGCACCGTGAGGCAAAAA
GTGGCCTCCAACCACAGTCCTTTCAGCAGCGAGTCTCG
AGCTCTCTCCACCTCATCCAATTTGGGGTCCCAATACC
AGTGTGAGAATGGTGTTTCCGGCCCCTCCCAGGACCTC
CTGCCTCCACCCAACCCATACCCACTGCCCCAGGAGCA
TAGCCAAATTTACCATTGTACCAAGAGGAAAGGTGAGT
GTGATCACCCCTGGTCAATTTGCTTTCTTTCTTACCTT TTCCTTTCCTTGGGTTGGGGGTGA
Homo sapiens T-box 5 (TBX5), transcript variant 3, mRNA Accession
Number-NM_080717.2| SEQ ID No. 5
CATGCCTTATGCAAGAGACCTCAGTCCCCCGGAACAAC
TCGATTTCCTTCCAATAGAGGTCTGAGGTGGACTCCCA
CCTCCCTTCGTGAAGAGTTCCCTCCTCTCCCCCTTCCT
AAGAAAGTCGATCTTGGCTCTATTTGTGTCTTATGTTC
ATCACCCTCATTCCTCCGGAGAAAGCCGGGTTGGTTTA
TGTCTTTATTTATTCCCGGGGCCAAGACGTCCGGAACC
TGTGGCTGCGCAGACCCGGCACTGATAGGCGAAGACGG
AGAGAAATTTACCTCCCGCCGCTGCCCCCCAGCCAAAC
GTGACAGCGCGCGGGCCGGTTGCGTGACTCGTGACGTC
TCCAAGTCCTATAGGTGCAGCGGCTGGTGAGATAGTCG
CTATCGCCTGGTTGCCTCTTTATTTTACTGGGGTATGC
CTGGTAATAAACAGTAATATTTAATTTGTCGGAGACCA
CAAACCAACCTTGAGCTGGGAGGTACGTGCTCTTCTTG
ACAGACGTTGGAAGAAGACCTGGCCTAAAGAGGTCTCT
TTTGGTGGTCCTTTTCAAAGTCTTCACCTGAGCCCTGC
TCTCCAGCGAGGCGCACTCCTGGCTTTTGCGCTCCAAA
GAAGAGGTGGGATAGTTGGAGGGCATGGAGGGAATCAA
AGTGTTTCTCCATGAAAGAGAACTGTGGCTAAAATTCC
ACGAAGTGGGCACGGAAATGATCATAACCAAGGCTGGA
AGGCGGATGTTTCCCAGTTACAAAGTGAAGGTGACGGG
CCTTAATCCCAAAACGAAGTACATTCTTCTCATGGACA
TTGTACCTGCCGACGATCACAGATACAAATTCGCAGAT
AATAAATGGTCTGTGACGGGCAAAGCTGAGCCCGCCAT
GCCTGGCCGCCTGTACGTGCACCCAGACTCCCCCGCCA
CCGGGGCGCATTGGATGAGGCAGCTCGTCTCCTTCCAG
AAACTCAAGCTCACCAACAACCACCTGGACCCATTTGG
GCATATTATTCTAAATTCCATGCACAAATACCAGCCTA
GATTACACATCGTGAAAGCGGATGAAAATAATGGATTT
GGCTCAAAAAATACAGCGTTCTGCACTCACGTCTTTCC
TGAGACTGCGTTTATAGCAGTGACTTCCTACCAGAACC
ACAAGATCACGCAATTAAAGATTGAGAATAATCCCTTT
GCCAAAGGATTTCGGGGCAGTGATGACATGGAGCTGCA
CAGAATGTCAAGAATGCAAAGTAAAGAATATCCCGTGG
TCCCCAGGAGCACCGTGAGGCAAAAAGTGGCCTCCAAC
CACAGTCCTTTCAGCAGCGAGTCTCGAGCTCTCTCCAC
CTCATCCAATTTGGGGTCCCAATACCAGTGTGAGAATG
GTGTTTCCGGCCCCTCCCAGGACCTCCTGCCTCCACCC
AACCCATACCCACTGCCCCAGGAGCATAGCCAAATTTA
CCATTGTACCAAGAGGAAAGAGGAAGAATGTTCCACCA
CAGACCATCCCTATAAGAAGCCCTACATGGAGACATCA
CCCAGTGAAGAAGATTCCTTCTACCGCTCTAGCTATCC
ACAGCAGCAGGGCCTGGGTGCCTCCTACAGGACAGAGT
CGGCACAGCGGCAAGCTTGCATGTATGCCAGCTCTGCG
CCCCCCAGCGAGCCTGTGCCCAGCCTAGAGGACATCAG
CTGCAACACGTGGCCAAGCATGCCTTCCTACAGCAGCT
GCACCGTCACCACCGTGCAGCCCATGGACAGGCTACCC
TACCAGCACTTCTCCGCTCACTTCACCTCGGGGCCCCT
GGTCCCTCGGCTGGCTGGCATGGCCAACCATGGCTCCC
CACAGCTGGGAGAGGGAATGTTCCAGCACCAGACCTCC
GTGGCCCACCAGCCTGTGGTCAGGCAGTGTGGGCCTCA
GACTGGCCTGCAGTCCCCTGGCACCCTTCAGCCCCCTG
AGTTCCTCTACTCTCATGGCGTGCCAAGGACTCTATCC
CCTCATCAGTACCACTCTGTGCACGGAGTTGGCATGGT
GCCAGAGTGGAGCGACAATAGCTAAAGTGAGGCCTGCT
TCACAACAGACATTTCCTAGAGAAAGAGAGAGAGAGAG
GAGAAAGAGAGAGAAGGAGAGAGACAGTAGCCAAGAGA
ACCCCACGGACAAGATTTTTCATTTCACCCAATGTTCA
CATCTGCACTCAAGGTCGCTGGATGCTGATCTAATCAG
TAGCTTGAAACCACAATTTTAAAAATGTGACTTTCTTG
TTTTGTCTCAAAACTTAAAAAAACAAACACAAAAAGAT
GAGTCCCACCCCCCACTACCACCACACCCATCAACCAG
CCACATTCACGCTACTCCCCAGATCTCTTCCCCCATTC
CTTCTTTTGGGCTCTAGAAAGTCTTGCCTCATTGAGTG
TTTTTCCCTAGTGCGTAGTTGGAGTCTGTCCCTGTCTT
GGTGTTAATGTTGACATTGTTATATAATAAATGATAAT
ATATTTTTTTCTTTCAATTTTCTTAATGGGACCCAGTC
CCTTATTTGGGGGGAGGTCTGAGGCAAGTATATTTCAA
AATATGTACTTGCGGGATTCCCTTCAAGTAAACCATCC
CTGAAACCTAAATTCACGTTTCCCCTTGACTAAGAAAA
GCACCTACCTCTGCCATGTGATGTTTCTGAAAAGCCTC
TGTATGTCCCCATTTGCTTTGGTTTTGTCCTGCCTTCT
CCAATATCACGTGCTCAGTTTTGCCTCTACTTACCCAT
GGAGTCAGGATAACACTGACGCTCCCTGGCATCCTATC
TTATTCAGCCCTACCATCTTGCCAGCTCTGTCTTTCCA
GCTGTCTGTCGCTAAAACGTGGCCTATAGCTTCCCTTC
CGGAAAGCTTGCTTTGAAAAACTTAAAAAGCCCCCGTT
TACATGTAGGCAGGACTGTGATAACAGTGCAAGCTCTG
TGTTGACAAGAGTTGTGGACAAAAAGCCAAAATAAATA
TTCTTCCTGATTAAAAAAATTTTTTTTGAAAAAAACAA
GGCCAGCCCCAACCTTCCAAACCTCCATCACCAACAAC
CCAAACTGGATGTCAAGCAAAATGCACAATTCCTACAG
AAGAGGCAAGACACAGTCACCAATGATATCTCGCCAAA
GAAACCACGCCCACACCAATGCCAACACAAAACTGTGT
TTACTGAAAGCCGAAAACAGTATTAAAAAAAGTGTGTA
AGTAAAGTGTTATGGTAGGGTTCTTCAGATGTAATATT
TTACTGGTACTATTTATTTATAAATAGGAATTCTAATT
AAGTAATAACATGAAATGAAACCCAGCATAGGAGCTGG
CCAAGAGCTTTTAATTTTATTGATACTCAAAACCAAGT
TTGTGTTTTTTTGTTTTTTTTTGTTTTTTTCCTCTTTC
GAATGTGCTTTGCTTTTTTTGATTAAAAAGAATTTTTT
TTTTCCTTTTTTATAAACAGACCCTAATAAAGAGAACA
GGGTAAGATGTGAGGCTGAGTGTGTTTAAGTACGTGAG
AGAGTGTGAGTGTGTTTGTAAGTGAGTGTCCCTATGCG
ATTATGTCTCTTTACGTTGCTAAGGGGGGAGGGTGAGG
ATTAAGTACTCGTGCCTTATATTTGTGTGCCAATTAAT
GCCTAATAAATACCATGTGCTTAAACAAGTAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAA Homo sapiens
T-box 5 (TBX5), transcript variant 4, mRNA Accession
Number-NM_181486.1 SEQ ID No. 6
TTCAGAGAGAGAGAGAGAGGGAGAGAGAGTGAGAGAGA
CTGACTCTTACCTCGAATCCGGGAACTTTAATCCTGAA
AGCTGCGCTCAGAAAGGACTTCGACCATTCACTGGGCT
TCCAACTTTCCCTCCCTGGGGGTGTAAAGGAGGAGCGG
GGCACTGAGATTATATGGTTGCCGGTGCTCTTGGAGGC
TATTTTGTGTTCTTTGGCGCTTGCCAACTGGGAAGTAT
TTAGGGAGAGCAAGCGCACAGCAGAGGAGGTGTGTGTT
GGAGGTGGGCAGTCGCCGCGGAGGCTCCAGCGGTAGGT
GCGCCCTAGTAGGCAGCAGTAGCCGCTATTCTGGGTAA
GCAGTAAACCCCGCATAAACCCCGGAGCCACCATGCCT
GCTCCCCCGCCTCACCGCCGGCTTCCCTGCTAGGAGCA
GCAGAGGATGTGGTGAATGCACCGGCTTCACCGAACGA
GAGCAGAACCTTGCGCGGGCACAGGGCCCTGGGCGCAC
CATGGCCGACGCAGACGAGGGCTTTGGCCTGGCGCACA
CGCCTCTGGAGCCTGACGCAAAAGACCTGCCCTGCGAT
TCGAAACCCGAGAGCGCGCTCGGGGCCCCCAGCAAGTC
CCCGTCGTCCCCGCAGGCCGCCTTCACCCAGCAGGGCA
TGGAGGGAATCAAAGTGTTTCTCCATGAAAGAGAACTG
TGGCTAAAATTCCACGAAGTGGGCACGGAAATGATCAT
AACCAAGGCTGGAAGGCGGATGTTTCCCAGTTACAAAG
TGAAGGTGACGGGCCTTAATCCCAAAACGAAGTACATT
CTTCTCATGGACATTGTACCTGCCGACGATCACAGATA
CAAATTCGCAGATAATAAATGGTCTGTGACGGGCAAAG
CTGAGCCCGCCATGCCTGGCCGCCTGTACGTGCACCCA
GACTCCCCCGCCACCGGGGCGCATTGGATGAGGCAGCT
CGTCTCCTTCCAGAAACTCAAGCTCACCAACAACCACC
TGGACCCATTTGGGCATATTATTCTAAATTCCATGCAC
AAATACCAGCCTAGATTACACATCGTGAAAGCGGATGA
AAATAATGGATTTGGCTCAAAAAATACAGCGTTCTGCA
CTCACGTCTTTCCTGAGACTGCGTTTATAGCAGTGACT
TCCTACCAGAACCACAAGATCACGCAATTAAAGATTGA
GAATAATCCCTTTGCCAAAGGATTTCGGGGCAGTGATG
ACATGGAGCTGCACAGAATGTCAAGAATGCAAAGTAAA
GAATATCCCGTGGTCCCCAGGAGCACCGTGAGGCAAAA
AGTGGCCTCCAACCACAGTCCTTTCAGCAGCGAGTCTC
GAGCTCTCTCCACCTCATCCAATTTGGGGTCCCAATAC
CAGTGTGAGAATGGTGTTTCCGGCCCCTCCCAGGACCT
CCTGCCTCCACCCAACCCATACCCACTGCCCCAGGAGC
ATAGCCAAATTTACCATTGTACCAAGAGGAAAGAGGAA
GAATGTTCCACCACAGACCATCCCTATAAGAAGCCCTA
CATGGAGACATCACCCAGTGAAGAAGATTCCTTCTACC
GCTCTAGCTATCCACAGCAGCAGGGCCTGGGTGCCTCC
TACAGGACAGAGTCGGCACAGCGGCAAGCTTGCATGTA
TGCCAGCTCTGCGCCCCCCAGCGAGCCTGTGCCCAGCC
TAGAGGACATCAGCTGCAACACGTGGCCAAGCATGCCT
TCCTACAGCAGCTGCACCGTCACCACCGTGCAGCCCAT
GGACAGGCTACCCTACCAGCACTTCTCCGCTCACTTCA
CCTCGGGGCCCCTGGTCCCTCGGCTGGCTGGCATGGCC
AACCATGGCTCCCCACAGCTGGGAGAGGGAATGTTCCA
GCACCAGACCTCCGTGGCCCACCAGCCTGTGGTCAGGC
AGTGTGGGCCTCAGACTGGCCTGCAGTCCCCTGGCACC
CTTCAGCCCCCTGAGTTCCTCTACTCTCATGGCGTGCC
AAGGACTCTATCCCCTCATCAGTACCACTCTGTGCACG
GAGTTGGCATGGTGCCAGAGTGGAGCGACAATAGCTAA
AGTGAGGCCTGCTTCACAACAGACATTTCCTAGAGAAA
GAGAGAGAGAGAGGAGAAAGAGAGAGAAGGAGAGAGAC
AGTAGCCAAGAGAACCCCACGGACAAGATTTTTCATTT
CACCCAATGTTCACATCTGCACTCAAGGTCGCTGGATG
CTGATCTAATCAGTAGCTTGAAACCACAATTTTAAAAA
TGTGACTTTCTTGTTTTGTCTCAAAACTTAAAAAAACA
AACACAAAAAGATGAGTCCCACCCCCCACTACCACCAC
ACCCATCAACCAGCCACATTCACGCTACTCCCCAGATC
TCTTCCCCCATTCCTTCTTTTGGGCTCTAGAAAGTCTT
GCCTCATTGAGTGTTTTTCCCTAGTGCGTAGTTGGAGT
CTGTCCCTGTCTTGGTGTTAATGTTGACATTGTTATAT
AATAAATGATAATATATTTTTTTCTTTCAATTTTCTTA
ATGGGACCCAGTCCCTTATTTGGGGGGAGGTCTGAGGC
AAGTATATTTCAAAATATGTACTTGCGGGATTCCCTTC
AAGTAAACCATCCCTGAAACCTAAATTCACGTTTCCCC
TTGACTAAGAAAAGCACCTACCTCTGCCATGTGATGTT
TCTGAAAAGCCTCTGTATGTCCCCATTTGCTTTGGTTT
TGTCCTGCCTTCTCCAATATCACGTGCTCAGTTTTGCC
TCTACTTACCCATGGAGTCAGGATAACACTGACGCTCC
CTGGCATCCTATCTTATTCAGCCCTACCATCTTGCCAG
CTCTGTCTTTCCAGCTGTCTGTCGCTAAAACGTGGCCT
ATAGCTTCCCTTCCGGAAAGCTTGCTTTGAAAAACTTA
AAAAGCCCCCGTTTACATGTAGGCAGGACTGTGATAAC
AGTGCAAGCTCTGTGTTGACAAGAGTTGTGGACAAAAA
GCCAAAATAAATATTCTTCCTGATTAAAAAAATTTTTT
TTGAAAAAAACAAGGCCAGCCCCAACCTTCCAAACCTC
CATCACCAACAACCCAAACTGGATGTCAAGCAAAATGC
ACAATTCCTACAGAAGAGGCAAGACACAGTCACCAATG
ATATCTCGCCAAAGAAACCACGCCCACACCAATGCCAA
CACAAAACTGTGTTTACTGAAAGCCGAAAACAGTATTA
AAAAAAGTGTGTAAGTAAAGTGTTATGGTAGGGTTCTT
CAGATGTAATATTTTACTGGTACTATTTATTTATAAAT
AGGAATTCTAATTAAGTAATAACATGAAATGAAACCCA
GCATAGGAGCTGGCCAAGAGCTTTTAATTTTATTGATA
CTCAAAACCAAGTTTGTGTTTTTTTGTTTTTTTTTGTT
TTTTTCCTCTTTCGAATGTGCTTTGCTTTTTTTGATTA
AAAAGAATTTTTTTTTTCCTTTTTTATAAACAGACCCT
AATAAAGAGAACAGGGTAAGATGTGAGGCTGAGTGTGT
TTAAGTACGTGAGAGAGTGTGAGTGTGTTTGTAAGTGA
GTGTCCCTATGCGATTATGTCTCTTTACGTTGCTAAGGG
GGGAGGGTGAGGATTAAGTACTCGTGCCTTATATTTGTG
TGCCAATTAATGCCTAATAAATACCATGTGCTTAAACAA
GTAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA
AAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA AAAAAAAAAAAAAAAAAAAA Homo
sapiens T-box 18 (TBX18), mRNA Accession Number-NM_001080508.1 SEQ
ID No. 7 ATGGCCGAGAAGCGAAGGGGCTCGCCGTGCAGCATGCTA
AGCCTCAAGGCGCACGCTTTCTCGGTGGAGGCGCTGATC
GGCGCCGAGAAGCAGCAACAGCTTCAGAAGAAGCGGCGA
AAACTGGGCGCCGAAGAGGCGGCGGGGGCCGTGGACGAC
GGAGGCTGCAGCCGCGGCGGCGGCGCGGGCGAAAAGGGT
TCTTCTGAGGGAGACGAAGGCGCTGCGCTCCCGCCGCCG
GCTGGGGCGACGTCTGGGCCGGCTCGGAGTGGCGCAGAC
CTGGAGCGCGGAGCCGCGGGCGGCTGTGAGGACGGCTTC
CAGCAGGGAGCTTCCCCTCTGGCGTCACCGGGAGGCTCC
CCCAAGGGGTCTCCGGCGCGCTCCCTGGCCCGGCCCGGG
ACCCCTCTGCCCTCGCCGCAGGCCCCGCGGGTGGATCTG
CAGGGAGCCGAGCTCTGGAAGCGCTTTCATGAGATAGGC
ACTGAGATGATCATCACCAAGGCCGGCAGGCGCATGTTT
CCAGCAATGAGAGTGAAGATCTCTGGATTAGATCCTCAC
CAGCAATATTACATTGCCATGGATATTGTACCAGTGGAC
AACAAAAGATACAGGTATGTTTACCACAGTTCGAAATGG
ATGGTGGCAGGTAATGCTGACTCGCCTGTGCCACCCCGT
GTGTACATTCATCCAGACTCGCCTGCCTCGGGGGAGACT
TGGATGAGACAAGTTATCAGCTTCGACAAGCTGAAGCTC
ACCAACAATGAACTGGATGACCAAGGCCATATTATTCTT
CATTCTATGCACAAATACCAACCGCGAGTGCACGTCATC
CGTAAAGACTGTGGAGACGATCTTTCTCCCATCAAGCCT
GTTCCATCCGGGGAGGGAGTAAAGGCATTCTCCTTTCCA
GAAACTGTCTTCACAACCGTCACTGCCTATCAGAATCAG
CAGATTACTCGCCTGAAGATAGATAGGAATCCATTTGCT
AAAGGCTTCCGAGACTCCGGGCGCAACAGAATGGGTTTG
GAAGCCTTGGTGGAATCATATGCATTCTGGCGACCATCA
CTACGGACTCTGACCTTTGAAGATATCCCTGGAATTCCCA
AGCAAGGCAATGCAAGTTCCTCCACCTTGCTCCAAGGTAC
TGGGAATGGCGTTCCTGCCACTCACCCTCACCTTTTGTCT
GGCTCCTCTTGCTCCTCTCCTGCCTTCCATCTGGGGCCCA
ACACCAGCCAGCTGTGTAGTCTGGCCCCTGCTGACTATTC
TGCCTGTGCCCGCTCAGGCCTCACCCTCAACCGATACAGC
ACATCTTTGGCAGAGACCTACAACAGGCTCACCAACCAGG
CTGGTGAGACCTTTGCCCCGCCCAGGACTCCCTCCTATGT
GGGCGTGAGCAGCAGCACCTCCGTGAACATGTCCATGGGT
GGCACTGATGGGGACACCTTCAGCTGCCCACAGACCAGCT
TATCCATGCAGATTTCGGGAATGTCCCCCCAGCTCCAGTA
TATCATGCCATCACCCTCCAGCAATGCCTTCGCCACTAAC
CAGACCCATCAGGGTTCCTATAATACTTTTAGATTACACA
GCCCCTGTGCACTATATGGATATAACTTCTCCACATCCCC
CAAACTGGCTGCCAGTCCTGAGAAAATTGTTTCTTCCCAA
GGAAGTTTCTTGGGGTCCTCACCGAGTGGGACCATGACGG
ATCGGCAGATGTTGCCCCCTGTGGAAGGAGTGCACCTGCT
TAGCAGTGGGGGTCAGCAGAGTTTCTTTGACTCTAGGACC
CTAGGAAGCTTAACTCTGTCATCATCTCAAGTATCTGCAC
ATATGGTCTGATGAAGCCTTTAAGTTAAATGACATTTGGA
TCTGTCTAACATATTTTCTTTTTCTTTTTTAAAAGCTATG
TGGAAAGAAACTCTCTGTGGTTTATAAAATGTACATATAA
TAGAAAATGAAGGCTCACTGGGTTTTTTGACTTTATCATG
GTGAGATTGTAATTATCTATGGTATATATGTATGCTGTAT
ATACATAGCACATGGAGTATCACGGCCCCTATTGTTCCCC
TGTTTCATCCAGTTGCACGGAGTATTGGCATGCGTGTAGT
ATGTTTAAGCAAAGTTCTCAGACTCTTTTAAAAACAAGAT
GGTAAACTTAAAACTTGGCAATTATACTATCCAGAAGAAC
ACTTATAACTTAATTTATCAGAAAAATGCTCTAAACGGTT
TCATACTTGATGTATTGATAACCAGCAGTAACCAGCATGT
AGAGTCTTGTGATTTCTGTTATTCTTGGACACAGTGTGAG
AATCTAAAATACAAAAGCCAGTTGAAGTCTTAGTGTTAGT
CCTGAGGTATTTGTAATCATGAAGGATCAGCTTTTTCATT
CCTGCTTATTATTTACCACACATACTATATGACCTTGGGT
CTATAAAAAAATCATAACCCATAATAATTGTTATTTTCTT
AAGGAAGGTAAAGGAGAGGCTTGTGATTTTTTTTTTTACA
CTTTCCATTGGGCACATAAGAGGTTCTTATTCATCTGTAG
AGAACAAATTTCCAGTATTTTCGATTTTTTGCTTATTTTA
TATATCAAATAGACCATTAAAGAATGTTCTATAAACATTT
TTAAATTCCAATTTTCACCAGGGGAGGAATATGTGATATG
AGTGGAATGGCAAAAGGAAAATAAATCCACCTCAAATTCA
TTGATTCCAATGAGAAATGTCTATCTTTTAAATCAAGAGT
AATACTATTGTTAACTATACCTTATGTTTTTGTATAGTTT
GTTTTTAAATTTAGAATATTTTTTCCATCTTGCTCTGAGC
TTCCTGACCGATAGTATATAAGTAAAAAAAATGCATTTAT
GCTACTTATTTATATCTTGTAATTCCTACACATTGAACCC
TTTTCCCCTTCTTAACCTTGTCCGTCTGCCTGAGTCTTTC
CCAAAACAGATAGTTCCTAGGCCTGTATGGTGTTAAATAA
CACGGTGAGGAATTTCAGTAGGTTATCTCCAGCAATCTGT
CTTTTGGGAGCTATAGTGCAAAGGCCAAAGCCCATTACTA
TAAAGACCCTCTTGGAGGACTAAGAAGGAAGATACTAATT
ATGATAAAGGAACTATAAAACTTTTAACCTCAACAGAATT
TGTAATGTCAGAACTGGAGAAATTAAAATCAGTATTAAAT
TTTTTAATTCCTAAAATAATATATGCATGGTTGAAGAGTT
AAAAACAAGTAACTTTGAGAGCACAGTATGAGATAAATAA
AAAAGGCTAAGAATACATGATGAGGCACATTCCCCTTCTG
AGGAGAAAGCGAAATAACATGTCTGTGCATTGACCCATTC
ATTACATTTCATGTATCTTAAGCAAAAGAGCATGATTTTC
TCTCATTGCTAAAAAGAGTTGCTTTAACTCATCCCTGGAT
TTGGTGGGGAAAGGGTACAACTCCTGATTTGCTGTTTCAC
TTTGAAACAACACAATTTGTTAGATACTTAGGGAGATATA
CTGTTGAATTTGCACAGGATGTGACTCTGTTTATACATAT
TAACAAATTTCCTTTTGGATTCCTTAGCAGTTCATCAAAT
TAGTATTAAATTTTTAAATTTAAAACTAGCATGAAGGGAC
ATGAAATATTTGCAGTAGGTGGATCTATGTAAGATGTTTG
GGTATGGCATTAATAGCTTGACAAAGATTTGGGGAAAGGT
GTTAAGAATGAGTCCATCTCAGCCAATAGTGCTTGGTGTA
TAATTCAAGAACAGAGAGTTTTCCATCTTGAAAAAACATG
GAAAGTAATGCTCTATACCCATATGTATTAATAAGAGCAT
TTTCCTTCTTGCCGTTGATCATTTCAGATGATACCACAAT
ATGAGTATAATTTTTTATTAATCTTTTTTCTGGTAAAATT
TTAGCAATATTGTACAAATGCTTTTTTTAGGTTTTACTGT
AAATATTAATCACCACGTCACTTCAGAGACTAGCCTTTTA
TTGCTGAATTAAATGACATGCATACATTGATAATTATATA
TCTGTATTTTATTAAAAAGTACTTAAAATTATATTAAAAT ATGTTATTAAACCCTTT Homo
sapiens short stature homeobox 2 (SHOX2), transcript variant 1,
mRNA Accession Number NM_003030.4 SEQ ID No. 8
CCTCCTCCCTCTCCTCCCCCACCTCCTGTCCCATTGAT
GTGTTATTATTGGGGGGGCTGGAGCAGTAAAAAAAGAA
GAAGGAAAAAAAGAGCGGGGCTCTGCTGGCAGAGGTTG
AGCGCCGGGCTGACGTGCGGCGGCGATGGAAGAACTTA
CGGCGTTCGTCTCCAAGTCTTTTGACCAGAAAGTGAAG
GAGAAGAAGGAGGCGATCACGTACCGGGAGGTGCTGGA
GAGCGGGCCGCTGCGCGGGGCCAAGGAGCCGACCGGCT
GCACCGAGGCGGGCCGCGACGACCGCAGCAGCCCGGCA
GTCCGGGCGGCCGGCGGAGGCGGCGGCGGAGGAGGCGG
AGGCGGCGGCGGAGGAGGCGGAGGAGGTGTAGGAGGAG
GAGGAGCAGGCGGAGGAGCTGGAGGAGGGCGCTCTCCC
GTCCGGGAGCTGGACATGGGCGCCGCCGAGAGAAGCAG
GGAGCCGGGCAGCCCGCGACTGACGGAGGGTAGAAGGA
AGCCAACGAAAGCTGAGGTCCAGGCTACGCTGCTTCTC
CCGGGCGAGGCGTTTCGGTTTCTTGTGTCCCCGGAGCT
GAAAGATCGCAAAGAGGATGCGAAAGGGATGGAGGACG
AAGGCCAGACCAAAATCAAGCAGAGGCGAAGTCGGACC
AATTTCACCCTGGAACAACTCAATGAGCTGGAGAGGCT
TTTTGACGAGACCCACTATCCCGACGCCTTCATGCGAG
AGGAACTGAGCCAGCGACTGGGCCTGTCGGAGGCCCGA
GTGCAGGTTTGGTTTCAAAATCGAAGAGCTAAATGTAG
AAAACAAGAAAATCAACTCCATAAAGGTGTTCTCATAG
GGGCCGCCAGCCAGTTTGAAGCTTGTAGAGTCGCACCT
TATGTCAACGTAGGTGCTTTAAGGATGCCATTTCAGCA
GGATAGTCATTGCAACGTGACGCCCTTGTCCTTTCAGG
TTCAGGCGCAGCTGCAGCTGGACAGCGCTGTGGCGCAC
GCGCACCACCACCTGCATCCGCACCTGGCCGCGCACGC
GCCCTACATGATGTTCCCAGCACCGCCCTTCGGACTGC
CGCTCGCCACGCTGGCCGCGGATTCGGCTTCCGCCGCC
TCGGTAGTGGCGGCCGCAGCAGCCGCCAAGACCACCAG
CAAGAACTCCAGCATCGCCGATCTCAGACTGAAAGCCA
AAAAGCACGCCGCAGCCCTGGGTCTGTGACGCCAACGC
CAGCACCAATGTCGCGCCTGTCCCGCGGCACTCAGCCT
GCACGCCCTCCGCGCCCCGCTGCTTCTCCGTTACCCCT
TTGAGACCTCGGGAGCCGGCCCTCTTCCCGCCTCACTG
ACCATCCCTCGTCCCCTATCGCATCTTGGACTCGGAAA
GCCAGACTCCACGCAGGACCAGGGATCTCACGAGGCAC
GCAGGCTCCGTGGCTCCTGCCCGTTTTCCTACTCGAGG
GCCTAGAATTGGGTTTTGTAGGAGCGGGTTTGGGGGAG
TCTGGAGAGAGACTGGACAGGGGAGTGCTGGAACCGCG
GAGTTTGGCTCACCGCAAAGCTGCAACGATGGACTCTT
GCATAGAAAAAAAAATCTTGTTAACAATGAAAAAATGA
GCAAACAAAAAAATCGAAAGACAAACGGGAGAGAAAAA
GAGGAAGGGAACTTATTTCTTAACTGCTATTTGGCAGA
AGCTGAAATTGGAGAACCAAGGAGCAAAAACAAATTTT
AAAATTAAAGTATTTTATACATTTAAAAATATGGAAAA
ACAACCCAGACGATTCTCGAGAGACTGGGGGGAGTTAC
CAACTTAAATGTGTGTTTTTAAAAATGCGCTAAGAAGG
CAAAGCAGAAAGAAGAGGTATACTTATTTAAAAAACTA
AGATGAAAAAAGTGCGCAGCTGGGAAGTTCACAGGTTT
TGAAACTGACCTTTTTCTGCGAAGTTCACGTTAACACG
AGAAATTTGATGAGAGAGGCGGGCCTCCTTTTACGTTG
AATCAGATGCTTTGAGTTTAAACCCACCATGTATGGAA
GAGCAAGAAAAGAGAAAATATTAAAACGAGGAGAGAGA
AAAATAATATTAACACAAAAAAATGCCACAGACAATGA
TTTCTCTGAGAAATTATTATGGCAAAACTGTCTGGACT
GCTGACAGTAAATTCCGGTTTGCATGTTACTTGTATTC
CATTGATGGTGTGTCTCCTCCCACCCCCTTATCTCCCA
TGCACTCACTCCATTTTCATCTTCACTATGAAAAACAA
TACCAAAAGTATCTGGAAATTGATATATATATATCCAT
ATATATATATCATATATTTGCCATATATATATATATAT
ATATATATATATATATATATATATATTTGCCCTGTCTT
TGATCCTGGGGAACAAAAGAAAAAAGTCAGAAAGGGAA
AAAATTACACTCATTGTCCTAAGAAGACAGAGGTGGGC
AGAATATGTGGGGAAAGGAAAAAGAAAACAAGACCACC
AAATGAAATAATGAAGGTACAGCGCCTCGCTGTGCCAG
ACACAGTAGGCGCTCAATCAGTATTAGTTCCCACCATT
CCCCTTTTCTTGTGTTCCTTCTTGTTGGTTTCCTGAAG
TCCTATTTGAAGACAGTGGTTTATTTCCCCCTCTCTAT
CCCGTCAAATTCACCTTAAATAACACCCAGCTAGATAC
AGGCACTAGGTTTGTGTAAGATATGTTGATACACACGA
ACAAAGTTTATTTTGACTATAATGTGTGGACTGACTTT
CAACATTTGCATTTTATCTCACAAAGGTGTATCTATTC
AAGTAACCTTTTTTTTTTGTTTGTTTGTTTCTTTTTTG
TTTTTTTTTTTCTTTTGGTTGTTTGTTTCAATTCATGT
AGCTATTTAAACTGGGATACCTTGGACTAAGCCAGTCT
GTATCCCAATTCGCTAGCAAGCCTAAGTTTGTGGGGTT
TTGTTTTTGTTTTTGTTTTACCTTCTAATTTACAAGAA
AGAGGAAAAGCTCTTCTAACTGAACTTTGGTATGCGGT
TGAGCTTTGTAACTATTTGTTCTCCATGAAAACAAAAT
TATTTATATTTGACATATTTTTTTCTAGTGTATTAAGT
TATTTTAAACAAAAGATGTTATCTCATGACGTGTTGT
CAGTACAAAATGTGTCGCCTCCAATTCTGTTAAACCT
TTTAAATAAGTGCCAAGTTATTAATTGAAGACACTTT
GCGATCAATTGAATGAAAATATCGTTTCATTTGAAAA AAAAAAA Homo sapiens short
stature homeobox 2 (SHOX2), transcript variant 2, mRNA Accession
Number-NM_006884.3 SEQ ID No. 9
CCTCCTCCCTCTCCTCCCCCACCTCCTGTCCCATTGAT
GTGTTATTATTGGGGGGGCTGGAGCAGTAAAAAAAGAA
GAAGGAAAAAAAGAGCGGGGCTCTGCTGGCAGAGGTTG
AGCGCCGGGCTGACGTGCGGCGGCGATGGAAGAACTTA
CGGCGTTCGTCTCCAAGTCTTTTGACCAGAAAGTGAAG
GAGAAGAAGGAGGCGATCACGTACCGGGAGGTGCTGGA
GAGCGGGCCGCTGCGCGGGGCCAAGGAGCCGACCGGCT
GCACCGAGGCGGGCCGCGACGACCGCAGCAGCCCGGCA
GTCCGGGCGGCCGGCGGAGGCGGCGGCGGAGGAGGCGG
AGGCGGCGGCGGAGGAGGCGGAGGAGGTGTAGGAGGAG
GAGGAGCAGGCGGAGGAGCTGGAGGAGGGCGCTCTCCC
GTCCGGGAGCTGGACATGGGCGCCGCCGAGAGAAGCAG
GGAGCCGGGCAGCCCGCGACTGACGGAGGTGTCCCCGG
AGCTGAAAGATCGCAAAGAGGATGCGAAAGGGATGGAG
GACGAAGGCCAGACCAAAATCAAGCAGAGGCGAAGTCG
GACCAATTTCACCCTGGAACAACTCAATGAGCTGGAGA
GGCTTTTTGACGAGACCCACTATCCCGACGCCTTCATG
CGAGAGGAACTGAGCCAGCGACTGGGCCTGTCGGAGGC
CCGAGTGCAGGTTTGGTTTCAAAATCGAAGAGCTAAAT
GTAGAAAACAAGAAAATCAACTCCATAAAGGTGTTCTC
ATAGGGGCCGCCAGCCAGTTTGAAGCTTGTAGAGTCGC
ACCTTATGTCAACGTAGGTGCTTTAAGGATGCCATTTC
AGCAGGATAGTCATTGCAACGTGACGCCCTTGTCCTTT
CAGGTTCAGGCGCAGCTGCAGCTGGACAGCGCTGTGGC
GCACGCGCACCACCACCTGCATCCGCACCTGGCCGCGC
ACGCGCCCTACATGATGTTCCCAGCACCGCCCTTCGGA
CTGCCGCTCGCCACGCTGGCCGCGGATTCGGCTTCCGC
CGCCTCGGTAGTGGCGGCCGCAGCAGCCGCCAAGACCA
CCAGCAAGAACTCCAGCATCGCCGATCTCAGACTGAAA
GCCAAAAAGCACGCCGCAGCCCTGGGTCTGTGACGCCA
ACGCCAGCACCAATGTCGCGCCTGTCCCGCGGCACTCA
GCCTGCACGCCCTCCGCGCCCCGCTGCTTCTCCGTTAC
CCCTTTGAGACCTCGGGAGCCGGCCCTCTTCCCGCCTC
ACTGACCATCCCTCGTCCCCTATCGCATCTTGGACTCG
GAAAGCCAGACTCCACGCAGGACCAGGGATCTCACGAG
GCACGCAGGCTCCGTGGCTCCTGCCCGTTTTCCTACTC
GAGGGCCTAGAATTGGGTTTTGTAGGAGCGGGTTTGGG
GGAGTCTGGAGAGAGACTGGACAGGGGAGTGCTGGAAC
CGCGGAGTTTGGCTCACCGCAAAGCTGCAACGATGGAC
TCTTGCATAGAAAAAAAAATCTTGTTAACAATGAAAAA
ATGAGCAAACAAAAAAATCGAAAGACAAACGGGAGAGA
AAAAGAGGAAGGGAACTTATTTCTTAACTGCTATTTGG
CAGAAGCTGAAATTGGAGAACCAAGGAGCAAAAACAAA
TTTTAAAATTAAAGTATTTTATACATTTAAAAATATGG
AAAAACAACCCAGACGATTCTCGAGAGACTGGGGGGAG
TTACCAACTTAAATGTGTGTTTTTAAAAATGCGCTAAG
AAGGCAAAGCAGAAAGAAGAGGTATACTTATTTAAAAA
ACTAAGATGAAAAAAGTGCGCAGCTGGGAAGTTCACAG
GTTTTGAAACTGACCTTTTTCTGCGAAGTTCACGTTAA
CACGAGAAATTTGATGAGAGAGGCGGGCCTCCTTTTAC
GTTGAATCAGATGCTTTGAGTTTAAACCCACCATGTAT
GGAAGAGCAAGAAAAGAGAAAATATTAAAACGAGGAGA
GAGAAAAATAATATTAACACAAAAAAATGCCACAGACA
ATGATTTCTCTGAGAAATTATTATGGCAAAACTGTCTG
GACTGCTGACAGTAAATTCCGGTTTGCATGTTACTTGT
ATTCCATTGATGGTGTGTCTCCTCCCACCCCCTTATCT
CCCATGCACTCACTCCATTTTCATCTTCACTATGAAAA
ACAATACCAAAAGTATCTGGAAATTGATATATATATAT
CCATATATATATATCATATATTTGCCATATATATATAT
ATATATATATATATATATATATATATATATTTGCCCTG
TCTTTGATCCTGGGGAACAAAAGAAAAAAGTCAGAAAG
GGAAAAAATTACACTCATTGTCCTAAGAAGACAGAGGT
GGGCAGAATATGTGGGGAAAGGAAAAAGAAAACAAGAC
CACCAAATGAAATAATGAAGGTACAGCGCCTCGCTGTG
CCAGACACAGTAGGCGCTCAATCAGTATTAGTTCCCAC
CATTCCCCTTTTCTTGTGTTCCTTCTTGTTGGTTTCCT
GAAGTCCTATTTGAAGACAGTGGTTTATTTCCCCCTCT
CTATCCCGTCAAATTCACCTTAAATAACACCCAGCTAG
ATACAGGCACTAGGTTTGTGTAAGATATGTTGATACAC
ACGAACAAAGTTTATTTTGACTATAATGTGTGGACTGA
CTTTCAACATTTGCATTTTATCTCACAAAGGTGTATCT
ATTCAAGTAACCTTTTTTTTTTGTTTGTTTGTTTCTTT
TTTGTTTTTTTTTTTCTTTTGGTTGTTTGTTTCAATTC
ATGTAGCTATTTAAACTGGGATACCTTGGACTAAGCCA
GTCTGTATCCCAATTCGCTAGCAAGCCTAAGTTTGTGG
GGTTTTGTTTTTGTTTTTGTTTTACCTTCTAATTTACA
AGAAAGAGGAAAAGCTCTTCTAACTGAACTTTGGTATG
CGGTTGAGCTTTGTAACTATTTGTTCTCCATGAAAACA
AAATTATTTATATTTGACATATTTTTTTCTAGTGTATT
AAGTTATTTTAAACAAAAGATGTTATCTCATGACGTGT
TGTCAGTACAAAATGTGTCGCCTCCAATTCTGTTAAAC
CTTTTAAATAAGTGCCAAGTTATTAATTGAAGACACTT
TGCGATCAATTGAATGAAAATATCGTTTCATTTGAAAA AAAAAAA Homo sapiens short
stature homeobox 2 (SHOX2), transcript variant 3, mRNA Accession
Number-NM_001163678.1 SEQ ID No. 10
CCTCCTCCCTCTCCTCCCCCACCTCCTGTCCCATTGAT
GTGTTATTATTGGGGGGGCTGGAGCAGTAAAAAAAGAA
GAAGGAAAAAAAGAGCGGGGCTCTGCTGGCAGAGGTTG
AGCGCCGGGCTGACGTGCGGCGGCGATGGAAGAACTTA
CGGCGTTCGTCTCCAAGTCTTTTGACCAGAAAGTGAAG
GAGAAGAAGGAGGCGATCACGTACCGGGAGGTGCTGGA
GAGCGGGCCGCTGCGCGGGGCCAAGGAGCCGACCGGCT
GCACCGAGGCGGGCCGCGACGACCGCAGCAGCCCGGCA
GTCCGGGCGGCCGGCGGAGGCGGCGGCGGAGGAGGCGG
AGGCGGCGGCGGAGGAGGCGGAGGAGGTGTAGGAGGAG
GAGGAGCAGGCGGAGGAGCTGGAGGAGGGCGCTCTCCC
GTCCGGGAGCTGGACATGGGCGCCGCCGAGAGAAGCAG
GGAGCCGGGCAGCCCGCGACTGACGGAGGTGTCCCCGG
AGCTGAAAGATCGCAAAGAGGATGCGAAAGGGATGGAG
GACGAAGGCCAGACCAAAATCAAGCAGAGGCGAAGTCG
GACCAATTTCACCCTGGAACAACTCAATGAGCTGGAGA
GGCTTTTTGACGAGACCCACTATCCCGACGCCTTCATG
CGAGAGGAACTGAGCCAGCGACTGGGCCTGTCGGAGGC
CCGAGTGCAGGTTTGGTTTCAAAATCGAAGAGCTAAAT
GTAGAAAACAAGAAAATCAACTCCATAAAGGTGTTCTC
ATAGGGGCCGCCAGCCAGTTTGAAGCTTGTAGAGTCGC
ACCTTATGTCAACGTAGGTGCTTTAAGGATGCCATTTC
AGCAGGTTCAGGCGCAGCTGCAGCTGGACAGCGCTGTG
GCGCACGCGCACCACCACCTGCATCCGCACCTGGCCGC
GCACGCGCCCTACATGATGTTCCCAGCACCGCCCTTCG
GACTGCCGCTCGCCACGCTGGCCGCGGATTCGGCTTCC
GCCGCCTCGGTAGTGGCGGCCGCAGCAGCCGCCAAGAC
CACCAGCAAGAACTCCAGCATCGCCGATCTCAGACTGA
AAGCCAAAAAGCACGCCGCAGCCCTGGGTCTGTGACGC
CAACGCCAGCACCAATGTCGCGCCTGTCCCGCGGCACT
CAGCCTGCACGCCCTCCGCGCCCCGCTGCTTCTCCGTT
ACCCCTTTGAGACCTCGGGAGCCGGCCCTCTTCCCGCC
TCACTGACCATCCCTCGTCCCCTATCGCATCTTGGACT
CGGAAAGCCAGACTCCACGCAGGACCAGGGATCTCACG
AGGCACGCAGGCTCCGTGGCTCCTGCCCGTTTTCCTAC
TCGAGGGCCTAGAATTGGGTTTTGTAGGAGCGGGTTTG
GGGGAGTCTGGAGAGAGACTGGACAGGGGAGTGCTGGA
ACCGCGGAGTTTGGCTCACCGCAAAGCTGCAACGATGG
ACTCTTGCATAGAAAAAAAAATCTTGTTAACAATGAAA
AAATGAGCAAACAAAAAAATCGAAAGACAAACGGGAGA
GAAAAAGAGGAAGGGAACTTATTTCTTAACTGCTATTT
GGCAGAAGCTGAAATTGGAGAACCAAGGAGCAAAAACA
AATTTTAAAATTAAAGTATTTTATACATTTAAAAATAT
GGAAAAACAACCCAGACGATTCTCGAGAGACTGGGGGG
AGTTACCAACTTAAATGTGTGTTTTTAAAAATGCGCTA
AGAAGGCAAAGCAGAAAGAAGAGGTATACTTATTTAAA
AAACTAAGATGAAAAAAGTGCGCAGCTGGGAAGTTCAC
AGGTTTTGAAACTGACCTTTTTCTGCGAAGTTCACGTT
AACACGAGAAATTTGATGAGAGAGGCGGGCCTCCTTTT
ACGTTGAATCAGATGCTTTGAGTTTAAACCCACCATGT
ATGGAAGAGCAAGAAAAGAGAAAATATTAAAACGAGGA
GAGAGAAAAATAATATTAACACAAAAAAATGCCACAGA
CAATGATTTCTCTGAGAAATTATTATGGCAAAACTGTC
TGGACTGCTGACAGTAAATTCCGGTTTGCATGTTACTT
GTATTCCATTGATGGTGTGTCTCCTCCCACCCCCTTAT
CTCCCATGCACTCACTCCATTTTCATCTTCACTATGAA
AAACAATACCAAAAGTATCTGGAAATTGATATATATAT
ATCCATATATATATATCATATATTTGCCATATATATAT
ATATATATATATATATATATATATATATATATTTGCCC
TGTCTTTGATCCTGGGGAACAAAAGAAAAAAGTCAGAA
AGGGAAAAAATTACACTCATTGTCCTAAGAAGACAGAG
GTGGGCAGAATATGTGGGGAAAGGAAAAAGAAAACAAG
ACCACCAAATGAAATAATGAAGGTACAGCGCCTCGCTG
TGCCAGACACAGTAGGCGCTCAATCAGTATTAGTTCCC
ACCATTCCCCTTTTCTTGTGTTCCTTCTTGTTGGTTTC
CTGAAGTCCTATTTGAAGACAGTGGTTTATTTCCCCCT
CTCTATCCCGTCAAATTCACCTTAAATAACACCCAGCT
AGATACAGGCACTAGGTTTGTGTAAGATATGTTGATAC
ACACGAACAAAGTTTATTTTGACTATAATGTGTGGACT
GACTTTCAACATTTGCATTTTATCTCACAAAGGTGTAT
CTATTCAAGTAACCTTTTTTTTTTGTTTGTTTGTTTCT
TTTTTGTTTTTTTTTTTCTTTTGGTTGTTTGTTTCAAT
TCATGTAGCTATTTAAACTGGGATACCTTGGACTAAGC
CAGTCTGTATCCCAATTCGCTAGCAAGCCTAAGTTTGT
GGGGTTTTGTTTTTGTTTTTGTTTTACCTTCTAATTTA
CAAGAAAGAGGAAAAGCTCTTCTAACTGAACTTTGGTA
TGCGGTTGAGCTTTGTAACTATTTGTTCTCCATGAAAA
CAAAATTATTTATATTTGACATATTTTTTTCTAGTGTA
TTAAGTTATTTTAAACAAAAGATGTTATCTCATGACGT
GTTGTCAGTACAAAATGTGTCGCCTCCAATTCTGTTAA
ACCTTTTAAATAAGTGCCAAGTTATTAATTGAAGACAC
TTTGCGATCAATTGAATGAAATATCGTTTCATTTGAAA AAAAAAAA
Sequence CWU 1
1
1014754DNAHomo sapiensmisc_featureHomo sapiens T-box 3 (TBX3),
transcript variant 1misc_featureNM_005996.3 1gaattctaga ggcggcggag
ggtggcgagg agctctcgct ttctctcgct ccctccctct 60ccgactccgt ctctctctct
ctctctctct ctcccctccc tctctttccc tctgttccat 120tttttccccc
tctaaatcct ccctgccctg cgcgcctgga cacagattta ggaagcgaat
180tcgctcacgt tttaggacaa ggaagagaga gaggcacggg agaagagccc
agcaagattt 240ggattgaaac cgagacaccc tccggaggct cggagcagag
gaaggaggag gagggcggcg 300aacggaagcc agtttgcaat tcaagttttg
atagcgctgg tagaaggggg tttaaatcag 360attttttttt ttttaaagga
gagagacttt ttccgctctc tcgctccctg ttaaagccgg 420gtctagcaca
gctgcagacg ccaccagcga gaaagaggga gaggaagaca gatagggggc
480gggggaagaa gaaaaagaaa ggtaaaaagt cttctaggag aacctttcac
atttgcaaca 540aaagacctag gggctggaga gagattcctg ggacgcaggg
ctggagtgtc tatttcgagc 600tcagcggcag ggctcgggcg cgagtcgaga
ccctgctcgc tcctctcgct tctgaaaccg 660acgttcagga gcggcttttt
aaaaacgcaa ggcacaagga cggtcacccg cgcgactatg 720tttgctgatt
tttcgccttg ccctctttaa aagcggcctc ccattctcca aaagacactt
780cccctcctcc ctttgaagtg cattagttgt gatttctgcc tccttttctt
ttttctttct 840tttttgtttt gctttttccc cccttttgaa ttatgtgctg
ctgttaaaca acaacaaaaa 900aacaacaaaa cacagcagct gcggacttgt
ccccggctgg agcccagcgc cccgcctgga 960gtggatgagc ctctccatga
gagatccggt cattcctggg acaagcatgg cctaccatcc 1020gttcctacct
caccgggcgc cggacttcgc catgagcgcg gtgctgggtc accagccgcc
1080gttcttcccc gcgctgacgc tgcctcccaa cggcgcggcg gcgctctcgc
tgccgggcgc 1140cctggccaag ccgatcatgg atcaattggt gggggcggcc
gagaccggca tcccgttctc 1200ctccctgggg ccccaggcgc atctgaggcc
tttgaagacc atggagcccg aagaagaggt 1260ggaggacgac cccaaggtgc
acctggaggc taaagaactt tgggatcagt ttcacaagcg 1320gggcaccgag
atggtcatta ccaagtcggg aaggcgaatg tttcctccat ttaaagtgag
1380atgttctggg ctggataaaa aagccaaata cattttattg atggacatta
tagctgctga 1440tgactgtcgt tataaatttc acaattctcg gtggatggtg
gctggtaagg ccgaccccga 1500aatgccaaag aggatgtaca ttcacccgga
cagccccgct actggggaac agtggatgtc 1560caaagtcgtc actttccaca
aactgaaact caccaacaac atttcagaca aacatggatt 1620tactatattg
aactccatgc acaaatacca gccccggttc cacattgtaa gagccaatga
1680catcttgaaa ctcccttata gtacatttcg gacatacttg ttccccgaaa
ctgaattcat 1740cgctgtgact gcataccaga atgataagat aacccagtta
aaaatagaca acaacccttt 1800tgcaaaaggt ttccgggaca ctggaaatgg
ccgaagagaa aaaagaaaac agctcaccct 1860gcagtccatg agggtgtttg
atgaaagaca caaaaaggag aatgggacct ctgatgagtc 1920ctccagtgaa
caagcagctt tcaactgctt cgcccaggct tcttctccag ccgcctccac
1980tgtagggaca tcgaacctca aagatttatg tcccagcgag ggtgagagcg
acgccgaggc 2040cgagagcaaa gaggagcatg gccccgaggc ctgcgacgcg
gccaagatct ccaccaccac 2100gtcggaggag ccctgccgtg acaagggcag
ccccgcggtc aaggctcacc ttttcgctgc 2160tgagcggccc cgggacagcg
ggcggctgga caaagcgtcg cccgactcac gccatagccc 2220cgccaccatc
tcgtccagca ctcgcggcct gggcgcggag gagcgcagga gcccggttcg
2280cgagggcaca gcgccggcca aggtggaaga ggcgcgcgcg ctcccgggca
aggaggcctt 2340cgcgccgctc acggtgcaga cggacgcggc cgccgcgcac
ctggcccagg gccccctgcc 2400tggcctcggc ttcgccccgg gcctggcggg
ccaacagttc ttcaacgggc acccgctctt 2460cctgcacccc agccagtttg
ccatgggggg cgccttctcc agcatggcgg ccgctggcat 2520gggtcccctc
ctggccacgg tttctggggc ctccaccggt gtctcgggcc tggattccac
2580ggccatggcc tctgccgctg cggcgcaggg actgtccggg gcgtccgcgg
ccaccctgcc 2640cttccacctc cagcagcacg tcctggcctc tcagggcctg
gccatgtccc ctttcggaag 2700cctgttccct tacccctaca cgtacatggc
cgcagcggcg gccgcctcct ctgcggcagc 2760ctccagctcg gtgcaccgcc
accccttcct caatctgaac accatgcgcc cgcggctgcg 2820ctacagcccc
tactccatcc cggtgccggt cccggacggc agcagtctgc tcaccaccgc
2880cctgccctcc atggcggcgg ccgcggggcc cctggacggc aaagtcgccg
ccctggccgc 2940cagcccggcc tcggtggcag tggactcggg ctctgaactc
aacagccgct cctccacgct 3000ctcctccagc tccatgtcct tgtcgcccaa
actctgcgcg gagaaagagg cggccaccag 3060cgaactgcag agcatccagc
ggttggttag cggcttggaa gccaagccgg acaggtcccg 3120cagcgcgtcc
ccgtagaccc gtcccagaca cgtcttttca ttccagtcca gttcaggctg
3180ccgtgcactt tgtcggatat aaaataaacc acgggcccgc catggcgtta
gcccttcctt 3240ttgcagttgc gtctgggaag gggccccgga ctccctcgag
agaatgtgct agagacagcc 3300cctgtcttct tggcgtggtt tatatgtccg
ggatctggat cagattctgg gggctcagaa 3360acgtcggttg cattgagcta
ctgggggtag gagttccaac atttatgtcc agagcaactt 3420ccagcaaggc
tggtctgggt ctctgcccac caggcgggga ggtgttcaaa gacatctccc
3480tcagtgcgga tttatatata tatttttcct tcactgtgtc aagtggaaac
aaaaacaaaa 3540tctttcaaaa aaaaaatcgg gacaagtgaa cacattaaca
tgattctgtt tgtgcagatt 3600aaaaacttta tagggacttg cattatcggt
tctcaataaa ttactgagca gctttgtttg 3660gggagggaag tccctaccat
ccttgtttag tctatattaa gaaaatctgt gtctttttaa 3720tattcttgtg
atgttttcag agccgctgta ggtctcttct tgcatgtcca cagtaatgta
3780tttgtggttt ttattttgaa cgcttgcttt tagagagaaa acaatatagc
cccctaccct 3840tttcccaatc ctttgccctc aaatcagtga cccaagggag
ggggggattt aaagggaagg 3900agtgggcaaa acacataaaa tgaatttatt
atatctaagc tctgtagcag gattcatgtc 3960gttctttgac agttctttct
ctttcctgta tatgcaataa caaggtttta aaaaaataat 4020aaagaagtga
gactattaga caaagtattt atgtaattat ttgataactc ttgtaaatag
4080gtggaatatg aatgcttgga aaattaaact ttaatttatt gacattgtac
atagctctgt 4140gtaaatagaa ttgcaactgt caggttttgt gttcttgttt
tcctttagtt gggtttattt 4200ccaggtcaca gaattgctgt taacactaga
aaacacactt cctgcaccaa caccaatacc 4260ctttcaaaag agttgtctgc
aacatttttg ttttcttttt taatgtccaa aagtggggga 4320aagtgctatt
tcctattttc accaaaattg gggaaggagt gccactttcc agctccactt
4380caaattcctt aaaatataac tgagattgct gtggggaggg aggagggcag
aggctgcggt 4440ttgacttttt aatttttctt ttgttatttg tatttgctag
tctctgattt cctcaaaacg 4500aagtggaatt tactactgtt gtcagtatcg
gtgttttgaa ttggtgcctg cctatagaga 4560tatattcaca gttcaaaagt
caggtgctga gagatggttt aaagacaaat tcatgaaggt 4620atattttgtg
ttatagttgt tgatgagttc tttggttttc tgtatttttc cccctctctt
4680taaaacatca ctgaaatttc aataaatttt tattgaaatg tctaaaaaaa
aaaaaaaaaa 4740aaaaaaaaaa aaaa 475424814DNAHomo
sapiensmisc_featureHomo sapiens T-box 3 (TBX3), transcript variant
2misc_featureAccession Number - NM_016569.3 2gaattctaga ggcggcggag
ggtggcgagg agctctcgct ttctctcgct ccctccctct 60ccgactccgt ctctctctct
ctctctctct ctcccctccc tctctttccc tctgttccat 120tttttccccc
tctaaatcct ccctgccctg cgcgcctgga cacagattta ggaagcgaat
180tcgctcacgt tttaggacaa ggaagagaga gaggcacggg agaagagccc
agcaagattt 240ggattgaaac cgagacaccc tccggaggct cggagcagag
gaaggaggag gagggcggcg 300aacggaagcc agtttgcaat tcaagttttg
atagcgctgg tagaaggggg tttaaatcag 360attttttttt ttttaaagga
gagagacttt ttccgctctc tcgctccctg ttaaagccgg 420gtctagcaca
gctgcagacg ccaccagcga gaaagaggga gaggaagaca gatagggggc
480gggggaagaa gaaaaagaaa ggtaaaaagt cttctaggag aacctttcac
atttgcaaca 540aaagacctag gggctggaga gagattcctg ggacgcaggg
ctggagtgtc tatttcgagc 600tcagcggcag ggctcgggcg cgagtcgaga
ccctgctcgc tcctctcgct tctgaaaccg 660acgttcagga gcggcttttt
aaaaacgcaa ggcacaagga cggtcacccg cgcgactatg 720tttgctgatt
tttcgccttg ccctctttaa aagcggcctc ccattctcca aaagacactt
780cccctcctcc ctttgaagtg cattagttgt gatttctgcc tccttttctt
ttttctttct 840tttttgtttt gctttttccc cccttttgaa ttatgtgctg
ctgttaaaca acaacaaaaa 900aacaacaaaa cacagcagct gcggacttgt
ccccggctgg agcccagcgc cccgcctgga 960gtggatgagc ctctccatga
gagatccggt cattcctggg acaagcatgg cctaccatcc 1020gttcctacct
caccgggcgc cggacttcgc catgagcgcg gtgctgggtc accagccgcc
1080gttcttcccc gcgctgacgc tgcctcccaa cggcgcggcg gcgctctcgc
tgccgggcgc 1140cctggccaag ccgatcatgg atcaattggt gggggcggcc
gagaccggca tcccgttctc 1200ctccctgggg ccccaggcgc atctgaggcc
tttgaagacc atggagcccg aagaagaggt 1260ggaggacgac cccaaggtgc
acctggaggc taaagaactt tgggatcagt ttcacaagcg 1320gggcaccgag
atggtcatta ccaagtcggg aaggcgaatg tttcctccat ttaaagtgag
1380atgttctggg ctggataaaa aagccaaata cattttattg atggacatta
tagctgctga 1440tgactgtcgt tataaatttc acaattctcg gtggatggtg
gctggtaagg ccgaccccga 1500aatgccaaag aggatgtaca ttcacccgga
cagccccgct actggggaac agtggatgtc 1560caaagtcgtc actttccaca
aactgaaact caccaacaac atttcagaca aacatggatt 1620tactttggcc
ttcccaagtg atcacgctac gtggcagggg aattatagtt ttggtactca
1680gactatattg aactccatgc acaaatacca gccccggttc cacattgtaa
gagccaatga 1740catcttgaaa ctcccttata gtacatttcg gacatacttg
ttccccgaaa ctgaattcat 1800cgctgtgact gcataccaga atgataagat
aacccagtta aaaatagaca acaacccttt 1860tgcaaaaggt ttccgggaca
ctggaaatgg ccgaagagaa aaaagaaaac agctcaccct 1920gcagtccatg
agggtgtttg atgaaagaca caaaaaggag aatgggacct ctgatgagtc
1980ctccagtgaa caagcagctt tcaactgctt cgcccaggct tcttctccag
ccgcctccac 2040tgtagggaca tcgaacctca aagatttatg tcccagcgag
ggtgagagcg acgccgaggc 2100cgagagcaaa gaggagcatg gccccgaggc
ctgcgacgcg gccaagatct ccaccaccac 2160gtcggaggag ccctgccgtg
acaagggcag ccccgcggtc aaggctcacc ttttcgctgc 2220tgagcggccc
cgggacagcg ggcggctgga caaagcgtcg cccgactcac gccatagccc
2280cgccaccatc tcgtccagca ctcgcggcct gggcgcggag gagcgcagga
gcccggttcg 2340cgagggcaca gcgccggcca aggtggaaga ggcgcgcgcg
ctcccgggca aggaggcctt 2400cgcgccgctc acggtgcaga cggacgcggc
cgccgcgcac ctggcccagg gccccctgcc 2460tggcctcggc ttcgccccgg
gcctggcggg ccaacagttc ttcaacgggc acccgctctt 2520cctgcacccc
agccagtttg ccatgggggg cgccttctcc agcatggcgg ccgctggcat
2580gggtcccctc ctggccacgg tttctggggc ctccaccggt gtctcgggcc
tggattccac 2640ggccatggcc tctgccgctg cggcgcaggg actgtccggg
gcgtccgcgg ccaccctgcc 2700cttccacctc cagcagcacg tcctggcctc
tcagggcctg gccatgtccc ctttcggaag 2760cctgttccct tacccctaca
cgtacatggc cgcagcggcg gccgcctcct ctgcggcagc 2820ctccagctcg
gtgcaccgcc accccttcct caatctgaac accatgcgcc cgcggctgcg
2880ctacagcccc tactccatcc cggtgccggt cccggacggc agcagtctgc
tcaccaccgc 2940cctgccctcc atggcggcgg ccgcggggcc cctggacggc
aaagtcgccg ccctggccgc 3000cagcccggcc tcggtggcag tggactcggg
ctctgaactc aacagccgct cctccacgct 3060ctcctccagc tccatgtcct
tgtcgcccaa actctgcgcg gagaaagagg cggccaccag 3120cgaactgcag
agcatccagc ggttggttag cggcttggaa gccaagccgg acaggtcccg
3180cagcgcgtcc ccgtagaccc gtcccagaca cgtcttttca ttccagtcca
gttcaggctg 3240ccgtgcactt tgtcggatat aaaataaacc acgggcccgc
catggcgtta gcccttcctt 3300ttgcagttgc gtctgggaag gggccccgga
ctccctcgag agaatgtgct agagacagcc 3360cctgtcttct tggcgtggtt
tatatgtccg ggatctggat cagattctgg gggctcagaa 3420acgtcggttg
cattgagcta ctgggggtag gagttccaac atttatgtcc agagcaactt
3480ccagcaaggc tggtctgggt ctctgcccac caggcgggga ggtgttcaaa
gacatctccc 3540tcagtgcgga tttatatata tatttttcct tcactgtgtc
aagtggaaac aaaaacaaaa 3600tctttcaaaa aaaaaatcgg gacaagtgaa
cacattaaca tgattctgtt tgtgcagatt 3660aaaaacttta tagggacttg
cattatcggt tctcaataaa ttactgagca gctttgtttg 3720gggagggaag
tccctaccat ccttgtttag tctatattaa gaaaatctgt gtctttttaa
3780tattcttgtg atgttttcag agccgctgta ggtctcttct tgcatgtcca
cagtaatgta 3840tttgtggttt ttattttgaa cgcttgcttt tagagagaaa
acaatatagc cccctaccct 3900tttcccaatc ctttgccctc aaatcagtga
cccaagggag ggggggattt aaagggaagg 3960agtgggcaaa acacataaaa
tgaatttatt atatctaagc tctgtagcag gattcatgtc 4020gttctttgac
agttctttct ctttcctgta tatgcaataa caaggtttta aaaaaataat
4080aaagaagtga gactattaga caaagtattt atgtaattat ttgataactc
ttgtaaatag 4140gtggaatatg aatgcttgga aaattaaact ttaatttatt
gacattgtac atagctctgt 4200gtaaatagaa ttgcaactgt caggttttgt
gttcttgttt tcctttagtt gggtttattt 4260ccaggtcaca gaattgctgt
taacactaga aaacacactt cctgcaccaa caccaatacc 4320ctttcaaaag
agttgtctgc aacatttttg ttttcttttt taatgtccaa aagtggggga
4380aagtgctatt tcctattttc accaaaattg gggaaggagt gccactttcc
agctccactt 4440caaattcctt aaaatataac tgagattgct gtggggaggg
aggagggcag aggctgcggt 4500ttgacttttt aatttttctt ttgttatttg
tatttgctag tctctgattt cctcaaaacg 4560aagtggaatt tactactgtt
gtcagtatcg gtgttttgaa ttggtgcctg cctatagaga 4620tatattcaca
gttcaaaagt caggtgctga gagatggttt aaagacaaat tcatgaaggt
4680atattttgtg ttatagttgt tgatgagttc tttggttttc tgtatttttc
cccctctctt 4740taaaacatca ctgaaatttc aataaatttt tattgaaatg
tctaaaaaaa aaaaaaaaaa 4800aaaaaaaaaa aaaa 481433921DNAHomo
sapiensmisc_featureHomo sapiens T-box 5 (TBX5), transcript variant
1misc_featureAccession Number - NM_000192.3 3catgccttat gcaagagacc
tcagtccccc ggaacaactc gatttccttc caatagaggt 60ctgaggtgga ctcccacctc
ccttcgtgaa gagttccctc ctctccccct tcctaagaaa 120gtcgatcttg
gctctatttg tgtcttatgt tcatcaccct cattcctccg gagaaagccg
180ggttggttta tgtctttatt tattcccggg gccaagacgt ccggaacctg
tggctgcgca 240gacccggcac tgataggcga agacggagag aaatttacct
cccgccgctg ccccccagcc 300aaacgtgaca gcgcgcgggc cggttgcgtg
actcgtgacg tctccaagtc ctataggtgc 360agcggctggt gagatagtcg
ctatcgcctg gttgcctctt tattttactg gggtatgcct 420ggtaataaac
agtaatattt aatttgtcgg agaccacaaa ccaaccttga gctgggaggt
480acgtgctctt cttgacagac gttggaagaa gacctggcct aaagaggtct
cttttggtgg 540tccttttcaa agtcttcacc tgagccctgc tctccagcga
ggcgcactcc tggcttttgc 600gctccaaaga agaggtggga tagttggaga
gcagaacctt gcgcgggcac agggccctgg 660gcgcaccatg gccgacgcag
acgagggctt tggcctggcg cacacgcctc tggagcctga 720cgcaaaagac
ctgccctgcg attcgaaacc cgagagcgcg ctcggggccc ccagcaagtc
780cccgtcgtcc ccgcaggccg ccttcaccca gcagggcatg gagggaatca
aagtgtttct 840ccatgaaaga gaactgtggc taaaattcca cgaagtgggc
acggaaatga tcataaccaa 900ggctggaagg cggatgtttc ccagttacaa
agtgaaggtg acgggcctta atcccaaaac 960gaagtacatt cttctcatgg
acattgtacc tgccgacgat cacagataca aattcgcaga 1020taataaatgg
tctgtgacgg gcaaagctga gcccgccatg cctggccgcc tgtacgtgca
1080cccagactcc cccgccaccg gggcgcattg gatgaggcag ctcgtctcct
tccagaaact 1140caagctcacc aacaaccacc tggacccatt tgggcatatt
attctaaatt ccatgcacaa 1200ataccagcct agattacaca tcgtgaaagc
ggatgaaaat aatggatttg gctcaaaaaa 1260tacagcgttc tgcactcacg
tctttcctga gactgcgttt atagcagtga cttcctacca 1320gaaccacaag
atcacgcaat taaagattga gaataatccc tttgccaaag gatttcgggg
1380cagtgatgac atggagctgc acagaatgtc aagaatgcaa agtaaagaat
atcccgtggt 1440ccccaggagc accgtgaggc aaaaagtggc ctccaaccac
agtcctttca gcagcgagtc 1500tcgagctctc tccacctcat ccaatttggg
gtcccaatac cagtgtgaga atggtgtttc 1560cggcccctcc caggacctcc
tgcctccacc caacccatac ccactgcccc aggagcatag 1620ccaaatttac
cattgtacca agaggaaaga ggaagaatgt tccaccacag accatcccta
1680taagaagccc tacatggaga catcacccag tgaagaagat tccttctacc
gctctagcta 1740tccacagcag cagggcctgg gtgcctccta caggacagag
tcggcacagc ggcaagcttg 1800catgtatgcc agctctgcgc cccccagcga
gcctgtgccc agcctagagg acatcagctg 1860caacacgtgg ccaagcatgc
cttcctacag cagctgcacc gtcaccaccg tgcagcccat 1920ggacaggcta
ccctaccagc acttctccgc tcacttcacc tcggggcccc tggtccctcg
1980gctggctggc atggccaacc atggctcccc acagctggga gagggaatgt
tccagcacca 2040gacctccgtg gcccaccagc ctgtggtcag gcagtgtggg
cctcagactg gcctgcagtc 2100ccctggcacc cttcagcccc ctgagttcct
ctactctcat ggcgtgccaa ggactctatc 2160ccctcatcag taccactctg
tgcacggagt tggcatggtg ccagagtgga gcgacaatag 2220ctaaagtgag
gcctgcttca caacagacat ttcctagaga aagagagaga gagaggagaa
2280agagagagaa ggagagagac agtagccaag agaaccccac ggacaagatt
tttcatttca 2340cccaatgttc acatctgcac tcaaggtcgc tggatgctga
tctaatcagt agcttgaaac 2400cacaatttta aaaatgtgac tttcttgttt
tgtctcaaaa cttaaaaaaa caaacacaaa 2460aagatgagtc ccacccccca
ctaccaccac acccatcaac cagccacatt cacgctactc 2520cccagatctc
ttcccccatt ccttcttttg ggctctagaa agtcttgcct cattgagtgt
2580ttttccctag tgcgtagttg gagtctgtcc ctgtcttggt gttaatgttg
acattgttat 2640ataataaatg ataatatatt tttttctttc aattttctta
atgggaccca gtcccttatt 2700tggggggagg tctgaggcaa gtatatttca
aaatatgtac ttgcgggatt cccttcaagt 2760aaaccatccc tgaaacctaa
attcacgttt ccccttgact aagaaaagca cctacctctg 2820ccatgtgatg
tttctgaaaa gcctctgtat gtccccattt gctttggttt tgtcctgcct
2880tctccaatat cacgtgctca gttttgcctc tacttaccca tggagtcagg
ataacactga 2940cgctccctgg catcctatct tattcagccc taccatcttg
ccagctctgt ctttccagct 3000gtctgtcgct aaaacgtggc ctatagcttc
ccttccggaa agcttgcttt gaaaaactta 3060aaaagccccc gtttacatgt
aggcaggact gtgataacag tgcaagctct gtgttgacaa 3120gagttgtgga
caaaaagcca aaataaatat tcttcctgat taaaaaaatt ttttttgaaa
3180aaaacaaggc cagccccaac cttccaaacc tccatcacca acaacccaaa
ctggatgtca 3240agcaaaatgc acaattccta cagaagaggc aagacacagt
caccaatgat atctcgccaa 3300agaaaccacg cccacaccaa tgccaacaca
aaactgtgtt tactgaaagc cgaaaacagt 3360attaaaaaaa gtgtgtaagt
aaagtgttat ggtagggttc ttcagatgta atattttact 3420ggtactattt
atttataaat aggaattcta attaagtaat aacatgaaat gaaacccagc
3480ataggagctg gccaagagct tttaatttta ttgatactca aaaccaagtt
tgtgtttttt 3540tgtttttttt tgtttttttc ctctttcgaa tgtgctttgc
tttttttgat taaaaagaat 3600tttttttttc cttttttata aacagaccct
aataaagaga acagggtaag atgtgaggct 3660gagtgtgttt aagtacgtga
gagagtgtga gtgtgtttgt aagtgagtgt ccctatgcga 3720ttatgtctct
ttacgttgct aaggggggag ggtgaggatt aagtactcgt gccttatatt
3780tgtgtgccaa ttaatgccta ataaatacca tgtgcttaaa caagtaaaaa
aaaaaaaaaa 3840aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
aaaaaaaaaa aaaaaaaaaa 3900aaaaaaaaaa aaaaaaaaaa a 392141050DNAHomo
sapiensmisc_featureHomo sapiens T-box 5 (TBX5), transcript variant
2misc_featureAccession Number - NM_080718.1 4atggccgacg cagacgaggg
ctttggcctg gcgcacacgc ctctggagcc tgacgcaaaa 60gacctgccct gcgattcgaa
acccgagagc gcgctcgggg cccccagcaa gtccccgtcg 120tccccgcagg
ccgccttcac ccagcagggc atggagggaa tcaaagtgtt tctccatgaa
180agagaactgt ggctaaaatt ccacgaagtg ggcacggaaa tgatcataac
caaggctgga 240aggcggatgt ttcccagtta caaagtgaag gtgacgggcc
ttaatcccaa aacgaagtac 300attcttctca tggacattgt acctgccgac
gatcacagat acaaattcgc agataataaa 360tggtctgtga cgggcaaagc
tgagcccgcc atgcctggcc gcctgtacgt gcacccagac 420tcccccgcca
ccggggcgca ttggatgagg cagctcgtct ccttccagaa actcaagctc
480accaacaacc acctggaccc atttgggcat attattctaa attccatgca
caaataccag 540cctagattac acatcgtgaa agcggatgaa aataatggat
ttggctcaaa aaatacagcg 600ttctgcactc acgtctttcc tgagactgcg
tttatagcag tgacttccta ccagaaccac 660aagatcacgc aattaaagat
tgagaataat ccctttgcca aaggatttcg gggcagtgat 720gacatggagc
tgcacagaat gtcaagaatg caaagtaaag aatatcccgt ggtccccagg
780agcaccgtga ggcaaaaagt ggcctccaac cacagtcctt tcagcagcga
gtctcgagct 840ctctccacct catccaattt ggggtcccaa taccagtgtg
agaatggtgt ttccggcccc 900tcccaggacc tcctgcctcc acccaaccca
tacccactgc cccaggagca tagccaaatt 960taccattgta ccaagaggaa
aggtgagtgt gatcacccct ggtcaatttg
ctttctttct 1020taccttttcc tttccttggg ttgggggtga 105053736DNAHomo
sapiensmisc_featureHomo sapiens T-box 5 (TBX5), transcript variant
3misc_featureAccession Number - NM_080717.2 5catgccttat gcaagagacc
tcagtccccc ggaacaactc gatttccttc caatagaggt 60ctgaggtgga ctcccacctc
ccttcgtgaa gagttccctc ctctccccct tcctaagaaa 120gtcgatcttg
gctctatttg tgtcttatgt tcatcaccct cattcctccg gagaaagccg
180ggttggttta tgtctttatt tattcccggg gccaagacgt ccggaacctg
tggctgcgca 240gacccggcac tgataggcga agacggagag aaatttacct
cccgccgctg ccccccagcc 300aaacgtgaca gcgcgcgggc cggttgcgtg
actcgtgacg tctccaagtc ctataggtgc 360agcggctggt gagatagtcg
ctatcgcctg gttgcctctt tattttactg gggtatgcct 420ggtaataaac
agtaatattt aatttgtcgg agaccacaaa ccaaccttga gctgggaggt
480acgtgctctt cttgacagac gttggaagaa gacctggcct aaagaggtct
cttttggtgg 540tccttttcaa agtcttcacc tgagccctgc tctccagcga
ggcgcactcc tggcttttgc 600gctccaaaga agaggtggga tagttggagg
gcatggaggg aatcaaagtg tttctccatg 660aaagagaact gtggctaaaa
ttccacgaag tgggcacgga aatgatcata accaaggctg 720gaaggcggat
gtttcccagt tacaaagtga aggtgacggg ccttaatccc aaaacgaagt
780acattcttct catggacatt gtacctgccg acgatcacag atacaaattc
gcagataata 840aatggtctgt gacgggcaaa gctgagcccg ccatgcctgg
ccgcctgtac gtgcacccag 900actcccccgc caccggggcg cattggatga
ggcagctcgt ctccttccag aaactcaagc 960tcaccaacaa ccacctggac
ccatttgggc atattattct aaattccatg cacaaatacc 1020agcctagatt
acacatcgtg aaagcggatg aaaataatgg atttggctca aaaaatacag
1080cgttctgcac tcacgtcttt cctgagactg cgtttatagc agtgacttcc
taccagaacc 1140acaagatcac gcaattaaag attgagaata atccctttgc
caaaggattt cggggcagtg 1200atgacatgga gctgcacaga atgtcaagaa
tgcaaagtaa agaatatccc gtggtcccca 1260ggagcaccgt gaggcaaaaa
gtggcctcca accacagtcc tttcagcagc gagtctcgag 1320ctctctccac
ctcatccaat ttggggtccc aataccagtg tgagaatggt gtttccggcc
1380cctcccagga cctcctgcct ccacccaacc catacccact gccccaggag
catagccaaa 1440tttaccattg taccaagagg aaagaggaag aatgttccac
cacagaccat ccctataaga 1500agccctacat ggagacatca cccagtgaag
aagattcctt ctaccgctct agctatccac 1560agcagcaggg cctgggtgcc
tcctacagga cagagtcggc acagcggcaa gcttgcatgt 1620atgccagctc
tgcgcccccc agcgagcctg tgcccagcct agaggacatc agctgcaaca
1680cgtggccaag catgccttcc tacagcagct gcaccgtcac caccgtgcag
cccatggaca 1740ggctacccta ccagcacttc tccgctcact tcacctcggg
gcccctggtc cctcggctgg 1800ctggcatggc caaccatggc tccccacagc
tgggagaggg aatgttccag caccagacct 1860ccgtggccca ccagcctgtg
gtcaggcagt gtgggcctca gactggcctg cagtcccctg 1920gcacccttca
gccccctgag ttcctctact ctcatggcgt gccaaggact ctatcccctc
1980atcagtacca ctctgtgcac ggagttggca tggtgccaga gtggagcgac
aatagctaaa 2040gtgaggcctg cttcacaaca gacatttcct agagaaagag
agagagagag gagaaagaga 2100gagaaggaga gagacagtag ccaagagaac
cccacggaca agatttttca tttcacccaa 2160tgttcacatc tgcactcaag
gtcgctggat gctgatctaa tcagtagctt gaaaccacaa 2220ttttaaaaat
gtgactttct tgttttgtct caaaacttaa aaaaacaaac acaaaaagat
2280gagtcccacc ccccactacc accacaccca tcaaccagcc acattcacgc
tactccccag 2340atctcttccc ccattccttc ttttgggctc tagaaagtct
tgcctcattg agtgtttttc 2400cctagtgcgt agttggagtc tgtccctgtc
ttggtgttaa tgttgacatt gttatataat 2460aaatgataat atattttttt
ctttcaattt tcttaatggg acccagtccc ttatttgggg 2520ggaggtctga
ggcaagtata tttcaaaata tgtacttgcg ggattccctt caagtaaacc
2580atccctgaaa cctaaattca cgtttcccct tgactaagaa aagcacctac
ctctgccatg 2640tgatgtttct gaaaagcctc tgtatgtccc catttgcttt
ggttttgtcc tgccttctcc 2700aatatcacgt gctcagtttt gcctctactt
acccatggag tcaggataac actgacgctc 2760cctggcatcc tatcttattc
agccctacca tcttgccagc tctgtctttc cagctgtctg 2820tcgctaaaac
gtggcctata gcttcccttc cggaaagctt gctttgaaaa acttaaaaag
2880cccccgttta catgtaggca ggactgtgat aacagtgcaa gctctgtgtt
gacaagagtt 2940gtggacaaaa agccaaaata aatattcttc ctgattaaaa
aaattttttt tgaaaaaaac 3000aaggccagcc ccaaccttcc aaacctccat
caccaacaac ccaaactgga tgtcaagcaa 3060aatgcacaat tcctacagaa
gaggcaagac acagtcacca atgatatctc gccaaagaaa 3120ccacgcccac
accaatgcca acacaaaact gtgtttactg aaagccgaaa acagtattaa
3180aaaaagtgtg taagtaaagt gttatggtag ggttcttcag atgtaatatt
ttactggtac 3240tatttattta taaataggaa ttctaattaa gtaataacat
gaaatgaaac ccagcatagg 3300agctggccaa gagcttttaa ttttattgat
actcaaaacc aagtttgtgt ttttttgttt 3360ttttttgttt ttttcctctt
tcgaatgtgc tttgcttttt ttgattaaaa agaatttttt 3420ttttcctttt
ttataaacag accctaataa agagaacagg gtaagatgtg aggctgagtg
3480tgtttaagta cgtgagagag tgtgagtgtg tttgtaagtg agtgtcccta
tgcgattatg 3540tctctttacg ttgctaaggg gggagggtga ggattaagta
ctcgtgcctt atatttgtgt 3600gccaattaat gcctaataaa taccatgtgc
ttaaacaagt aaaaaaaaaa aaaaaaaaaa 3660aaaaaaaaaa aaaaaaaaaa
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 3720aaaaaaaaaa aaaaaa
373663749DNAHomo sapiensmisc_featureHomo sapiens T-box 5 (TBX5),
transcript variant 4misc_featureAccession Number - NM_181486.1
6ttcagagaga gagagagagg gagagagagt gagagagact gactcttacc tcgaatccgg
60gaactttaat cctgaaagct gcgctcagaa aggacttcga ccattcactg ggcttccaac
120tttccctccc tgggggtgta aaggaggagc ggggcactga gattatatgg
ttgccggtgc 180tcttggaggc tattttgtgt tctttggcgc ttgccaactg
ggaagtattt agggagagca 240agcgcacagc agaggaggtg tgtgttggag
gtgggcagtc gccgcggagg ctccagcggt 300aggtgcgccc tagtaggcag
cagtagccgc tattctgggt aagcagtaaa ccccgcataa 360accccggagc
caccatgcct gctcccccgc ctcaccgccg gcttccctgc taggagcagc
420agaggatgtg gtgaatgcac cggcttcacc gaacgagagc agaaccttgc
gcgggcacag 480ggccctgggc gcaccatggc cgacgcagac gagggctttg
gcctggcgca cacgcctctg 540gagcctgacg caaaagacct gccctgcgat
tcgaaacccg agagcgcgct cggggccccc 600agcaagtccc cgtcgtcccc
gcaggccgcc ttcacccagc agggcatgga gggaatcaaa 660gtgtttctcc
atgaaagaga actgtggcta aaattccacg aagtgggcac ggaaatgatc
720ataaccaagg ctggaaggcg gatgtttccc agttacaaag tgaaggtgac
gggccttaat 780cccaaaacga agtacattct tctcatggac attgtacctg
ccgacgatca cagatacaaa 840ttcgcagata ataaatggtc tgtgacgggc
aaagctgagc ccgccatgcc tggccgcctg 900tacgtgcacc cagactcccc
cgccaccggg gcgcattgga tgaggcagct cgtctccttc 960cagaaactca
agctcaccaa caaccacctg gacccatttg ggcatattat tctaaattcc
1020atgcacaaat accagcctag attacacatc gtgaaagcgg atgaaaataa
tggatttggc 1080tcaaaaaata cagcgttctg cactcacgtc tttcctgaga
ctgcgtttat agcagtgact 1140tcctaccaga accacaagat cacgcaatta
aagattgaga ataatccctt tgccaaagga 1200tttcggggca gtgatgacat
ggagctgcac agaatgtcaa gaatgcaaag taaagaatat 1260cccgtggtcc
ccaggagcac cgtgaggcaa aaagtggcct ccaaccacag tcctttcagc
1320agcgagtctc gagctctctc cacctcatcc aatttggggt cccaatacca
gtgtgagaat 1380ggtgtttccg gcccctccca ggacctcctg cctccaccca
acccataccc actgccccag 1440gagcatagcc aaatttacca ttgtaccaag
aggaaagagg aagaatgttc caccacagac 1500catccctata agaagcccta
catggagaca tcacccagtg aagaagattc cttctaccgc 1560tctagctatc
cacagcagca gggcctgggt gcctcctaca ggacagagtc ggcacagcgg
1620caagcttgca tgtatgccag ctctgcgccc cccagcgagc ctgtgcccag
cctagaggac 1680atcagctgca acacgtggcc aagcatgcct tcctacagca
gctgcaccgt caccaccgtg 1740cagcccatgg acaggctacc ctaccagcac
ttctccgctc acttcacctc ggggcccctg 1800gtccctcggc tggctggcat
ggccaaccat ggctccccac agctgggaga gggaatgttc 1860cagcaccaga
cctccgtggc ccaccagcct gtggtcaggc agtgtgggcc tcagactggc
1920ctgcagtccc ctggcaccct tcagccccct gagttcctct actctcatgg
cgtgccaagg 1980actctatccc ctcatcagta ccactctgtg cacggagttg
gcatggtgcc agagtggagc 2040gacaatagct aaagtgaggc ctgcttcaca
acagacattt cctagagaaa gagagagaga 2100gaggagaaag agagagaagg
agagagacag tagccaagag aaccccacgg acaagatttt 2160tcatttcacc
caatgttcac atctgcactc aaggtcgctg gatgctgatc taatcagtag
2220cttgaaacca caattttaaa aatgtgactt tcttgttttg tctcaaaact
taaaaaaaca 2280aacacaaaaa gatgagtccc accccccact accaccacac
ccatcaacca gccacattca 2340cgctactccc cagatctctt cccccattcc
ttcttttggg ctctagaaag tcttgcctca 2400ttgagtgttt ttccctagtg
cgtagttgga gtctgtccct gtcttggtgt taatgttgac 2460attgttatat
aataaatgat aatatatttt tttctttcaa ttttcttaat gggacccagt
2520cccttatttg gggggaggtc tgaggcaagt atatttcaaa atatgtactt
gcgggattcc 2580cttcaagtaa accatccctg aaacctaaat tcacgtttcc
ccttgactaa gaaaagcacc 2640tacctctgcc atgtgatgtt tctgaaaagc
ctctgtatgt ccccatttgc tttggttttg 2700tcctgccttc tccaatatca
cgtgctcagt tttgcctcta cttacccatg gagtcaggat 2760aacactgacg
ctccctggca tcctatctta ttcagcccta ccatcttgcc agctctgtct
2820ttccagctgt ctgtcgctaa aacgtggcct atagcttccc ttccggaaag
cttgctttga 2880aaaacttaaa aagcccccgt ttacatgtag gcaggactgt
gataacagtg caagctctgt 2940gttgacaaga gttgtggaca aaaagccaaa
ataaatattc ttcctgatta aaaaaatttt 3000ttttgaaaaa aacaaggcca
gccccaacct tccaaacctc catcaccaac aacccaaact 3060ggatgtcaag
caaaatgcac aattcctaca gaagaggcaa gacacagtca ccaatgatat
3120ctcgccaaag aaaccacgcc cacaccaatg ccaacacaaa actgtgttta
ctgaaagccg 3180aaaacagtat taaaaaaagt gtgtaagtaa agtgttatgg
tagggttctt cagatgtaat 3240attttactgg tactatttat ttataaatag
gaattctaat taagtaataa catgaaatga 3300aacccagcat aggagctggc
caagagcttt taattttatt gatactcaaa accaagtttg 3360tgtttttttg
tttttttttg tttttttcct ctttcgaatg tgctttgctt tttttgatta
3420aaaagaattt tttttttcct tttttataaa cagaccctaa taaagagaac
agggtaagat 3480gtgaggctga gtgtgtttaa gtacgtgaga gagtgtgagt
gtgtttgtaa gtgagtgtcc 3540ctatgcgatt atgtctcttt acgttgctaa
ggggggaggg tgaggattaa gtactcgtgc 3600cttatatttg tgtgccaatt
aatgcctaat aaataccatg tgcttaaaca agtaaaaaaa 3660aaaaaaaaaa
aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa
3720aaaaaaaaaa aaaaaaaaaa aaaaaaaaa 374974070DNAHomo
sapiensmisc_featureHomo sapiens T-box 18
(TBX18)misc_featureAccession Number - NM_001080508.1 7atggccgaga
agcgaagggg ctcgccgtgc agcatgctaa gcctcaaggc gcacgctttc 60tcggtggagg
cgctgatcgg cgccgagaag cagcaacagc ttcagaagaa gcggcgaaaa
120ctgggcgccg aagaggcggc gggggccgtg gacgacggag gctgcagccg
cggcggcggc 180gcgggcgaaa agggttcttc tgagggagac gaaggcgctg
cgctcccgcc gccggctggg 240gcgacgtctg ggccggctcg gagtggcgca
gacctggagc gcggagccgc gggcggctgt 300gaggacggct tccagcaggg
agcttcccct ctggcgtcac cgggaggctc ccccaagggg 360tctccggcgc
gctccctggc ccggcccggg acccctctgc cctcgccgca ggccccgcgg
420gtggatctgc agggagccga gctctggaag cgctttcatg agataggcac
tgagatgatc 480atcaccaagg ccggcaggcg catgtttcca gcaatgagag
tgaagatctc tggattagat 540cctcaccagc aatattacat tgccatggat
attgtaccag tggacaacaa aagatacagg 600tatgtttacc acagttcgaa
atggatggtg gcaggtaatg ctgactcgcc tgtgccaccc 660cgtgtgtaca
ttcatccaga ctcgcctgcc tcgggggaga cttggatgag acaagttatc
720agcttcgaca agctgaagct caccaacaat gaactggatg accaaggcca
tattattctt 780cattctatgc acaaatacca accgcgagtg cacgtcatcc
gtaaagactg tggagacgat 840ctttctccca tcaagcctgt tccatccggg
gagggagtaa aggcattctc ctttccagaa 900actgtcttca caaccgtcac
tgcctatcag aatcagcaga ttactcgcct gaagatagat 960aggaatccat
ttgctaaagg cttccgagac tccgggcgca acagaatggg tttggaagcc
1020ttggtggaat catatgcatt ctggcgacca tcactacgga ctctgacctt
tgaagatatc 1080cctggaattc ccaagcaagg caatgcaagt tcctccacct
tgctccaagg tactgggaat 1140ggcgttcctg ccactcaccc tcaccttttg
tctggctcct cttgctcctc tcctgccttc 1200catctggggc ccaacaccag
ccagctgtgt agtctggccc ctgctgacta ttctgcctgt 1260gcccgctcag
gcctcaccct caaccgatac agcacatctt tggcagagac ctacaacagg
1320ctcaccaacc aggctggtga gacctttgcc ccgcccagga ctccctccta
tgtgggcgtg 1380agcagcagca cctccgtgaa catgtccatg ggtggcactg
atggggacac cttcagctgc 1440ccacagacca gcttatccat gcagatttcg
ggaatgtccc cccagctcca gtatatcatg 1500ccatcaccct ccagcaatgc
cttcgccact aaccagaccc atcagggttc ctataatact 1560tttagattac
acagcccctg tgcactatat ggatataact tctccacatc ccccaaactg
1620gctgccagtc ctgagaaaat tgtttcttcc caaggaagtt tcttggggtc
ctcaccgagt 1680gggaccatga cggatcggca gatgttgccc cctgtggaag
gagtgcacct gcttagcagt 1740gggggtcagc agagtttctt tgactctagg
accctaggaa gcttaactct gtcatcatct 1800caagtatctg cacatatggt
ctgatgaagc ctttaagtta aatgacattt ggatctgtct 1860aacatatttt
ctttttcttt tttaaaagct atgtggaaag aaactctctg tggtttataa
1920aatgtacata taatagaaaa tgaaggctca ctgggttttt tgactttatc
atggtgagat 1980tgtaattatc tatggtatat atgtatgctg tatatacata
gcacatggag tatcacggcc 2040cctattgttc ccctgtttca tccagttgca
cggagtattg gcatgcgtgt agtatgttta 2100agcaaagttc tcagactctt
ttaaaaacaa gatggtaaac ttaaaacttg gcaattatac 2160tatccagaag
aacacttata acttaattta tcagaaaaat gctctaaacg gtttcatact
2220tgatgtattg ataaccagca gtaaccagca tgtagagtct tgtgatttct
gttattcttg 2280gacacagtgt gagaatctaa aatacaaaag ccagttgaag
tcttagtgtt agtcctgagg 2340tatttgtaat catgaaggat cagctttttc
attcctgctt attatttacc acacatacta 2400tatgaccttg ggtctataaa
aaaatcataa cccataataa ttgttatttt cttaaggaag 2460gtaaaggaga
ggcttgtgat tttttttttt acactttcca ttgggcacat aagaggttct
2520tattcatctg tagagaacaa atttccagta ttttcgattt tttgcttatt
ttatatatca 2580aatagaccat taaagaatgt tctataaaca tttttaaatt
ccaattttca ccaggggagg 2640aatatgtgat atgagtggaa tggcaaaagg
aaaataaatc cacctcaaat tcattgattc 2700caatgagaaa tgtctatctt
ttaaatcaag agtaatacta ttgttaacta taccttatgt 2760ttttgtatag
tttgttttta aatttagaat attttttcca tcttgctctg agcttcctga
2820ccgatagtat ataagtaaaa aaaatgcatt tatgctactt atttatatct
tgtaattcct 2880acacattgaa cccttttccc cttcttaacc ttgtccgtct
gcctgagtct ttcccaaaac 2940agatagttcc taggcctgta tggtgttaaa
taacacggtg aggaatttca gtaggttatc 3000tccagcaatc tgtcttttgg
gagctatagt gcaaaggcca aagcccatta ctataaagac 3060cctcttggag
gactaagaag gaagatacta attatgataa aggaactata aaacttttaa
3120cctcaacaga atttgtaatg tcagaactgg agaaattaaa atcagtatta
aattttttaa 3180ttcctaaaat aatatatgca tggttgaaga gttaaaaaca
agtaactttg agagcacagt 3240atgagataaa taaaaaaggc taagaataca
tgatgaggca cattcccctt ctgaggagaa 3300agcgaaataa catgtctgtg
cattgaccca ttcattacat ttcatgtatc ttaagcaaaa 3360gagcatgatt
ttctctcatt gctaaaaaga gttgctttaa ctcatccctg gatttggtgg
3420ggaaagggta caactcctga tttgctgttt cactttgaaa caacacaatt
tgttagatac 3480ttagggagat atactgttga atttgcacag gatgtgactc
tgtttataca tattaacaaa 3540tttccttttg gattccttag cagttcatca
aattagtatt aaatttttaa atttaaaact 3600agcatgaagg gacatgaaat
atttgcagta ggtggatcta tgtaagatgt ttgggtatgg 3660cattaatagc
ttgacaaaga tttggggaaa ggtgttaaga atgagtccat ctcagccaat
3720agtgcttggt gtataattca agaacagaga gttttccatc ttgaaaaaac
atggaaagta 3780atgctctata cccatatgta ttaataagag cattttcctt
cttgccgttg atcatttcag 3840atgataccac aatatgagta taatttttta
ttaatctttt ttctggtaaa attttagcaa 3900tattgtacaa atgctttttt
taggttttac tgtaaatatt aatcaccacg tcacttcaga 3960gactagcctt
ttattgctga attaaatgac atgcatacat tgataattat atatctgtat
4020tttattaaaa agtacttaaa attatattaa aatatgttat taaacccttt
407083233DNAHomo sapiensmisc_featuresapiens short stature homeobox
2 (SHOX2), transcript variant 1misc_featureAccession Number -
NM_003030.4 8cctcctccct ctcctccccc acctcctgtc ccattgatgt gttattattg
ggggggctgg 60agcagtaaaa aaagaagaag gaaaaaaaga gcggggctct gctggcagag
gttgagcgcc 120gggctgacgt gcggcggcga tggaagaact tacggcgttc
gtctccaagt cttttgacca 180gaaagtgaag gagaagaagg aggcgatcac
gtaccgggag gtgctggaga gcgggccgct 240gcgcggggcc aaggagccga
ccggctgcac cgaggcgggc cgcgacgacc gcagcagccc 300ggcagtccgg
gcggccggcg gaggcggcgg cggaggaggc ggaggcggcg gcggaggagg
360cggaggaggt gtaggaggag gaggagcagg cggaggagct ggaggagggc
gctctcccgt 420ccgggagctg gacatgggcg ccgccgagag aagcagggag
ccgggcagcc cgcgactgac 480ggagggtaga aggaagccaa cgaaagctga
ggtccaggct acgctgcttc tcccgggcga 540ggcgtttcgg tttcttgtgt
ccccggagct gaaagatcgc aaagaggatg cgaaagggat 600ggaggacgaa
ggccagacca aaatcaagca gaggcgaagt cggaccaatt tcaccctgga
660acaactcaat gagctggaga ggctttttga cgagacccac tatcccgacg
ccttcatgcg 720agaggaactg agccagcgac tgggcctgtc ggaggcccga
gtgcaggttt ggtttcaaaa 780tcgaagagct aaatgtagaa aacaagaaaa
tcaactccat aaaggtgttc tcataggggc 840cgccagccag tttgaagctt
gtagagtcgc accttatgtc aacgtaggtg ctttaaggat 900gccatttcag
caggatagtc attgcaacgt gacgcccttg tcctttcagg ttcaggcgca
960gctgcagctg gacagcgctg tggcgcacgc gcaccaccac ctgcatccgc
acctggccgc 1020gcacgcgccc tacatgatgt tcccagcacc gcccttcgga
ctgccgctcg ccacgctggc 1080cgcggattcg gcttccgccg cctcggtagt
ggcggccgca gcagccgcca agaccaccag 1140caagaactcc agcatcgccg
atctcagact gaaagccaaa aagcacgccg cagccctggg 1200tctgtgacgc
caacgccagc accaatgtcg cgcctgtccc gcggcactca gcctgcacgc
1260cctccgcgcc ccgctgcttc tccgttaccc ctttgagacc tcgggagccg
gccctcttcc 1320cgcctcactg accatccctc gtcccctatc gcatcttgga
ctcggaaagc cagactccac 1380gcaggaccag ggatctcacg aggcacgcag
gctccgtggc tcctgcccgt tttcctactc 1440gagggcctag aattgggttt
tgtaggagcg ggtttggggg agtctggaga gagactggac 1500aggggagtgc
tggaaccgcg gagtttggct caccgcaaag ctgcaacgat ggactcttgc
1560atagaaaaaa aaatcttgtt aacaatgaaa aaatgagcaa acaaaaaaat
cgaaagacaa 1620acgggagaga aaaagaggaa gggaacttat ttcttaactg
ctatttggca gaagctgaaa 1680ttggagaacc aaggagcaaa aacaaatttt
aaaattaaag tattttatac atttaaaaat 1740atggaaaaac aacccagacg
attctcgaga gactgggggg agttaccaac ttaaatgtgt 1800gtttttaaaa
atgcgctaag aaggcaaagc agaaagaaga ggtatactta tttaaaaaac
1860taagatgaaa aaagtgcgca gctgggaagt tcacaggttt tgaaactgac
ctttttctgc 1920gaagttcacg ttaacacgag aaatttgatg agagaggcgg
gcctcctttt acgttgaatc 1980agatgctttg agtttaaacc caccatgtat
ggaagagcaa gaaaagagaa aatattaaaa 2040cgaggagaga gaaaaataat
attaacacaa aaaaatgcca cagacaatga tttctctgag 2100aaattattat
ggcaaaactg tctggactgc tgacagtaaa ttccggtttg catgttactt
2160gtattccatt gatggtgtgt ctcctcccac ccccttatct cccatgcact
cactccattt 2220tcatcttcac tatgaaaaac aataccaaaa gtatctggaa
attgatatat atatatccat 2280atatatatat catatatttg ccatatatat
atatatatat atatatatat atatatatat 2340atatttgccc tgtctttgat
cctggggaac aaaagaaaaa agtcagaaag ggaaaaaatt 2400acactcattg
tcctaagaag acagaggtgg gcagaatatg tggggaaagg aaaaagaaaa
2460caagaccacc aaatgaaata atgaaggtac agcgcctcgc tgtgccagac
acagtaggcg 2520ctcaatcagt attagttccc accattcccc ttttcttgtg
ttccttcttg ttggtttcct 2580gaagtcctat ttgaagacag tggtttattt
ccccctctct atcccgtcaa attcacctta 2640aataacaccc agctagatac
aggcactagg tttgtgtaag atatgttgat acacacgaac 2700aaagtttatt
ttgactataa tgtgtggact gactttcaac atttgcattt tatctcacaa
2760aggtgtatct attcaagtaa cctttttttt ttgtttgttt gtttcttttt
tgtttttttt 2820tttcttttgg ttgtttgttt caattcatgt agctatttaa
actgggatac cttggactaa
2880gccagtctgt atcccaattc gctagcaagc ctaagtttgt ggggttttgt
ttttgttttt 2940gttttacctt ctaatttaca agaaagagga aaagctcttc
taactgaact ttggtatgcg 3000gttgagcttt gtaactattt gttctccatg
aaaacaaaat tatttatatt tgacatattt 3060ttttctagtg tattaagtta
ttttaaacaa aagatgttat ctcatgacgt gttgtcagta 3120caaaatgtgt
cgcctccaat tctgttaaac cttttaaata agtgccaagt tattaattga
3180agacactttg cgatcaattg aatgaaaata tcgtttcatt tgaaaaaaaa aaa
323393161DNAHomo sapiensmisc_featureHomo sapiens short stature
homeobox 2 (SHOX2), transcript variant 2misc_featureAccession
Number - NM_006884.3 9cctcctccct ctcctccccc acctcctgtc ccattgatgt
gttattattg ggggggctgg 60agcagtaaaa aaagaagaag gaaaaaaaga gcggggctct
gctggcagag gttgagcgcc 120gggctgacgt gcggcggcga tggaagaact
tacggcgttc gtctccaagt cttttgacca 180gaaagtgaag gagaagaagg
aggcgatcac gtaccgggag gtgctggaga gcgggccgct 240gcgcggggcc
aaggagccga ccggctgcac cgaggcgggc cgcgacgacc gcagcagccc
300ggcagtccgg gcggccggcg gaggcggcgg cggaggaggc ggaggcggcg
gcggaggagg 360cggaggaggt gtaggaggag gaggagcagg cggaggagct
ggaggagggc gctctcccgt 420ccgggagctg gacatgggcg ccgccgagag
aagcagggag ccgggcagcc cgcgactgac 480ggaggtgtcc ccggagctga
aagatcgcaa agaggatgcg aaagggatgg aggacgaagg 540ccagaccaaa
atcaagcaga ggcgaagtcg gaccaatttc accctggaac aactcaatga
600gctggagagg ctttttgacg agacccacta tcccgacgcc ttcatgcgag
aggaactgag 660ccagcgactg ggcctgtcgg aggcccgagt gcaggtttgg
tttcaaaatc gaagagctaa 720atgtagaaaa caagaaaatc aactccataa
aggtgttctc ataggggccg ccagccagtt 780tgaagcttgt agagtcgcac
cttatgtcaa cgtaggtgct ttaaggatgc catttcagca 840ggatagtcat
tgcaacgtga cgcccttgtc ctttcaggtt caggcgcagc tgcagctgga
900cagcgctgtg gcgcacgcgc accaccacct gcatccgcac ctggccgcgc
acgcgcccta 960catgatgttc ccagcaccgc ccttcggact gccgctcgcc
acgctggccg cggattcggc 1020ttccgccgcc tcggtagtgg cggccgcagc
agccgccaag accaccagca agaactccag 1080catcgccgat ctcagactga
aagccaaaaa gcacgccgca gccctgggtc tgtgacgcca 1140acgccagcac
caatgtcgcg cctgtcccgc ggcactcagc ctgcacgccc tccgcgcccc
1200gctgcttctc cgttacccct ttgagacctc gggagccggc cctcttcccg
cctcactgac 1260catccctcgt cccctatcgc atcttggact cggaaagcca
gactccacgc aggaccaggg 1320atctcacgag gcacgcaggc tccgtggctc
ctgcccgttt tcctactcga gggcctagaa 1380ttgggttttg taggagcggg
tttgggggag tctggagaga gactggacag gggagtgctg 1440gaaccgcgga
gtttggctca ccgcaaagct gcaacgatgg actcttgcat agaaaaaaaa
1500atcttgttaa caatgaaaaa atgagcaaac aaaaaaatcg aaagacaaac
gggagagaaa 1560aagaggaagg gaacttattt cttaactgct atttggcaga
agctgaaatt ggagaaccaa 1620ggagcaaaaa caaattttaa aattaaagta
ttttatacat ttaaaaatat ggaaaaacaa 1680cccagacgat tctcgagaga
ctggggggag ttaccaactt aaatgtgtgt ttttaaaaat 1740gcgctaagaa
ggcaaagcag aaagaagagg tatacttatt taaaaaacta agatgaaaaa
1800agtgcgcagc tgggaagttc acaggttttg aaactgacct ttttctgcga
agttcacgtt 1860aacacgagaa atttgatgag agaggcgggc ctccttttac
gttgaatcag atgctttgag 1920tttaaaccca ccatgtatgg aagagcaaga
aaagagaaaa tattaaaacg aggagagaga 1980aaaataatat taacacaaaa
aaatgccaca gacaatgatt tctctgagaa attattatgg 2040caaaactgtc
tggactgctg acagtaaatt ccggtttgca tgttacttgt attccattga
2100tggtgtgtct cctcccaccc ccttatctcc catgcactca ctccattttc
atcttcacta 2160tgaaaaacaa taccaaaagt atctggaaat tgatatatat
atatccatat atatatatca 2220tatatttgcc atatatatat atatatatat
atatatatat atatatatat atttgccctg 2280tctttgatcc tggggaacaa
aagaaaaaag tcagaaaggg aaaaaattac actcattgtc 2340ctaagaagac
agaggtgggc agaatatgtg gggaaaggaa aaagaaaaca agaccaccaa
2400atgaaataat gaaggtacag cgcctcgctg tgccagacac agtaggcgct
caatcagtat 2460tagttcccac cattcccctt ttcttgtgtt ccttcttgtt
ggtttcctga agtcctattt 2520gaagacagtg gtttatttcc ccctctctat
cccgtcaaat tcaccttaaa taacacccag 2580ctagatacag gcactaggtt
tgtgtaagat atgttgatac acacgaacaa agtttatttt 2640gactataatg
tgtggactga ctttcaacat ttgcatttta tctcacaaag gtgtatctat
2700tcaagtaacc tttttttttt gtttgtttgt ttcttttttg tttttttttt
tcttttggtt 2760gtttgtttca attcatgtag ctatttaaac tgggatacct
tggactaagc cagtctgtat 2820cccaattcgc tagcaagcct aagtttgtgg
ggttttgttt ttgtttttgt tttaccttct 2880aatttacaag aaagaggaaa
agctcttcta actgaacttt ggtatgcggt tgagctttgt 2940aactatttgt
tctccatgaa aacaaaatta tttatatttg acatattttt ttctagtgta
3000ttaagttatt ttaaacaaaa gatgttatct catgacgtgt tgtcagtaca
aaatgtgtcg 3060cctccaattc tgttaaacct tttaaataag tgccaagtta
ttaattgaag acactttgcg 3120atcaattgaa tgaaaatatc gtttcatttg
aaaaaaaaaa a 3161103125DNAHomo sapiensmisc_featureHomo sapiens
short stature homeobox 2 (SHOX2), transcript variant
3misc_featureAccession Number - NM_001163678.1 10cctcctccct
ctcctccccc acctcctgtc ccattgatgt gttattattg ggggggctgg 60agcagtaaaa
aaagaagaag gaaaaaaaga gcggggctct gctggcagag gttgagcgcc
120gggctgacgt gcggcggcga tggaagaact tacggcgttc gtctccaagt
cttttgacca 180gaaagtgaag gagaagaagg aggcgatcac gtaccgggag
gtgctggaga gcgggccgct 240gcgcggggcc aaggagccga ccggctgcac
cgaggcgggc cgcgacgacc gcagcagccc 300ggcagtccgg gcggccggcg
gaggcggcgg cggaggaggc ggaggcggcg gcggaggagg 360cggaggaggt
gtaggaggag gaggagcagg cggaggagct ggaggagggc gctctcccgt
420ccgggagctg gacatgggcg ccgccgagag aagcagggag ccgggcagcc
cgcgactgac 480ggaggtgtcc ccggagctga aagatcgcaa agaggatgcg
aaagggatgg aggacgaagg 540ccagaccaaa atcaagcaga ggcgaagtcg
gaccaatttc accctggaac aactcaatga 600gctggagagg ctttttgacg
agacccacta tcccgacgcc ttcatgcgag aggaactgag 660ccagcgactg
ggcctgtcgg aggcccgagt gcaggtttgg tttcaaaatc gaagagctaa
720atgtagaaaa caagaaaatc aactccataa aggtgttctc ataggggccg
ccagccagtt 780tgaagcttgt agagtcgcac cttatgtcaa cgtaggtgct
ttaaggatgc catttcagca 840ggttcaggcg cagctgcagc tggacagcgc
tgtggcgcac gcgcaccacc acctgcatcc 900gcacctggcc gcgcacgcgc
cctacatgat gttcccagca ccgcccttcg gactgccgct 960cgccacgctg
gccgcggatt cggcttccgc cgcctcggta gtggcggccg cagcagccgc
1020caagaccacc agcaagaact ccagcatcgc cgatctcaga ctgaaagcca
aaaagcacgc 1080cgcagccctg ggtctgtgac gccaacgcca gcaccaatgt
cgcgcctgtc ccgcggcact 1140cagcctgcac gccctccgcg ccccgctgct
tctccgttac ccctttgaga cctcgggagc 1200cggccctctt cccgcctcac
tgaccatccc tcgtccccta tcgcatcttg gactcggaaa 1260gccagactcc
acgcaggacc agggatctca cgaggcacgc aggctccgtg gctcctgccc
1320gttttcctac tcgagggcct agaattgggt tttgtaggag cgggtttggg
ggagtctgga 1380gagagactgg acaggggagt gctggaaccg cggagtttgg
ctcaccgcaa agctgcaacg 1440atggactctt gcatagaaaa aaaaatcttg
ttaacaatga aaaaatgagc aaacaaaaaa 1500atcgaaagac aaacgggaga
gaaaaagagg aagggaactt atttcttaac tgctatttgg 1560cagaagctga
aattggagaa ccaaggagca aaaacaaatt ttaaaattaa agtattttat
1620acatttaaaa atatggaaaa acaacccaga cgattctcga gagactgggg
ggagttacca 1680acttaaatgt gtgtttttaa aaatgcgcta agaaggcaaa
gcagaaagaa gaggtatact 1740tatttaaaaa actaagatga aaaaagtgcg
cagctgggaa gttcacaggt tttgaaactg 1800acctttttct gcgaagttca
cgttaacacg agaaatttga tgagagaggc gggcctcctt 1860ttacgttgaa
tcagatgctt tgagtttaaa cccaccatgt atggaagagc aagaaaagag
1920aaaatattaa aacgaggaga gagaaaaata atattaacac aaaaaaatgc
cacagacaat 1980gatttctctg agaaattatt atggcaaaac tgtctggact
gctgacagta aattccggtt 2040tgcatgttac ttgtattcca ttgatggtgt
gtctcctccc acccccttat ctcccatgca 2100ctcactccat tttcatcttc
actatgaaaa acaataccaa aagtatctgg aaattgatat 2160atatatatcc
atatatatat atcatatatt tgccatatat atatatatat atatatatat
2220atatatatat atatatttgc cctgtctttg atcctgggga acaaaagaaa
aaagtcagaa 2280agggaaaaaa ttacactcat tgtcctaaga agacagaggt
gggcagaata tgtggggaaa 2340ggaaaaagaa aacaagacca ccaaatgaaa
taatgaaggt acagcgcctc gctgtgccag 2400acacagtagg cgctcaatca
gtattagttc ccaccattcc ccttttcttg tgttccttct 2460tgttggtttc
ctgaagtcct atttgaagac agtggtttat ttccccctct ctatcccgtc
2520aaattcacct taaataacac ccagctagat acaggcacta ggtttgtgta
agatatgttg 2580atacacacga acaaagttta ttttgactat aatgtgtgga
ctgactttca acatttgcat 2640tttatctcac aaaggtgtat ctattcaagt
aacctttttt ttttgtttgt ttgtttcttt 2700tttgtttttt tttttctttt
ggttgtttgt ttcaattcat gtagctattt aaactgggat 2760accttggact
aagccagtct gtatcccaat tcgctagcaa gcctaagttt gtggggtttt
2820gtttttgttt ttgttttacc ttctaattta caagaaagag gaaaagctct
tctaactgaa 2880ctttggtatg cggttgagct ttgtaactat ttgttctcca
tgaaaacaaa attatttata 2940tttgacatat ttttttctag tgtattaagt
tattttaaac aaaagatgtt atctcatgac 3000gtgttgtcag tacaaaatgt
gtcgcctcca attctgttaa accttttaaa taagtgccaa 3060gttattaatt
gaagacactt tgcgatcaat tgaatgaaaa tatcgtttca tttgaaaaaa 3120aaaaa
3125
* * * * *